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Major Field: MANAGEMENT SCIENCE AND INFORMATION SYSTEMS 
 
Abstract: High dimensionality in Big Data can be modeled using network approach. The 
traditional networks (e.g. online social network) are explicit and easily observed. However, there 
are certain networks that are implicit and exist by virtue of some underlying collective behavior. 
Our focus is on these implicit networks, which can be inferred from the secondary data using 
statistical modeling. An example of such a network is a comorbidity network. In a comorbidity 
network, diseases form connections based on their co-occurrences in patients. We use data on the 
health history of 24.7 million patients recorded in US hospitals (2000-2016) to infer comorbidity 
networks. Since most statistical models depend upon sample size, it is important to study how 
sample size affects the structure of an implicit network. We study the impact of sample size on 
comorbidity networks developed using Pearson’s Correlation Coefficient (PCC) and Salton 
Cosine Index (SCI). We present a comparative analysis and show that a network developed using 
SCI is robust to sample size as compared to the PCC.   
 
Our first study of comorbidity networks employs descriptive analytics. We investigate how 
comorbidity networks are different across population groups. We compare networks based on 
gender, race and insurance types. Our analysis at the comorbidity level presents health disparities 
across population groups. 
 
These disparities across population groups are considered to study the impact of comorbidity 
network on patients’ hospital length of stay in second study. We develop an explanatory and 
predictive model to estimate length of stay using features extracted from comorbidity networks 
and compare with the extant models. We show that our model outperforms the existing models.  
 
Finally, we study how an implicit network can help theorize certain phenomenon related to it. 
With respect to the comorbidity network, we theorize clique property of a network as trap state. 
The trap state is hypothesized to be related to mortality risk of a patient. We identify eighteen 
such cliques in a comorbidity network.  
 
This dissertation contributes to network science, analytics and healthcare literature but the theory, 
models, algorithms, and processes developed are generalizable to other inferred networks.  
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CHAPTER I 
 
 
INTRODUCTION 
Across the disciplines, there are several phenomena that occur at a level that is not visible 
explicitly. It is a challenging problem to detect such hidden phenomena or structures, which are 
characterized by some implicit underlying behavior. The data analytics approach analogous to the 
grounded theory methodology can be applied to discern such hidden structures “from the data”. 
In grounded theory methodology, the broader idea is to discover features from the data (Glaser & 
Strauss, 2009) where hypotheses are not pre-formulated but emerge from the data. 
With the advancements in Information Systems, the collection, storage and analysis of large 
datasets are possible, which provide opportunities to discover hidden structures related to a 
particular phenomenon. Research using large datasets equivalent to the population has several 
advantages. First, the availability of large datasets mitigates issues related to the small sample 
size in research. And second, the conclusions from data can be validated across multiple samples 
and thus, their generalizability can be verified.  
Extremely large datasets are characterized as Big Data. These are known to include high volume, 
high velocity of data collection and often have high dimensionality with a large variety. Due to 
high dimensionality in Big Data, model building is challenging and requires much computational 
power. Big Data analytics is thus focused on taming this beast requiring much data storage and 
analytics capacity to handle the large variety.
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One of the models that can present a high dimensional space in a summarized manner is the 
network model. A network comprises of nodes connected to each other based on a well-defined 
relationship. In traditional networks such as an online social network, nodes (in case of an online 
social network, nodes are users), form a network based on their decision to connect to each other. 
The connections between friends or users on online social networks such as Twitter or Facebook 
are explicit and visible through features such as “followers”, “friends”, “likes”, etc. However, 
there are several networks in which the interactions are implicit and it is not easy to draw links 
between nodes. We call these networks implicit because the relationships between nodes exist by 
virtue of some underlying exchanges (Roth et al. 2010). One common example of an implicit 
network is the network formed by collaborative filtering in recommender systems (Konstas, 
Stathopoulos, & Jose, 2009). Recommender systems create virtual connections between users or 
products based on their common characteristics. Another example of an implicit network is the 
ingredient network in which ingredients are connected based on their co-occurrences in different 
recipes (Teng, Lin, & Adamic, 2012). One more interesting implicit network is the language 
network emerged from the co-occurrences of words in a sentence, semantics, and syntactic (Solé 
et al. 2010; Liu, 2009). Implicit networks are also common in medical science. The biological 
networks such as a protein network (Weston et al., 2004), brain network (Van Den Heuvel & Pol, 
2010), comorbidity network (Hidalgo et al. 2009), phenome-genome network (Butte & Kohane, 
2006) and many others are all created through some underlying relationships and thus, are 
implicit networks. 
The focus of this dissertation is the implicit networks which are inferred from historical patterns. 
These networks are data-driven and are inferred theoretically using mathematical formulas. To 
create relationships between nodes in a network, joint probabilities, co-occurrences, or 
similarities between the nodes are used (Hidalgo et al., 2009; Roth et al., 2010; Teng et al., 2012). 
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Therefore, it entirely depends on how a researcher defines a relationship between nodes. Most 
often, a similarity index is used to define a relationship between two nodes mathematically. 
Since relationships emerge from data, the size of sample is an issue in the inferred networks. If 
the definition of a relationship between two nodes depends on sample size, it can result into an 
invalid and unreliable network. Therefore, to define a valid relationship between two nodes in a 
network, it is important to study the impact of sample size on inferred networks developed using 
different similarity indexes. This gives rise to the first research question of this dissertation:  
Research Question 1: What is the impact of sample size on the structure of an inferred 
network created using a similarity index? 
The traditional networks (e.g. social network) have been shown in the past to be related to 
performance outcomes of the network source (Coleman, 1988; Provan and Sebastian 1998). For 
example, Sparrowe et al. (2001) found individual job performance was positively related to 
position of an employee in the advice network. Similarly, in this study, we study how a structure 
or network emerged implicitly from the unintended actions of source impact the performance 
outcomes of source? This broader question is studied in the context of US health explained in 
next section 
1.1. PROBLEM DOMAIN 
The broader problem domain of this dissertation is the health of US population recorded in 
hospitals electronically. The health history recorded in an Electronic Medical Record (EMR) 
includes different types of clinical information such as lab procedures, medications, diseases 
diagnosed and other hospital related variables. In this dissertation, we are specifically interested 
in the collective behavior of diseases in patients. We use network approach to study this 
underlying behavior. The network studied here is a network of diseases where diagnoses are 
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related to each other based on their co-occurrences in millions of patients admitted in US 
hospitals. To define a connection between two diseases in the network, we use an important 
medical concept known as comorbidity. Comorbidity is a medical condition in a patient when he 
or she develops multiple diseases simultaneously. For instance, the presence of diabetes and 
depression simultaneously in a patient is a comorbidity. 
The comorbidity network contains diseases linked to each other whereby representing a 
summarized underlying joint behavior of the diseases. This joint behavior can be different across 
different groups of patients, thus leading to different health consequences. The health disparities 
across population groups can be caused by genetic, hormonal, physiological, behavioral, and 
sociocultural factors. Therefore, it is important to understand how diseases form relationships 
across different population groups. This provokes the second research question of this 
dissertation: 
Research Question 2: How do diseases co-occur differently and form different network 
structures across population groups? 
The second research question discussed above is entirely exploratory and set the stage to find 
how the underlying interactions of diseases can affect some health outcomes of patients. Because 
the foundation of our network is co-occurrence of diseases, it can help predict other likely 
diseases in a patient in future based on his current condition. Thus, we use this idea to understand 
how network can be used to ex-ante predict the health outcomes, specifically the hospital length 
of stay. This gives rise to the third research question of this dissertation: 
Research Question 3: How does the implicit relationships among diseases help ex-ante 
predict the health outcomes, specifically the hospital length of stay? 
The comorbidity network embeds risk in its structure, analogous to the social capital in social 
network (Coleman, 1988). This structural risk is not identified and analyzed yet in medical 
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literature, particularly with respect to comorbidity. Moreover, this structural risk can be used to 
theorize medical concepts. We use the structural risk embedded in comorbidity network to 
understand mortality, which is an important health outcome. We use an important structural 
property of a network known as a clique (a sub-network where all nodes are adjacent to each 
other) to explain mortality. Because a clique has maximum possible interactions among nodes, its 
presence in a patient can be critical due to high risk. It indicates a trap state in a patient from 
where the exit is difficult. Identifying such clique can help physicians take preemptive actions 
related to the health of a patient. Therefore, the final research question is related to the impact of 
cliques on mortality. 
Research Question 4: Can we identify clique as trap state where its presence in a patient 
increases mortality risk?  
1.2. SCOPE OF THE DISSERTATION 
This interdisciplinary dissertation draws upon healthcare, network science and 
analytics/Information Systems literature. The healthcare problems are studied by applying 
network theories and using Information Systems tools and techniques. Figure 1.1 presents a Venn 
diagram describing the scope of this dissertation at the intersection of three areas: healthcare, 
network science and analytics/IS. 
In the healthcare area, we enhance the understanding of comorbidity and its impact on the health 
outcomes such as patients’ hospital length of stay and mortality. Our study applies network 
science concepts to study the comorbidities. Studying disease associations or comorbidities 
generates more insights than studying diseases independently.  
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Figure 1.1 Venn diagram explaining scope of the dissertation 
We apply analytical tools and techniques of the IS field to develop models, measures and 
algorithms, which are the explicit IT artifacts (March & Smith, 1995; Von Alan et al. 2004). The 
measures and models are expected to augment the performance of current Information Systems 
used to predict length of stay and mortality rate. The analytics has a transformational impact on 
the healthcare discipline (Agarwal & Lucas Jr, 2005; Markus & Mao, 2004). 
1.3. DATA SOURCE 
We obtained data from the Center for Health Systems Innovation (CHSI), a center at Oklahoma 
State University which houses data provided by Cerner Corporation, a major Electronic Medical 
Record (EMR) provider. The data warehouse contains records of visits of 58 million unique 
patients across 662 US hospitals (2000-2016). It includes more than 84 million admissions, 
emergency and ambulatory visits. It is the largest and industry's only relational database that 
includes comprehensive records with pharmacy, laboratory, clinical events, admission and billing 
data. Diagnoses are classified according to the International Classification of Diseases, 9th 
Healthcare 
Analytics using 
Network Science 
Healthcare 
 
Information 
Systems/Analytics 
Network Science 
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Revision, Clinical Modification (ICD-9-CM). This data warehouse has recently been made 
available to OSU’s Center for Health Systems Innovation through a gift from Cerner Corporation, 
a major EMR provider. The database also includes more than 2.4 billion laboratory results and 
more than 295 million orders for nearly 4,500 drugs categorized by name and brand. It is one of 
the largest compilation of de-identified, real-world, HIPAA-compliant data of its type that can 
permit such a large scale network analysis. The use of this massive dataset is one of the strengths 
of our study. 
1.4. OUTLINE OF THE CHAPTERS 
The rest of the dissertation is organized as follows. In Chapter 2, we answer the first research 
question using dataset described in the previous section. It describes the method to create network 
using Pearson’s correlation coefficient and Salton Cosine Index in addition to a process to find 
statistical significance of the relationship using Salton Cosine Index. This chapter provides an 
appropriate index to define a relationship between two diseases, which is used in all other 
chapters later. 
Following the method described in Chapter 2, in Chapter 3, we create two different comorbidity 
networks for men and women to find health disparity by gender. This comparison shows which 
comorbidities are more prevalent in one population group and not in others. This study is under 
review at a journal.  
Following the same approach as Chapter 3, comorbidity network differences are discovered in 
races and different insurance holders in Chapter 4. The comparison between different population 
groups results into several research questions for medical, economics, social, public health, policy 
and analytics researchers. The third and fourth chapters are the responses to our second research 
question. 
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In Chapter 5, we answer the third research question. We extend the applicability of the network to 
create explanatory and predictive models to estimate the patient’s length of stay. To ex-ante 
predict the length of stay, we only use information available at the point of admission. In 
addition, we also compare our models with the extant models and show our models perform 
better. 
The fourth research question is addressed in Chapter 6. We use the clique concept to understand 
mortality risk embedded in the structure of a comorbidity network. A clique forms a trap state and 
thus, its presence in a patient is likely to increase mortality risk. 
Finally, in Chapter 7, we conclude by discussing the contributions, generalizability and future 
work of the models, processes and algorithms developed in this dissertation.
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CHAPTER II 
 
 
IMPACT OF SAMPLE SIZE ON AN IMPLICIT NETWORK 
ABSTRACT 
Networks can be observed in different problem domains. Some networks are explicit where 
members make direct connections (e.g. Facebook network), whereas other networks are formed 
through some underlying implicit relationships, which are not directly visible (e.g. collaborative 
filtering network). Since implicit networks are present in almost every field of science and 
developed from a sample of some population, it is necessary to understand how sample size 
influences their structures given that the conclusions from network analysis can be biased if a 
network does not represent true relationships. The purpose of this paper is to understand how 
sample size impacts the structure of an implicit network. We compare the networks created using 
two indexes: Pearson’s Correlation Coefficient (PCC) and Salton Cosine Index (SCI). For 
demonstration, we present an implicit network called a comorbidity network. The networks 
created using PCC and SCI from a large dataset containing health records of 22.1 million patients 
are compared based on their overall topologies and node centralities. The results show that the 
network formed using SCI is less affected by the sample size as compared to the network created 
using PCC. With respect to the overall structure of a network, the comorbidity network using SCI 
follows a small-world topology irrespective of the sample size; however, the structure of network 
using PCC is inconsistent in its structure. Regarding node centralities, the betweenness centrality  
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of the network is most affected by sample size. Our analysis is valuable as it establishes a need for 
choosing a right measure to create an implicit network for making valid conclusions. 
2.1.INTRODUCTION 
A network emerges from the interactions between elements or nodes (Euler, 1953). For example, 
online social networks (OSN) are one of the main research topics in Information Systems field. In 
an online social network, friends or users form a network based on their direct connections. The 
connections between friends or users on online social networks such as Twitter or Facebook are 
explicit and visible through features such as “followers”, “friends”, “likes”, etc. These networks 
are easy to construct because one can easily define a relationship between two elements. 
However, there are several networks in which the interactions are implicit and it is not easy to 
draw links between nodes. We call these networks implicit networks because the relationships 
between nodes exist by virtue of some underlying exchanges (Roth et al. 2010). One common 
example of an implicit network is the network formed by collaborative filtering in recommender 
systems (Konstas, Stathopoulos, & Jose, 2009). Recommender systems try to create virtual 
connections between users or products based on their common characteristics. Another example 
of an implicit network is an ingredient network in which ingredients are connected based on their 
co-occurrences in different recipes (Teng, Lin, & Adamic, 2012). Another interesting implicit 
network is the language network developed based on co-occurrences of words in a sentence, 
semantics, and syntactic (Solé et al. 2010; Liu, 2009). Implicit networks are also widely studied 
in medical science. The biological networks such as a protein network (Weston et al., 2004), 
brain network (Van Den Heuvel & Pol, 2010), comorbidity network (Hidalgo et al. 2009), 
phenome-genome network (Butte & Kohane, 2006) and many others are all created through some 
underlying relationships and thus, are implicit networks.  
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Implicit networks are created using joint probabilities, co-occurrences, or similarities of nodes 
(Hidalgo et al., 2009; Roth et al., 2010; Teng et al., 2012). Therefore, it entirely depends on how a 
researcher defines a relationship between nodes. Mostly, researchers use a similarity index to 
define a relationship mathematically. One of the most common indexes is Pearson’s correlation 
coefficient. It has often been used in author co-citation network analysis to find an intellectual 
structure in a given field (McCain, 1990). It has also been used in medical sciences for creating a 
network of diseases from electronic health records (Hidalgo et al., 2009; Divo et al., 2015). In 
contrast, some researchers have supported the use of other indexes such as cosine indexes over 
Pearson’s correlation coefficient. Van Eck & Waltman (2008) argued that Pearson’s correlation 
coefficient captures the linear relationship between two variables, which is not same as the 
commonality between two variables; therefore, it is not an appropriate measure to create a 
network. Instead, the authors suggested to use a cosine index to develop a network from the data. 
Similarly, Ahlgren, Jarneving, & Rousseau, (2003) also criticized the use of Pearson’s correlation 
coefficient because it is sensitive to sparseness in the network. The authors argued that it results 
in low overlap between nodes. In addition, Pearson’s correlation coefficient depends on the 
sample size and therefore it can influence the structure of a network (Ahlgren, Jarneving, & 
Rousseau, 2003).  
Since implicit networks are present in almost every field of science and inferred from a sample of 
some population, it is necessary to see how sample size influences their structures. The 
conclusions from network analysis can be biased if the network is invalid. Therefore, it becomes 
important to study the behaviour of networks created using different indexes and different sample 
sizes. In this paper, the primary objective is to understand how sample size impacts the structure 
of an implicit network developed using different indexes. We want to study the impact of sample 
size on networks created using Pearson’s correlation Index and a cosine index known as Salton 
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Cosine Index (Salton & McGill, 1986). Salton Cosine Index is unaffected by the sample size and 
only considers the co-occurrences and prevalence of nodes.  
As mentioned earlier, we want to study how sample size impacts the structure of networks. The 
structure of a network can be measured using multiple network properties such as node centrality, 
clustering coefficient, density and others. In addition, the overall topology of a network (random, 
scale-free or small-world) can be assessed to understand the overall structure. Moreover, using a 
large real-world dataset, we offer useful and well-supported recommendations on desirable 
sample sizes for creating a valid implicit network. 
To demonstrate our method and analysis, we demonstrate an implicit network known as 
comorbidity network. Comorbidity is a medical condition when two or more diseases are present 
simultaneously in a patient (Feinstein, 1970). Comorbidity networks have been mostly developed 
using inductive reasoning and are data driven. The relationships between diseases are inferred 
from the sample. We illustrate how sample size impacts the structure of a comorbidity network 
developed using Pearson’s correlation coefficient and Salton Cosine Index.  
The rest of the paper is organized as follows. In the next section, we elaborate on the 
mathematical formulations of a network, overall topologies, and network properties. Then, we 
explain comorbidity and a process to create comorbidity networks using Pearson’s correlations 
coefficient and Salton’s Cosine Index. We then explore and compare the disease associations in 
different sample sizes. Next, the results are discussed. Finally, we conclude by discussing 
implications. 
2.2. METHODOLOGY 
2.2.1. NETWORK 
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A network comprises nodes connected through defined edges. To create an undirected implicit 
network i.e. a network with no directions in the relationships, one has to define a transaction 
containing the related nodes. These transactions will be used to explain whether the connection 
between two nodes exists or not. A network C developed from N transactions is denoted by C (D, 
E) in which D is a set of n nodes and E is a set of edges.  
An edge Eij is created between two nodes di and dj (i, j = 1 to n) where i<j in the undirected 
network. Since we want to compare networks created using two indexes, we define an edge 
mathematically based on these two indexes i.e. Pearson’s correlation coefficient (PCC) and 
Salton Cosine Index (SCI). We want to select the appropriate index to create a network.  
In the network using PCC, the coefficient Sij of an edge Eij between nodes di and dj is calculated as 
 𝑆𝑖𝑗 =
(𝑐𝑖𝑗∗𝑁)(𝑐𝑖∗𝑐𝑗)
√(𝑐𝑖∗𝑐𝑗)(𝑁−𝑐𝑖)(𝑁−𝑐𝑗)
  -(2.1) 
where cij is the count of transactions containing both i and j nodes, ci is the count of transactions 
containing i and cj is the count of transactions containing j. The maximum number of edges 
possible among n nodes is (n(n-1)/2). However, we considered edges based on statistical 
significance of the PCC. We calculated T-statistic using Sij of the edges as in equation 2.2. 
Following the most conservative approach, we used the cij (minimum of cij, ci, and cj) as the 
degrees of the freedom. Using the T-statistic, we developed networks at α=0.01, T>2.58 and 
cij>∑cij /p, where p is maximum number of pairs. 
 T=
𝑆𝑖𝑗√𝑐𝑖𝑗−2
√1−𝑆𝑖𝑗
2
     -(2.2) 
In the network using Salton Cosine Index, SCIij, of an edge between diseases di and dj is 
calculated as in equation 2.3. It considers the individual prevalence of the two nodes (ci and cj) 
and their joint prevalence (cij).  
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 𝑆𝐶𝐼𝑖𝑗 =
(𝑐𝑖𝑗)
√(𝑐𝑖∗𝑐𝑗)
   -(2.3) 
Unlike the correlation coefficient, this measure is unaffected by the sample size, N; however, it is 
difficult to find its statistical significance. Usually, a cut-off for SCI is defined. We use the 
relationship between PCC and SCI to find a cut-off for SCI as suggested by Egghe & Leydesdorff 
(2009). We present an approach that results into edges that are correlated significantly. The steps 
followed to find a cut-off are as follows: 
Step 1.  For each pair of nodes, calculate number of co-occurrences, Pearson’s 
Correlation Coefficient and Salton Cosine Index in the population dataset (largest 
sample size) 
Step 2. Find number of pairs (q) significantly correlated at α=0.01 and cij>∑ 𝑐𝑖𝑗/p, where 
p is maximum number of pairs 
Step 3. Find Salton Cosine Index as the cutoff (Sc) where the number of pairs is equal to 
q and cij>∑ 𝑐𝑖𝑗/p 
Step 4. Use Sc as the cutoff to find edges in different sample sizes 
 
We use the above process to create networks from samples of different sizes using PCC and SCI 
and then compare them. The effect of sample size is measured in terms of overall network 
topologies and node properties as explained in the next section.  
2.2.2. NETWORK TOPOLOGIES 
To understand the structure of a network as a whole, one can find the topology of a network. A 
topology is a global property of a network. Knowing the overall structure will specify the 
behavior of a network in a particular context. For example, epidemic spread depends on the 
network topology (Ganesh, Massoulié, & Towsley, 2005). In this research, we look at the overall 
structure of a network and understand its dependency on the sample size. 
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Figure 2.1. Network 1 
The most common topologies are random, scale-free and small-world. A network is called a 
random network if connections between a set of nodes are randomly connected using a defined 
probability (Erdos & Rényi, 1960; Erdős & Rényi, 1959). The degree of a random network 
follows binomial distribution. A network is called a scale-free network when a network contains 
hubs in it (Barabási & Albert, 1999). The degree distribution of the nodes in a scale-free network 
follow a power-law distribution. Finally, a network is called a small-world network when there 
are several clusters in a network, making the distance between nodes smaller (Watts & Strogatz, 
1998). The degree of a small-world network can follow any distribution but the average 
clustering property is higher than the random network.  
2.2.3. NETWORK METRICS 
The structure of a network can be measured using several network metrics. A network has several 
inherent properties that can be observed at the node level. We describe multiple network 
properties briefly in the sub-sections below. The definitions are also listed in Table 1.1, which we 
will use to analyze the impact of sample size on a network in later sections.  
2.2.3.1.NODES AND EDGES 
Nodes are the elements among which relationships are studied. In 
Figure 2.1, the circles A, B, C and D are four different nodes that 
are related to each other.  
It can be observed in Figure 2.1 that A is connected to C, C is connected 
 to A and B, B is connected to C and D and finally D is connected to B.  
These connections are represented by the lines or edges. These lines represent some relationships. 
So, before creating a network, there is a need to define the relationship between the nodes.  
B 
A 
C 
D 
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The edges in Figure 2.1 do not have directions and hence, it is an undirected network. In addition, 
the edges can also have weights. The weight represents the strength of a relationship. The edges 
in Figure 2.1 have weights and are represented by their thickness. The weight of the edge between 
B and C is the largest, followed by the edge between A and C, and then the edge between B and 
D have the smallest weight.  
2.2.3.2.DEGREE AND WEIGHTED DEGREE CENTRALITY 
An important property of a node in a network is its centrality. Centrality can be broadly defined 
as the importance of a node in the network. There are multiple ways to define a centrality. We 
report on four types of node centralities: degree, betweenness, closeness and eigenvector 
centrality. 
Degree centrality is a simplest property of the nodes in a network. Degree of a node explains its 
number of direct connections (Freeman, 1979). Let us reconsider the Figure 2.1. Here degree of 
node A is 1, B is 2, C is 2 and D is 1. As discussed earlier, the edges are undirected in our 
networks. However, if an edge has direction, two types of degrees are there: in-degree (number of 
edges coming in) and out-degree (number of edges going out).  
Moreover, if weights of the edges are considered to calculate 
degree, it is called the weighted degree of a node. Let us consider 
the network shown in Figure 2.2 where the weight of an edge 
between A and C is Wac, B and C is Wbc and B and D is Wbd. Then 
the weighted degree of a node is given by the sum of the weights of 
the direct connections. 
Weighted Degree of A = Wac, 
Weighted Degree of B = Wbc + Wbd, 
Figure 2.2. Network 2 
B 
A 
C 
D 
Wac 
Wbc 
Wbd 
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Figure 2.3. Network 3 
Figure 2.4. Network 4 
Weighted Degree of C = Wbc + Wac and 
Weighted Degree of D = Wbd 
2.2.3.3. BETWEENNESS CENTRALITY 
Another important network property of a node is its betweenness. The number of times a node is 
on a shortest path among all shortest paths (Freeman, 1979). In an undirected network, 
betweenness of a node i is 
              bi = ∑
𝜎𝑠𝑡(𝑖)
𝜎𝑠𝑡
𝑠≠𝑖≠𝑡  ,          
                                                                                                                         
where 𝜎𝑠𝑡 is total number of shortest paths from node s to node t 
and 𝜎𝑠𝑡(𝑖)  is the number of those paths that pass through i. In 
Figure 2.3, betweenness of A is 15 because it is on every path 
from all other pair of nodes and there are total 15 paths. All other 
nodes have betweenness of 0. 
2.2.3.4. CLOSENESS CENTRALITY 
Closeness of a node i gives the average shortest distance of that node to all other nodes in the 
network. Closeness is a node i in the network of n nodes is given by  
                                        Cc(i) = 
∑ 𝑑(𝑖,𝑗)𝑛−1
𝑛−1
 ,                                                                               
where d(i, j) is the shortest distance between i and j. 
 
 
 
In Figure 2.4, the closeness centrality of G is given by (1+2+3+4+5+6/6) = 3.5. Similarly, the 
closeness centrality of D is (1+2+3+1+2+3) = 2. It means that the average shortest distance of 
A 
B 
C 
G 
D 
F 
E 
A B C G D F E 
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Figure 2.5. Network 5 
node D is smaller than the node G. An inverse of the number is usually calculated to present that 
the higher the number, the higher the closeness.  
2.2.3.5. EIGENVECTOR CENTRALITY 
An eigenvector centrality of a node explains how well the direct connections of a node are also 
connected (Bonacich, 1987). It considers all the relationships in the network and assigns a relative 
score to every node. It can be understood as a degree centrality that spans the entire network. 
2.2.3.6. CLUSTERING COEFFICENT 
The clustering coefficient explains the small clusters formed by the nodes. The clustering 
coefficient of a node explains how well the neighbors of a node are connected (Watts & Strogatz, 
1998).  The clustering coefficient of a node, i, explains how well the direct connections of the 
node, i, are connected to each other. The clustering coefficient, Ci, of a node can be 
mathematically written as 
𝐶𝑖 =
2𝑙𝑖
𝑘𝑖(𝑘𝑖−1)
, 
where li is the number of links among the neighbors of the node i and ki is the degree of a node i. 
In Figure 2.5, node i has three connections (A, B and C). Among 
three nodes, maximum three links are possible (A-B, B-C and A-C). 
However, only one link i.e. A-B is present. Hence, the clustering co-
efficient of the node i is 1/3. Similarly, the clustering co-efficient of 
the other nodes can be calculated. 
 
 
i 
A 
B 
C 
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2.2.3.7.NETWORK DENSITY 
Density of a network is the proportion of edges present in the network. Density of a network with 
n nodes and E edges (undirected) is given by the ratio of number of edges present to the 
maximum number of edges possible. 
Network Density = 
𝐸
𝑛(𝑛−1)/2
 
Table 2.1. Definitions of network measures 
Network Measure Definition 
Nodes Nodes or vertexes are the elements among which relationships are studied. 
Edges An edge represents the relationship between nodes. 
Degree centrality Degree of a node explains its number of direct connections (Freeman, 
1979) 
Weighted Degree Degree calculated considering the strength of an edge. 
Betweenness 
Centrality 
Number of times a node is on a shortest path among all shortest paths 
(Freeman, 1979) 
Closeness 
Centrality 
Closeness of a node gives the average shortest distance of that node to all 
other nodes in the network (Freeman, 1979). 
Eigenvector 
Centrality 
Eigenvector centrality of a node explains how well the direct connections 
of a node are also connected (Bonacich, 1987). 
Clustering 
Coefficient 
The clustering coefficient of a node explains how well its neighbors are 
connected (Watts & Strogatz, 1998).   
Network Density Density of a network is the proportion of edges present in the network. 
2.3. ILLUSTRATION 
We illustrate the impact of sample size on the comorbidity network, an implicit network. We will 
first define comorbidity in our context and then explain the process to create a comorbidity 
network. 
2.3.1. COMORBIDITY 
Comorbidity is a medical condition when a patient is diagnosed with two or more diseases. 
Feinstein (1970) defined comorbidity as the presence of any other disease or complication in 
addition to the primary disease. The diseases present simultaneously can exist independently, or 
one disease causes another making them interdependent (Jakovljevic & Ostojic, 2013). These 
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conceptualizations do not consider the lifetime history of a patient but looks into the presence of 
diseases during a hospital visit. In other words, previous definitions focus on a much smaller 
timespan of a patient. Focusing on current patient information can help physicians to control 
comorbidities, but how the history of a patient is related to the current situation is not understood. 
If we look into the lifetime history of patients and find relationships between diseases, this can 
provide us additional understanding about comorbidities. In this paper, we delineate comorbidity 
considering the lifetime history of a patient rather than a single hospital visit. We define 
comorbidity as the presence of multiple diseases in the lifetime history of a patient. This 
definition has two advantages over previous definitions. First, the medical recording of a disease 
over multiple hospitals visits is only considered once. Considering the same disease as different 
across hospital visits can overestimate its presence and bias the analysis and conclusions. Second, 
our definition incorporates the impact of a disease on other diseases across multiple hospital 
visits, thereby incorporating the wider span of disease development. We use multiple similarity 
indexes to define a comorbidity that helps us to define it validly.  
2.3.2. COMORBIDITY NETWORK 
To create comorbidity networks, we used a real-world massive dataset from Electronic Medical 
Record (EMR). We obtained data from the Center for Health Systems Innovation (CHSI), a 
center at Oklahoma State University that houses data provided by Cerner Corporation, a major 
EMR provider. The data warehouse contains an EMR on the visits of more than 58 million 
unique patients across US hospitals (2000-2016). Among 58 million patients, nearly 24.7 million 
patients were diagnosed with at least one disease or a symptom. Moreover, there were 2.6 million 
patients who were coded only with symptoms. We did not use those patients in our analysis and 
extracted the remaining 22.1 million patient records for creating comorbidity networks. 
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We create a comorbidity network in which connections between diseases (nodes) are developed if 
diagnosed in the patients simultaneously. As noted in other implicit networks, a common way to 
define an association between two diseases is through their correlation in the database (Hidalgo et 
al., 2009). It can be useful to find the most correlated diagnoses but with a small sample, rare 
associations might not be captured because a correlation depends on the sample size (Egghe & 
Leydesdorff, 2009). Therefore, if the purpose is to find highly correlated diseases, Pearson’s 
Correlation Coefficient can be used to find them if the sample size is sufficient. However, if the 
purpose is to find rare or less correlated disease associations, PCC should only be used with large 
sample sizes. In contrast, Salton Cosine Index (Salton & McGill, 1986) does not account for the 
sample size but only considers the co-occurrences and prevalences of the diseases forming an 
edge. The cosine index has been used in the past to find phenotype overlaps (Chen et al. 2015; 
Lage et al. 2007); however, we propose it for finding the strength of a comorbidity. 
For this research, we require a transactional dataset to create a comorbidity network. In the past, a 
hospital visit in the EMR was considered as a transaction (Hidalgo et al., 2009), but as noted 
earlier, considering a hospital visit as a transaction to define a comorbidity has several 
shortcomings. Based on our definition of comorbidity, we consider the lifetime history of a 
patient as a transaction. A transaction contains multiple diseases diagnosed over time. The 
presence of multiple diseases in a patient throughout his lifetime are used to create associations 
between diseases. 
In our comorbidity network, nodes represent diagnoses. In an EMR, diagnoses are classified 
using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM). An ICD-9 code has three, four, or five digits (xxx.xx). The first three digits represent the 
broader category of a disease. The fourth and fifth digits represent the sub-divisions of a disease. 
For example, the ICD-9 code for viral hepatitis is 070. At the four-digit level (070.x), there are 
eight types of viral hepatitis and at the five-digit level (070.xx), two other viral hepatitis are 
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coded. We aggregated ICD-9-CM codes to the three-digit level. Thus, variations of the same 
disease were considered as one node in the network. For example, there were multiple types of 
viral hepatitis but there was only one node for this disorder in our network. There are both 
advantages and disadvantages of aggregation. An advantage is the reduction in measurement bias. 
In contrast, the disadvantage is the compromise of granularity as different classes of the same 
disease can have a dissimilar impact. 
An edge was created between two diseases if they were comorbid. As there is no strong evidence 
regarding which disease leads to which other disease, we created an undirected network with no 
direction in the relationships. Using the process explained in the method section, we created 
twenty different comorbidity networks, ten each using Pearson’s correlation coefficient and 
Salton Cosine Index from different samples described in the following sections.  
2.4. ANALYSIS AND RESULTS 
2.4.1. SAMPLING AND COMORBIDITY NETWORKS 
The steps to find the influence of sample size on network structures are presented in a flowchart 
in Figure 2.6. First, information about patients, hospitals, types of visits, and diseases developed 
by the patients were joined for further analyses. The diseases were recorded according to the 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). 
There were several hospital visits in which patients were not diagnosed with any type of disease 
at all. These patients and hospitals were not considered for further analyses. 
In the second step, entries with invalid admission and discharge date/time and those with invalid 
entries for the disease were removed. We then aggregated the ICD-9 disease codes into three-
digit codes. At this stage, we had approximately 22.1 million unique patients with sufficient 
information to perform analysis. After data cleaning and preparation, we created ten random 
samples of patients starting from 100% of the patients to as small as 1000 patients. The values of 
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the network measures can be evaluated by taking multiple random samples from the same pseudo 
population and analyzing the variation in the values, as suggested by Wolda (1981).  We followed 
the same process suggested by the Wolda (1981) and drew ten samples. The ten random samples 
included: 1) 22.1 million patients (100%), 2) 11.1 million patients (50%), 3) 5.5 million patients 
(25%), 4) 2.75 million patients (12.5%), 5) 1.38 million patients (6.25%), 6) 500,000 patients, 7) 
250,000 patients, 8) 100,000 patients, 9) 50,000 patients and 10) 1000 patients.  
 
Figure 2.6. Flowchart of data preparation and analysis 
Step 2: Data cleaning and Preparation 
 Used three-digit ICD-9-CM disease 
codes 
 Removed error entries in the disease 
coding 
 Removed invalid entries in 
admission and discharge date time 
 Removed NULLs in the diseases 
Disease data 
Patient Data 
Step 1: Joined Hospital visit dataset with 
patient and disease datasets  
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From the ten random samples, comorbidity networks were created using PCC and SCI. PCCs of 
the edges and their statistical significance were calculated. From the comorbidity network of 22.1 
million patients, we found 14,463 significant edges with Pearson’s correlation coefficient 
significant at α=0.01. In the network developed from 22.1 million patients with SCI, at 14,463 
edges, the cutoff for SCI was 0.04. We compared the edges incorporated by the two indexes and 
found more than 95% of the edges to be common. The relationship between the two indexes is 
depicted in Figure 2.7. The majority of edges (more than 95%) at the SCI cutoff of 0.04 were also 
highly correlated (p<0.01). Therefore, from here onwards, we consistently use SCI cutoff of 0.04 
for creating an edge in all comorbidity networks. 
 
 
 
We created twenty different networks, ten each using Pearson’s correlation coefficient at p<0.01 
and Salton Cosine Index with minimum value of 0.04. We present a visualization of one 
comorbidity network in Figure 2.8. In the visualization, the diseases are colored based on the 17 
categories described by the ICD-9-CM. Size of a node represents its number of direct 
connections. It can be observed that some diseases are highly connected to other diseases whereas 
some are not connected at all. Some groups of diseases can also be observed indicating that the 
cluster of diseases are often diagnosed together in the patients.  
Pearson’s Correlation Coefficient 
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Figure 2.7. Pearson’s Correlation Coefficient vs. Salton Cosine Index 
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Figure 2.8. Comorbidity Network. A circle is a disease; an edge represents a comorbidity. Size of a node explains how well it is connected 
to other nodes. 
ICD-9 Code: Description 
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The number of nodes and edges in all twenty networks are listed in Table 2.2. At the three-digit 
ICD-9 code level, there were 908 unique diseases or nodes in the network. The number of nodes 
remained the same until we decreased the random sample below 500,000 patients. The random 
sample of 250,000 patients contained almost 99% of nodes, the sample of 100,000 patients 
contained more than 97%, and the sample of 50,000 patients contained almost 95% of the nodes; 
however, the sample of 1000 contained substantially less diseases at only 63% of the total 
diseases. 
 
 
While the number of nodes did not decrease substantially until the patient sample was below 
50,000, the number of significantly correlated edges (p<0.01) in the network using PCC reduced 
with the decrease in sample size. The network created using 22.1 million patients comprised of 
14,463 edges but the network using half of the patients contained 11,088 edges. Further, the 
network developed using 1000 random patients only had five significantly correlated edges 
(comorbidities or pairs of diseases).  
On the other hand, the number of edges in the networks created using SCI did not change 
significantly with the number of edges remaining almost the same until the sample size decreased 
to 250,000 patients. In fact, looking at the density of the network, the density of networks using 
SCI remained the same throughout all the samples. On the other hand, the density drastically 
changed in the networks created using PCC. The change in density of the two types of networks 
with the indicated sample sizes are plotted in Figure 2.9. 
Table 2.2. Comorbidity networks nodes and edges 
No. of 
Patients 
22.1 M 11 M 5.5M 2.75M 1.38 M 500,000 250,000 100,000 50,000 1000 
Nodes 908 908 908 908 908 908 898 885 859 573 
Edges 
PCC 14,463 11,088 8,354 6,120 4,284 2,506 1,632 866 508 5 
SCI 14,463 14,311 14,283 14,238 14,195 14,178 14,073 13,769 13,502 5,935 
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2.4.2. EFFECT OF SAMPLE SIZE ON THE OVERALL STRUCTURE OF COMORBIDITY 
NETWORK 
Next, we demonstrate that the comorbidity network exhibits the small-world phenomenon (Watts 
& Strogatz, 1998). A network possesses a small-world property when multiple dense clusters are 
present in the network but the average path length (average distance between all pairs of nodes) is 
small, like a random network.  The clustering coefficient, C, is a measure of a small-world 
network and explains the small clusters formed by the diseases. The clustering coefficient of a 
node explains how well the neighbors of a node are connected (Watts & Strogatz, 1998).  With 
respect to the comorbidity network, the clustering coefficient of a disease, d, explains how well 
the direct connections of the disease, d, are connected to each other. The average clustering 
coefficient of the comorbidity network developed using 22.1 million patients was 0.487 
(including all nodes). This means that on average 48% of the links were present among the 
neighbors of every node. The clustering coefficient of a node d can be mathematically written as 
 𝐶𝑑 =
2𝑙𝑑
𝑘𝑑(𝑘𝑑−1)
, -(2.4) 
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Figure 2.9. Density of networks from different sample sizes using Correlation and Salton Cosine 
Index 
No. of Patients 
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where ld is the number of links among the neighbors of the node d and kd is the degree of a node 
d. For a network to possess small-world property, we require n>>k>>ln(n)>>1 (where n is the 
total number of nodes in the network) to make sure that the network is not disconnected into 
multiple sub-networks. In addition, two other conditions must be present: 1) the average path 
length of the network (Pcom) needs to be approximately the same as the random network (Prand) 
with the same parameters such as the number of nodes (n) and the average degree (k), and 2) the 
average clustering coefficient, Ccom, of the network requires it to be greater than the average 
clustering coefficient of an equivalent random network (Crand).  
To calculate the small-world property of all our networks, we focused on the giant connected 
component of each network. A giant component contains the maximum number of connected 
nodes either directly or indirectly connected. For example, the largest connected component of 
the network with 22.1 million patients using Pearson’s correlation coefficient contained 624 
nodes or diseases (n) with the average degree of this largest connected component being 46.3 (k).  
The average path length and clustering coefficient of a random network with n=624 and k=46.3 
can be calculated as Prand ~ ln(n)/ln (k) and Crand ~ k/n respectively. 
 Prand ~ ln (n)/ln (k) ~ 1.68 -(2.5) 
 Crand ~ k/n ~ 0.074 -(2.6) 
The actual average path length of our network is 2.452 (>~Prand) and the actual average clustering 
coefficient is 0.69 (>>Crand). These numbers meet the requirements for the small-world property 
and hence, we prove that our comorbidity network followed the small-world topology. The 
largest connected component’s number of nodes (n), average degree (k), average path length 
(Pcom), average clustering coefficient (Ccom), as well as the random network average path length 
(Prand) and average clustering coefficient (Crand) are listed in Table 2.3. 
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We compared the change in network structures of all the networks developed using PCC and SCI. 
Figures 2.10a to 2.10e compare the different features of the network topologies. As sample size 
decreases, the number of nodes in the largest connected component of network using Pearson’s 
correlation coefficient (PCC) decreases drastically. In contrast, the number of connected nodes in 
the network using Salton Cosine Index did not change until we decreased the sample size to 1.38 
million patients. Further reducing the sample size, the number of connected nodes started 
Table 2.3. Features of networks related to their topologies 
Sample Size n k Prand ~ ln (n)/ln (k) Crand ~ k/n Pcom Ccom 
22.1 Million Patients 
PCC 624 46.3 1.68 0.074 2.452 0.69 
SCI 631 45.8 1.69 0.072 2.460 0.69 
11 Million Patients 
PCC 591 37.5 1.76 0.060 2.620 0.67 
SCI 624 45.8 1.68 0.073 2.450 0.70 
5.5 Million Patients 
PCC 540 30.9 1.83 0.057 2.760 0.66 
SCI 619 46.0 1.68 0.074 2.440 0.70 
2.75 Million Patients 
PCC 483 25.2 1.91 0.052 2.900 0.61 
SCI 617 46.0 1.68 0.075 2.440 0.70 
1.38 Million Patients 
PCC 411 20.7 1.99 0.050 3.080 0.60 
SCI 612 46.0 1.68 0.075 2.430 0.70 
500,000 Patients 
PCC 310 15.8 2.08 0.050 3.158 0.59 
SCI 592 47.8 1.65 0.080 2.380 0.72 
250,000 Patients 
PCC 240 13.2 2.12 0.055 3.145 0.60 
SCI 584 48.0 1.65 0.080 2.362 0.73 
100,000 Patients 
PCC 171 9.80 2.25 0.057 3.930 0.55 
SCI 565 48.66 1.63 0.086 2.328 0.73 
50,000 Patients 
PCC 104 8.60 2.16 0.082 2.827 0.59 
SCI 550 49.0 1.62 0.089 2.273 0.73 
1000 Patients 
PCC - - - - - - 
SCI 399 29.7 1.77 0.074 2.204 0.72 
n-number of node  
k-average degree  
Prand-average path length of random network 
Pcom- average path length of our comorbidity network  
Crand-average clustering coefficient of random network  
Ccom-average clustering coefficient of comorbidity network 
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decreasing. With respect to the change in the path length of the networks, we can observe in 
Figures 2.10b and 2.10c that the difference between Prand and Pcom remained almost constant in 
the two types of networks. In the network using PCC, Prand and Pcom slightly increased with the 
decrease in sample size but the difference between the two remained constant until the sample 
size decreased to 250,000 patients. In contrast, in the network using SCI, Prand and Pcom remain 
almost the same with the decrease in sample size. The difference between the two remained 
constant until the sample size of 50,000 patients. 
A similar trend in the clustering coefficients of the two types of networks can be seen in Figures 
2.10d and 2.10e. In the network using PCC, there is a slight random variation in the Ccom with the 
change in sample size, but the difference between Crand and Ccom remained relatively large to keep 
the overall structure intact. We found the same dynamics in the network using SCI. The 
clustering coefficient Ccom remained the same in all samples and the difference between Crand and 
Ccom remained constant keeping the overall structure as same.  
For calculating the small-world property of each network, we require n>>k>>ln(n)>>1. As 
sample size decreased in the networks using PCC, the difference between k and ln(n) became 
small. This means the comorbidity network became disconnected and formed multiple 
disconnected sub-networks as the sample size decreased. This violates the requirement for 
calculating the small-world property of the network. Therefore, the decrease in sample size 
affects the small-world property in the network using PCC. However, in the networks using SCI, 
the small-world property persists throughout. Overall, SCI preserved the overall structure of the 
network with small sample size but PCC could not. 
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2.4.3. EFFECT OF SAMPLE SIZE ON NETWORK METRICS 
When comparing the network metrics, we found interesting results (Table 2.4 lists the definitions 
of each metric along with the interpretation within the disease network context of our study). 
First, the influence of sample size on the measures is presented in Table 2.5 and Figures 2.11a to 
2.11h. In the networks created using PCC, all measures decreased with the sample size as 
observed in the figures; however, in the networks using SCI, we found that the average degree, 
average weighted degree, average closeness, average clustering coefficient and average  
Figure 2.10a. Number of nodes in largest connected component 
Figure 2.10b. Average path length in PCC network Figure 2.10c. Average path length in SCI network 
Figure 2.10d. Average clustering coefficient in 
PCC network 
Figure 2.10e. Average clustering coefficient in 
SCI network 
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Table 2.4. Network measures and their interpretation in our context 
Network Measure Definition Interpretation in our context 
Degree centrality Degree of a node explains its number of 
direct connections (Freeman, 1979) 
Degree of a disease is the 
number of diseases directly 
connected. 
Weighted Degree Degree calculated considering the 
strength of an edge. 
Degree considering 
comorbidity strength. 
Betweenness 
Centrality 
Number of times a node is on a shortest 
path among all shortest paths (Freeman, 
1979) 
Number of times a disease is a 
bridge between pairs of 
diseases. 
Closeness 
Centrality 
Closeness of a node gives the average 
shortest distance of that node to all 
other nodes in the network (Freeman, 
1979). 
Closeness centrality of a 
disease would represent how 
close a disease is to all other 
diseases in the network. 
Eigenvector 
Centrality 
Eigenvector centrality of a node 
explains how well the direct 
connections of a node are also 
connected (Bonacich, 1987). 
How well the neighbors of a 
diseases are related to other 
diseases. 
Clustering 
Coefficient 
The clustering coefficient of a node 
explains how well its neighbors are 
connected (Watts & Strogatz, 1998).   
Clustering coefficient of a 
disease explains how well the 
direct connections of the 
disease are connected to each 
other. 
Network Density Density of a network is the proportion 
of edges present in the network. 
It explains how dense is the 
disease network. 
 
 
eigenvector centrality of the networks remained constant until we decreased the sample size to 
1000, where we see fluctuation in all the measures. Hence, the network using as small as 50,000 
patients remains consistent with respect to the network measures. On the other hand, we observed 
that the average betweenness of the networks is the most inconsistent network measure among all. 
The average betweenness of the network did not change until we decreased our sample size to 1.38 
million patients; however, it suddenly decreased with the smaller sample sizes. Hence, with the 
smaller sample size, average betweenness is not a valid measure to make conclusions. 
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Table 2.5. Comorbidity networks properties 
No. of 
Patients 
22.1 M 11 M 5.5M 2.75M 1.38 M 500,000 250,000 100,000 50,000 1000 
Average Degree Centrality 
PCC 31.857 24.42 18.4 13.48 9.436 5.52 3.635 1.957 1.183 0.017 
SCI 31.859 31.52 31.46 31.36 31.267 31.229 31.343 31.116 31.437 20.72 
Average Weighted Degree Centrality 
PCC 1.983 1.74 1.5 1.263 1.023 0.731 0.554 0.358 0.245 0.009 
SCI 2.516 2.498 2.494 2.49 2.48 2.478 2.493 2.505 2.557 2.989 
Average Betweenness Centrality 
PCC 310.78 311.1 282.94 243.69 193.49 114.1 68.72 48.29 11.74 -- 
SCI 319.9 311.2 303.96 301.88 293.41 265.39 258.23 239.1 223.82 166.9 
Average Closeness Centrality 
PCC 0.297 0.267 0.246 0.218 0.188 0.15 0.135 0.084 0.089 -- 
SCI 0.298 0.296 0.295 0.294 0.294 0.289 0.289 0.29 0.297 0.323 
Graph Density 
PCC 0.035 0.027 0.02 0.015 0.01 0.006 0.004 0.002 0.001 -- 
SCI 0.035 0.035 0.035 0.035 0.034 0.034 0.035 0.035 0.037 0.036 
Average Clustering Coefficient 
PCC 0.487 0.445 0.4 0.333 0.282 0.218 0.172 0.116 0.092 -- 
SCI 0.487 0.486 0.484 0.484 0.484 0.476 0.478 0.471 0.473 0.5 
Network Diameter 
PCC 6 6 7 8 9 9 8 11 8 1 
SCI 6 6 6 6 6 6 6 5 5 5 
Average Eigenvector Centrality 
PCC 0.146 0.126 0.11 0.092 0.076 0.058 0.046 0.033 0.027 -- 
SCI 0.143 0.142 0.142 0.141 0.141 0.141 0.144 0.145 0.148 0.139 
Figure 2.11b. Average Degree 
Figure 2.11c. Average Weighted Degree Figure 2.11d. Average Betweenness 
Figure 2.11a. Number of edges 
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2.5. DISCUSSION AND CONCLUSION 
In this paper, we set out to study the impact of sample size on an implicit network created using 
Pearson’s correlation coefficient (PCC) and Salton Cosine Index (SCI). We found that PCC is not 
an appropriate index to draw relationships between nodes in an implicit network. The network 
properties and overall topology of the network using PCC get affected by sample size. On the 
other hand, we showed SCI to be an applicable measure for creating an implicit network because 
it does not depend on the sample size.  
We observed that the decrease in sample size reduced the number of statistically significant 
correlated relationships between nodes. In other words, the number of edges in the network using 
PCC decreased with the decrease in sample size. The highly correlated nodes still existed in the 
small sample size but the rare connections did not. Therefore, if the purpose is to find highly 
correlated nodes, PCC can be used. However, if the objective is to make conclusions on rare 
Figure 2.11e. Average Closeness Figure 2.11f. Network Density 
Figure 2.11g. Average Clustering Coefficient Figure 2.11h. Average Eigenvector 
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connections, PCC will not be able to catch those. In contrast, if SCI is used to make an implicit 
network, the same relationships can be observed in the network using small sample size that were 
seen in the network with large sample size. Therefore, it is recommended to use SCI if the sample 
size is small. 
With respect to the overall structure of the network, the network using PCC became disconnected 
with the decrease in sample size. However, the network using SCI possessed the small-world 
topology in the networks from all sample sizes. Because our demonstration was on a small-world 
network, we note here that our conclusions are generalizable to other implicit networks that 
follow the small-world property. Small-world property is observed in the brain network (Bassett 
& Bullmore, 2006), language networks (Solé et al. 2010), social networks, actor-actor network, 
power-grid network, and many others (Watts & Strogatz, 1998).  
Overall, we recommend researchers to consider SCI over PCC to create implicit networks. Our 
analysis is valuable to researchers studying networks as it establishes the need for choosing a 
right measure to create an implicit network for making valid conclusions. 
The large dataset allowed us to study a much wider array of nodes. At the same time, the sample 
does not have to include all the millions of records to provide useful insights. In our analysis, we 
found that one can use a sample of 100,000 patients or 50,000 patients sample to study 
comorbidities or network properties (except betweenness) respectively. However, these numbers 
can vary with the type of network studied. Therefore, we encourage other researchers to perform 
the same analysis in other types of networks. Moreover, our network followed small-world 
topology but other networks may follow a different topology. One must find the specific topology 
of their specific network. 
We add to the network theory by comparing the structure of networks developed using different 
sample sizes. Our recommendation to use SCI over PCC can help study the true relationships in 
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an implicit network. The use of SCI for creating a network preserves its structural properties even 
with smaller sample size. 
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CHAPTER III 
 
 
EXAMINING HEALTH DISPARITIES BY GENDER: A MULTIMORBIDITY NETWORK 
ANALYSIS OF ELECTRONIC MEDICAL RECORD1 
ABSTRACT 
Multimorbidity health disparities have not been well examined by gender. Co-occurring diseases 
may be mutually deleterious, co-occurring independently, or co-occurring from a common 
antecedent. Diseases linked by a common antecedent may be caused by biological, behavioral, 
social, or environmental factors. This paper aims to address the co-occurrences of diseases using 
network analysis. We identify these multi-morbidities from a large Electronic Medical Record 
(EMR) containing diagnoses, symptoms and treatment data on more than 22.1 million patients. 
We create multimorbidity networks from males and females medical records and compare their 
structural properties. Our macro analysis at the organ-level indicates that females have a stronger 
multimorbidity network than males. For example, the female multimorbidity network includes six 
linkages to mental health, wherein the male multimorbidity network includes only two linkages to 
mental health.  The strength of some disease associations between lipid metabolism and chronic 
heart disorders is stronger in males than females. Our multimorbidity network analysis by gender 
identifies specific differences in disease diagnosis by gender, and presents questions for 
biological, behavioral, clinical, and policy research. 
                                                          
1 This paper is under review at a journal. 
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3.1 INTRODUCTION 
Multiple ecological levels interact to influence disparities in health and health outcomes by 
gender. Health disparities observed between genders are caused by genetic, hormonal, 
physiological, behavioral, and sociocultural factors. Life expectancy at birth is notably longer for 
females at 81.4 years compared to males at 76.4 years (National Center for Health Statistics, 
2016). During this longer lifetime, females are more likely to visit the hospital or health care 
provider, but less likely to die (Oksuzyan et al. 2008). Notably this male-female health-survival 
paradox is explained by chronic diseases which are most prevalent by gender: females are more 
likely to experience pain, reproductive cancers, and depression, while males are more likely to 
experience cardiovascular disease and diabetes (Case & Paxson, 2004). Additionally, when males 
and females are compared on the same chronic diseases, males may experience severe cases of 
chronic disease. Previous epidemiological studies of health disparities address individual diseases 
experienced by gender; however, most patients are diagnosed with multiple diseases. The goal of 
this paper is to explore disparities among males and females diagnosed with more than one 
disease, and present research and policy implications. 
Two terms are often used to discuss the presence of more than one disease in a patient: 
comorbidity and multimorbidity. Comorbidity is a condition when an additional disease is 
diagnosed in presence of an index disease (Feinstein, 1970).  Multimorbidity is defined as the 
coexistence of multiple chronic diseases and conditions in a patient (van den Akker, Buntinx, & 
Knottnerus, 1996; van den Akker et al., 1998). Throughout this manuscript we will use these 
terms interchangeably to denote co-occurrence of diseases, unless we need to specifically 
highlight the differences between comorbidity and multimorbidity. Previous studies on 
comorbidities have controlled for gender but rarely focused and reported differences in genders 
explicitly as pointed out by Short, Yang & Jenkins (2013). Further examination of comorbidities 
39 
 
by gender may be critically important for treatment of disease, and in identifying 
contraindications of common pharmaceuticals. The availability of large medical records affords 
the opportunity to study all possible disease relationships as observed in practice. 
We adapt a network approach to model the multimorbidities (Euler, 1953). Networks are formed 
from the interactions between the elements or nodes. Network analysis has been used in health 
and medical literature to understand the interaction of genes (Goh et al, 2007; Ferrazzi et al. 
2007), molecular involvement in disease (Barabási, Gulbahce, & Loscalzo, 2011), drug trials 
(Haslam and Perez-Breva, 2016), and historical epidemiological data on disease phenotypes 
(Hidalgo et al.,2009; Chen and Xu, 2014). Tai and Chiu (2009) applied association rule mining to 
create comorbidity network in ADHD patients using clinical database. Similarly, Chmiel, 
Klimek, and Thurner (2014) applied network approach to study the prevalence of different cluster 
of diseases over lifetime of genders. However, to the best of our knowledge, no one has applied 
this approach to study multimorbidity by gender in order to better understand health disparities.  
In this paper, we develop and compare multimorbidity networks for males and females based on 
ICD-9 (International Classification of Diseases, Clinical Modification) codes of diagnoses. Our 
network comprises diseases connected based on the co-occurrences of diseases in 22.1 million 
patient records. The use of large dataset is another strength of our study. Knowing the 
relationships between diseases at the network level will enhance our understanding about disease 
associations at the patient population level.  
3.2 METHOD AND ANALYSIS 
In this section, we begin by describing the data and explaining how we measure the 
multimorbidity in our context. Next, we present a method to develop a multimorbidity network. 
Then, we briefly describe the properties of the network that can explain the position of a disease 
in a web of other diseases, and help us understand differences between males and females. 
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3.2.1 DATA DESCRIPTION 
We obtained data from the Oklahoma State University Center for Health Systems Innovation 
(CHSI), which houses HIPAA compliant patient data provided by Cerner Corporation, a major 
Electronic Medical Record (EMR) provider. The data warehouse contains an EMR on the visits 
of 58 million unique patients across 662 US hospitals (2000-2016). We used information about 
the demographics of the patients, hospitals and disease diagnoses coded by ICD-9 system2. We 
removed several hospital visits in which patients were either not diagnosed with a disease or were 
marked only for symptoms. After data preprocessing, we had approximately 22.1 million unique 
patients with the sufficient information to perform analysis.   
We extracted medical records for males and females in two different datasets from this pseudo-
population dataset for comparing comorbidities by gender. The datasets were further cleaned 
based on the detected anomalies in particular category. For example, there were a few patients 
who were coded as a male during one visit and a female or null in another. Although males can 
also have breast diseases biologically, we removed the male patients diagnosed with such 
diseases with a suspicion that these are erroneously coded (ICD9: 610-612)3. We also removed 
males who were diagnosed with diseases such as inflammatory diseases of female pelvic organs 
(ICD9: 614-616)4, and complications of pregnancy, childbirth, and the puerperium (ICD9: 630-
679)5. Similarly, we removed female patients diagnosed with diseases of male genital organs 
(ICD9: 600-608)6. After cleaning the data, we had records of 12 million female patients and 9.9 
million male patients. From the two samples, networks were created, one each for males and 
females. 
                                                          
2 From the last quarter of 2016, the diagnoses in Cerner EMR are required to be coded in ICD-10 system. However, we 
did not consider the last quarter to maintain the consistency in our data analysis and considered only ICD-9 codes. 
3 There were 38,980 male patients with ICD-9 codes 610-612, which is 0.34% of the male database. 
4 1,594 patients 
5 20,009 patients 
6 8,627 patients 
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3.2.2 MEASURING MULTIMORBIDITY 
In the past, comorbidity and multimorbidity were largely defined at the cross-sectional level 
(Feinstein, 1970; Jakovljevic and Ostojic 2013). The chronic diseases, which we would not 
expect to go away in one hospital visit, could be overestimated from the medical records because 
they are recorded multiple times in an EMR. However, we delineate multimorbidity considering 
the lifetime history of a patient rather than a single hospital visit. We measure multimorbidity as 
the presence of multiple diseases in the lifetime history of a patient. This measurement has two 
advantages over previous definitions. First, the EMR recording of a disease over multiple 
hospitals visits is only considered once. Considering the same disease as different across hospital 
visits can overestimate its presence and bias the analysis and conclusions. Second, our definition 
considers the impact of a disease in one visit on subsequent visits. Therefore, it incorporates a 
wider span of disease developments. However, there is a concern of taking into account the 
association between diseases diagnosed across hospital visits occurring after long period of time. 
Given the relatively short time span of the database (17 years), short average length between first 
and last hospital visit in the database (527 days), average number of hospital visits of a patient 
being 5.1 (all types of visits including inpatient, outpatient, etc.) and statistical analysis on 
millions of patients, we mitigate the concern of false positives. 
3.2.3 MULTIMORBIDITY NETWORK  
A multimorbidity network developed from patients contains a set of nodes connected through 
edges. In our network, nodes represent diseases. In an EMR, an ICD-9 code of a disease has 
three, four or five digits (xxx.xx). The first three digits represent the broader category of a 
disease. The fourth and fifth digits represent the sub-divisions of the disease. For example, the 
ICD-9 code for personality disorder is 301. At four-digit level (301.x), there are ten types of 
personality disorders and at five-digit level (301.xx), two other specific personality disorders are 
coded. We aggregated ICD-9-CM codes to three-digit level. Thus, variations of the same disease 
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were considered as one node in the network. For example, multiple types of personality disorders 
mentioned above were aggregated into one node in our network.  
An edge or connection between two diseases is created if these are comorbid. Since our focus is 
not to establish causality of a multimorbidity, we created a network with no direction in the 
relationships. For example, the comorbidity comprising congestive heart failure and rheumatic 
heart disease will be represented as an undirected edge between the two nodes representing the 
two diseases regardless of their causal relationship. 
In the past, associations between diseases or comorbidities were modeled using a simple 
Pearson’s correlation coefficient (Divo et al., 2015; Hidalgo et al., 2009). However, number of 
significant correlations is directly proportional to the number of observations used. Power to 
detect rare comorbidities is low because of the rareness of events. Therefore, to establish the right 
measure to model a comorbidity, we use a cosine index known as Salton Cosine index (Salton & 
McGill, 1986). SCI is immune to the total number of observations used (Ahlgren, Jarneving, & 
Rousseau, 2003) and measures the prevalence of a relationship between two diseases considering 
their individual prevalence. Salton Cosine Index, SCI, is calculated as in equation (1), where cij is 
the number of co-occurrences of diseases i and j, ci is the prevalence of disease i and cj is the 
prevalence of disease j. The cosine similarity has been used in the past to find phenotype overlaps 
(Chen et al. 2015; Lage et al. 2007). We propose this as an appropriate measure for finding the 
strength of a comorbidity. 
𝑆𝐶𝐼𝑖𝑗 =
(𝑐𝑖𝑗)
√(𝑐𝑖∗𝑐𝑗)
  –  (1) 
Statistical significance of SCI was determined by assessing the relationship between correlation 
and SCI, because this approach has been suggested in the past to find the cut-off for SCI (Egghe 
& Leydesdorff, 2009). First, we determined the number of comorbidities significantly correlated 
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in a network created using Pearson’s correlation coefficient. Then, we related the number of 
comorbidities in the network created using Salton Cosine Index and found a cut-off where 
number of significantly correlated comorbidities are equal in both networks. In the network from 
entire database using Pearson’s Correlation Coefficient, at p<0.01, there were 14,463 
significantly correlated comorbidities. Meanwhile, at the SCI cut-off of 0.04, the number of 
comorbidities were 14,463. Therefore, we used the cut-off of 0.04 for creating different networks 
for males and females. Then, the comparison between the networks was made using the network 
measures briefly described in the next section. 
3.2.4 NETWORK METRICS 
The structural properties of a network can be measured using several network metrics. These 
include degree, weighted degree, closeness and betweenness centrality (Freeman, 1979). In a 
multimorbidity network, the degree centrality of a disease (node) denotes the number of direct 
connections with other diseases. The weighted degree centrality of a disease considers the 
strength of the relationships with others and is calculated as a weighted sum of the strengths of 
the relationships. The closeness centrality of a disease determines an average number of steps it is 
away from other diseases in the network. A disease with higher closeness has a higher risk of 
being diagnosed with other diseases in less number of steps. Finally, the betweenness centrality of 
a disease describes its bridgeness. In other words, a disease with higher betweenness tends to be 
forming more bridges between other diseases.  
3.3 RESULTS AND DISCUSSION 
3.3.1 COMPARISON OF MALE AND FEMALE MULTIMORBIDITY NETWORKS 
The visualizations of female and male multimorbidity networks are presented in Figures 3.1a and 
3.1b respectively. In the visualization, the diseases are color coded based on the 17 
categories/classes/organ systems described in the ICD-9 classification. These classes are also 
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listed in Figure 3.1. Size of a disease node represents an association with other disease(s), or its 
number of direct connections to other disease(s). The female multimorbidity network contains 
300 diseases not connected to any other disease as compared to 265 diseases in the male 
multimorbidity network. In the female network, the diseases that are connected to at least one 
other disease in the network form three different sub-networks labelled as connected components. 
There is a primary cluster of diseases in the female network labelled as connected component-1 
suggesting all diseases are associated to each other directly or indirectly. The two secondary 
clusters in the females were for burns (ICD9:941-945, 948, 949) and a pair of appendicitis codes 
(ICD9: 540-541).  
3.3.2 NETWORK PROPERTIES 
The properties of each network are listed in Table 3.1. The number of nodes or diseases in two 
networks are different as some diseases are unique to each gender. There were 839 diseases 
reported in males and 899 unique diseases in females at three-digit ICD-9 codes, that is, 7% more 
unique disease diagnoses in females. In the male network, there were 12,498 comorbidities as 
compared to 14,810 in females. Recall the edge strength denotes the magnitude of comorbidity. 
Out of all the edges detected above, 10,607 were common between both sexes. A pair-wise 
comparison of these 10,607 edge strengths indicates stronger comorbidities among females (t 
value=12.67, p<0.0001).  
Although females have stronger and more comorbidities overall, we found some disease 
associations to be stronger in males than females.7 These include disorders of lipid metabolism - 
chronic ischemic heart disease; disorders of fluid electrolyte and acid base balance - acute kidney 
                                                          
7 It has to be noted that we focus on the top comorbidities based on their strength and not the frequency. In 
addition, comorbidities are discussed if they belong to distinct classes or organ systems listed in Figure 1 and 
Table. 
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failure; benign neoplasm of parts of digestive system and hemorrhoids - diverticula of intestine; 
diabetes - chronic ischemic heart disease; anemias - hypertensive chronic kidney disease; and  
     
     
 
 
Connected  
Component 3: 
ICD-540,541  
(Appendicitis) 
Connected  
Component 1 
Connected  
Component 2: 
ICD-941-945,948,949 
(Burns) 
Connected  
Component 1 
001-139: Infectious and parasitic 
diseases  
140–239: Neoplasms 
240–279: Endocrine, nutritional and 
metabolic diseases, and immunity 
disorders 
280–289: Diseases of the blood and 
blood-forming organs 
290–319: Mental disorders 
320–359: Diseases of the nervous 
system 
360–389: Diseases of the sense 
organs 
390–459: Diseases of the circulatory 
system 
460–519: Diseases of the 
respiratory system 
520–579: Diseases of the digestive 
system 
 580–629: Diseases of the 
genitourinary system 
630–679: Complications of 
pregnancy, childbirth, and the 
puerperium 
680–709: Diseases of the skin and 
subcutaneous tissue 
ICD-9      Description 
Figure 3.1a. Female Multimorbidity Network 
Figure 3.1b. Male Multimorbidity Network 
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disorders of lipid metabolism – cardiac dysrhythmias. The average degree and weighted degree of 
the two networks were statistically different. Although the aggregated closeness and betweenness 
centralities of the two networks were not statistically different, we found several differences with 
respect to specific diseases in the two genders. For instance, acute upper respiratory infections 
and disorders of urethra & urinary tract form relatively more bridges between other diseases in 
females than males. On the other hand, the disorders of skin and subcutaneous tissue form a 
bridge between multiple other diseases more often in males than females. 
3.3.3 ORGAN LEVEL NETWORK COMPARISON 
We aggregated the relationships depicted in the networks in Figures 3.1a and 3.1b at the organ 
system level or class system categorized in the ICD-9 classification (See Table 3.2). We present 
two macro level networks at the class/organ system level in Figures 3.2a and 3.2b for females and 
males, respectively. The diseases of different classes were aggregated at the class level by adding 
up their weights (Salton Cosine Index). We highlight the connections between diagnoses of 
different classes if their aggregated weight is more than ten. This cut-off of ten is to study the 
Table 3.1. Gender multimorbidity networks properties 
 Female Male Pair-wise sample t 
test (Female-Male) 
No. of patients 12 M 9.9 M N/A 
Nodes (Diseases) 899 839 N/A 
Edges (Comorbidities) 14,810 12,498 N/A 
Avg. Degree (Degree of a disease is the number of 
diseases directly connected to it) 
32.948 29.793 6.15, p<0.0001 
Avg. Wt. Degree (Degree calculated as a weighted sum 
of the strength of the comorbidities) 
2.592 2.365 4.50, p<0.0001 
Avg. Betweenness ( Number of times a disease is a 
bridge between pairs of diseases) 
266.9 291.5 -1.78, p=0.07 
Avg. Closeness (Closeness centrality of a disease would 
represent how close a disease is to all the other diseases 
in the network) 
0.293 0.285 0.80, p=0.42 
Graph Density 0.037 0.036 N/A 
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most prevalent relationships. However, one could select a lower cut-off to analyze the rare 
connections.  
We present a unique way to visualize the relationships between disorders of different organ 
systems by creating an outline of a human body and mapping the categories of the diseases on it 
(See Figures 3.2a and 3.2b). In the ICD-9 classification, some categories can be directly related to 
the organ system present on a specific position in human body such as circulatory system (class-
8), mental disorders (class-5), digestive system (class-10), respiratory system (class-9), and 
genitourinary system (class-11). However, other classes such as 1-4, 6-7, and 12-18 cannot be 
related to a specific organ system as listed in Table 3.2.  The classes directly related to an organ 
system are mapped at the positions of the particular organ system in the human body. The classes 
that are not related to a specific organ system are presented outside the human sketch. The size of 
a node denotes the number of connections to other nodes. The width of an edge between two 
classes represents the aggregated weight (aggregated Salton Cosine Index) or the strength 
between them. The same connections can be observed in the Table 3.3 where a comparison is 
made between the two networks. 
Table 3.2. ICD-9 code classification 
Class 
No. 
Description ICD-9 codes 
range 
Mapped on organ 
system 
1 Infectious and parasitic diseases 001–139 No 
2 Neoplasms 140–239 No 
3 Endocrine, nutritional and metabolic diseases, and immunity disorders 240–279 No 
4 Diseases of the blood and blood-forming organs 280–289 No 
5 Mental disorders 290–319 Yes 
6 Diseases of the nervous system 320–359 No 
7 Diseases of the sense organs 360–389 No 
8 Diseases of the circulatory system 390–459 Yes 
9 Diseases of the respiratory system 460–519 Yes 
10 Diseases of the digestive system 520–579 Yes 
11 Diseases of the genitourinary system 580–629 Yes 
12 Complications of pregnancy, childbirth, and the puerperium 630–679 No 
13 Diseases of the skin and subcutaneous tissue 680–709 No 
14 Diseases of the musculoskeletal system and connective tissue 710–739 No 
15 Congenital anomalies 740–759 No 
16 Certain conditions originating in the perinatal period 760–779 No 
178 Symptoms, signs, and ill-defined conditions 780–799 N/A 
18 Injury and poisoning 800–999 No 
                                                          
8 Not considered in the analysis 
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* Class 17 is symptoms and thus not included in the analysis 
 
Table 3.3. Class associations in Female and Male Networks 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 18 
Infectious and parasitic [1]                  
Neoplasms [2]                  
Endocrine, nutritional, 
metabolic, and immunity 
disorders [3]                  
Blood and blood-forming 
organs [4]   M               
Mental disorders [5]   F               
Nervous system [6]   F               
Sense organs [7]                  
Circulatory system [8]   FM FM FM FM            
Respiratory system [9]   FM  F   FM          
Digestive system [10]   FM FM FM   FM FM         
Genitourinary system [11]   FM     FM F FM        
Pregnancy, childbirth, and 
the puerperium [12]                  
Skin and subcutaneous 
tissue [13]                  
Musculoskeletal system and 
connective tissue [14]   FM  F FM  FM F FM F       
Congenital anomalies [15]                  
Perinatal period [16]                  
Injury and poisoning [18]   F  F   FM F F    FM    
Figure 3.2a. Female Organ Comorbidity Network     Figure 3.2b. Male Organ Comorbidity 
Network 
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The Figures 3.2a-3.2b and Table 3.3 show which organ systems diseases are diagnosed 
simultaneously more often in different genders. The female network is clearly denser than the 
male network with more connections. Notably, there are several multimorbidities present in the 
female network not present in male network at the selected cut-off. These are highlighted in Table 
3.3 and notated by an F in each area of comorbidity. There is only one males-specific comorbidity 
as compared to eleven comorbidities noted as significant only among females. For example, 
mental disorders in males are associated with the disorders of circulatory and respiratory systems. 
However, female patients with mental disorders are at risk of diagnoses belonging to multiple 
other organ systems such as circulatory respiratory, digestive and musculoskeletal systems in 
addition to the injury, poisoning, endocrine, nutritional, metabolic, and immunity related 
disorders. Similarly, the disorders of genitourinary system are strongly associated with the 
disorders of respiratory system, musculoskeletal system and connective tissue in females than 
males. The disorders of musculoskeletal systems are also more strongly connected to other 
disorders in women than men. The musculoskeletal disorders such as osteoarthritis are known to 
be more prevalent in females (Woolf & Pfleger, 2003) but other observed multimorbidity 
differences by gender need further research. 
The above discussed relationships between diagnoses of different organ systems are more 
strongly connected in females than males. However, the comorbidity of endocrine, nutritional, 
metabolic diseases, and immunity disorders (3) with disorders of the blood and blood-forming 
organs (4) was only observed in males. Each connection needs further investigation so as to find 
the reasons for differences in genders. Recognition of these observed multimorbidities also may 
suggest greater precautions to be taken by patients themselves or the physicians to watch for 
related symptoms. 
Our observed networks of comorbidities from the EMR data confirm the prevalence of higher 
comorbidities in females than males as supported by the previous research (Blazer, et al. 2002; 
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Moller-Leimkuhler, 2007). Notably, this study conforms previous work which identified a greater 
proportion of diagnosis of reproductive cancers and mental health diagnoses among females. 
However, contrary to previous research, we also note that the strength of some comorbidities are 
stronger in males than females.  
Multimorbidity networks were different may be due to gender differences in care seeking 
behaviors among females because a greater frequency of care seeking behavior in females 
increases the risk of multiple disease diagnoses (Corrigan, 2004). Moreover, the disparity 
between mental health multimorbidities in males and females is striking: perhaps physician 
implicit bias (Chapman, Kaatz & Carnes, 2013) and patient care seeking behaviors play a role in 
the diagnosis of mental health disorders by gender.  Previous research suggests that social factors 
discourage men from seeking mental health care (Corrigan, 2004). Therefore, the absence of 
strong multimorbidities with mental health among men was expected.  
Notably, there was only one male dominated comorbidity in the network, disorders of blood and 
blood-forming collectively and disorders related to the endocrine, nutritional, metabolic, and 
immunity collectively, which were found more strongly connected in males than females. There 
could be a few potential explanations for this relationship: HIV infection or obesity. HIV 
infection is still the highest among men, and would be comorbid with an immunity diagnosis. 
Factors associated with obesity were strongly represented in the initial male multimorbidity 
network, many of these linked lipids, heart disease, diabetes, and digestive neoplasms; therefore, 
it is most likely that these diagnoses are linked to obesity, which has multiple antecedents 
addressed by public health.   
Analysis of the network centralities (particularly weighted degree) suggested acute kidney failure, 
chronic kidney disease and chronic ischemic heart disease to be more strongly connected to other 
diseases in males than females. Moreover, diabetes mellitus emerged to be one of top diseases in 
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males in terms of closeness (but the closeness number of diabetes in males was still smaller than 
females). Diabetes diagnosis is typically associated with overweight and obesity, and is often 
multimorbid with cardiovascular and other diagnoses related to overweight and obesity.  
3.4 CONCLUSIONS 
Better understanding of multimorbidity networks may allow for better screening and 
identification of diseases among patient populations, accounting for uniqueness for males and 
females in research measuring multimorbidity. These networks may improve health outcomes and 
reduce healthcare costs associated with hospital length of stay and readmission. The impact of 
comorbidity on the health outcomes has been studied in the past, but different network related 
properties have not been discussed in the public health literature. We shall establish the 
relationships between these concepts as a part of our future research.  
Our study contributes both to the method and practice. With respect to the method contributions, 
we presented a novel approach to study multimorbidities at a population level. The network 
approach allowed us to study all the multimorbidities at once. Our paper is one of the first to 
apply a network approach to understand public health, particularly in the context of 
comorbidity/multimorbidity. The knowledge extracted from the large historical data can improve 
clinical decisions and outcomes as discussed by Tierney (2001). 
The analysis presented in this study has several practical implications. We mainly developed 
insights for health researchers. However, our study has implications for policy makers. In 1993, 
National Institute of Health (NIH) Revitalization Act was passed to encourage researchers to 
include women and minorities in clinical trials. Our analysis validates the disparities in diagnoses 
by genders, and thus we reinforce the need for considering the gender multimorbidities in clinical 
trials. In addition, education at every level should reinforce teaching of multimorbidity 
differences across population groups. We provide evidence to the gender disparities in public 
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health through multimorbidity lens and support the global calls by Ovseiko, et al. (2016), 
Johnson, et al. (2014) and other thought leaders to recognize gender differences in health 
research.  
This study has few limitations. First, our multimorbidities were based on the electronic health 
records and therefore, only the diagnoses recorded in specific hospitals was included. It is perhaps 
impossible to record lifetime history of a human in medical records. Hence, this limitation 
remains in all studies based on medical records. Second, we focused on the gender. However, we 
also recognize that the health disparities exist based on race and ethnicity (Fine, Ibrahim & 
Thomas, 2005). Studying such disparities is part of our current research. Third, we only discussed 
simple network metrics such as degree, closeness and betweenness centrality. However, other 
complex measures such as clustering coefficient, cliques, clubs, eigenvector centrality, etc. can 
provide more information about the multimorbidities. Next, the differences were reported if the 
diseases were of different organ systems. However, the comorbidities related to the same organ 
system can also help enhance our understanding about the multimorbidities. We will explore 
these in future research. We also note that there were thousands of comorbidity differences in 
different population groups and we could not report them in this paper. Instead, we have attached 
supplementary materials containing information on relationship of every disease with others. One 
can focus on one particular disease and find multimorbidities in our provided material. 
Notwithstanding these limitations, our study shows that Big Data and advanced analytics of large 
information can help gain new insights previously hard to discern (Tierney, 2001). We showed 
that advanced analytics methods such as network analysis can provide additional dimensions to 
understand the public health. Our study analyzed a dataset of millions of patients where diseases 
form a network and suggest that the structure of a network can have several implications. 
Moreover, there are several differences in different population groups in terms of multimorbidity 
network that should be considered while dealing with the comorbidities. Our study opens up an 
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exciting and important area of research for policy makers, economists, social scientists and 
medical experts to treat different groups of population differently. 
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CHAPTER IV 
 
 
HEALTH ANALYTICS LEAD TO MORE QUESTIONS: A COMORBIDITY LENS 
APPROACH 
ABSTRACT 
As we amass more data, we have an opportunity to analyze a pseudo population to better 
understand differences in health across population groups. The way patients belonging to 
different population groups develop comorbidities can have a major impact on their health 
outcomes. The differences in the diagnoses associations across populations groups can be 
examined by studying comorbidities found in the historical Electronic Medical Record (EMR). In 
this chapter, we apply the data analytics approach to extract knowledge about the comorbidities 
rooted in EMR. To model comorbidities, we draw on the network theory and develop multiple 
comorbidity networks based on co-occurrences of diseases in different population groups. We 
create and compare comorbidity networks for different races, Medicaid/non-Medicaid patients 
and Medicare/non-Medicare patients. This leads to developing multiple research questions that 
need to be explored in the future research. The interesting findings and theory implications are 
discussed. 
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4.1 INTRODUCTION 
The sample size in many past studies looking at the impact of diagnoses on health has been an 
issue. New questions may emerge by knowing more about the diagnoses and their interactions 
among each other from a much larger sample that is more reflective of nearly the size of the 
population. Due to the lack of availability of sufficient data and advanced technologies, past 
clinical research has largely focused on studying the impact of diseases on fewer patients. The 
conclusions derived from studying fewer patients might not be rigorous, complete and 
generalizable.  
Due to the acceptance of Electronic Medical Record by the hospitals, availability of health data 
for pseudo population is now possible. This gives the opportunity to apply Big Data technologies 
and techniques for analyzing such large datasets and ask new questions. Due to availability of 
massive datasets, it is now possible to study all possible diagnoses and their interactions at the 
same time. The interaction of a disease with other diseases may have different consequences. 
Studying diseases at the relational or interactional level can provide additional insights about their 
joint impact on the health or health related metrics such as the expected hospital length of stay, 
readmission rate, etc. 
The objective of this chapter is to extend the analysis performed in Chapter 3 to other groups of 
population based on race and insurance type. For race, six different comorbidity networks are 
compared: Pacific Islander, Asian, Caucasian, African American, Hispanic and Native American. 
For insurance type, first a comparison between Medicaid and non-Medicaid patients is made. 
Then, networks for Medicare and non-Medicare patients are created and compared. These 
comparisons will help generate new research questions because such comparisons at the 
comorbidity level have not been possible in the past due to the lack of data. 
 
56 
 
4.2 COMORBIDITY NETWORK ANALYSES OF RACES 
Is race a socially constructed term or can it be characterized genetically? There has been a long 
argument going on for years among public health researchers. There are two groups in public 
health; one of which supports the argument of social construction and another argue for genetic 
differences. Although two groups are ideologically apart, both agree that there are health 
disparities among different races. The research on race health disparity can be divided into three 
components as postulated by Fine, Ibrahim, and Thomas (2005): 1) identifying health disparities, 
2) understanding the reasons for disparities, and 3) developing interventions to eliminate 
disparities. In this study, we contribute to the first line of research and identify differences in 
races using the administrative data of more than 22 million patients in US hospitals. 
Previously, researchers have identified differences in diagnoses among races using administrative 
data. For example, Bresnahan et al. (2007) found babies born from African Americans mothers 
were more likely than whites to be diagnosed with schizophrenia. However, to the best of our 
knowledge, no one has comprehensively studied the differences in races through comorbidity 
lens.  
For creating the race specific networks, we removed patients with ambiguous entries such as 
patients those were reported belonging to one race at one time and another at other time. In 
addition, the sample size difference in race was of higher moment of magnitude with 14 million 
Caucasians, 3.5 million Afro-Americans, 590,000 Hispanics, 400,000 Asians, 158,000 Native 
Americans and 25,500 Pacific Islanders. Since the lowest sample size was quite small among all 
the races (25,500 for Pacific Islanders), we randomly extracted almost equal number of patients 
as the second smaller sample i.e. 158,000, for all races. This led us compare the multimorbidity 
networks at the same level with balanced samples. Using each sample, a comorbidity network is 
created. Therefore, a total of six networks are created and compared. 
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Table 4.1 lists the properties of comorbidity networks of all races. All the networks have almost 
equal number of diagnoses except Hispanics. The number of unique diagnoses in Pacific 
Islanders is perhaps driven by the sample size but it forms the densest network of all with 15,064 
pairs of diagnoses. Considering others, the number of diagnoses pairs in African-Americans were 
found highest followed by the Caucasian, Native Americans, Asians and Hispanics being the 
least. Now the question arises that can these results be attributed to differences in genetics in the 
races? Or are these difference due to the differences in the facilities available to diagnose or 
record such data to some races? Although researchers have both types of arguments to answer 
these questions, these need further explanation with respect to multimorbidity. 
 
In the literature, the impact of comorbidities on the health outcomes of different races has been 
studied. For instance, Olson and authors studied the impact of race and comorbidity on survival 
rate in endometrial cancer patients (Olson et al., 2012). However, how and why comorbidities 
differ across different races and reasons for the differences are not much explored. Is it because 
the clinical trials are dominated by white males? (Oh et al., 2015). This is a very strong argument 
and needs to be addressed in future research. 
Like in Chapter 3, we present comorbidity network of different organ systems for each race in 
Figures 4.1a to 4.1f. To compare all differences at one place, we listed all connected in Table 4.2. 
We clearly see the differences in the networks. For example, the link between the disorders of 
      Table 4.1. Race comorbidity networks properties 
African American Caucasian Hispanics Asian Native American Pacific Islander 
 
No. of patients 
 
176,093 173,282 167,086 159,975 157,880 25,414 
 
Number of unique diagnoses 
 
892 884 872 889 887 829 
 
Number of Connections 
 
15,871 13,389 6,390 8,623 11,560 15,064 
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      Figure 4.1a. Caucasian Network             Figure 4.1b. African- American 
Network 
        Figure 4.1c. Asian Network  Figure 4.1d. Hispanic Network 
         Figure 4.1e. Native Network       Figure 4.1f. Pacific Network 
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Table 4.2. Comorbidities across races 
F – African Americans          A - Asians            C – Caucasians        H- Hispanics      N – Native Americans                 P-Pacific Islanders 
 4 5 6 7 8 9 10 11 12 14 15 18 
Infectious and parasitic [1] 
                        F     F                                         
                                                                        
Neoplasms [2]                                                             
Endocrine, nutritional & 
immunity disorders [3] 
F     F   C F           F A C F   C F A C F A C       F A C             
  N             P     P H N P   N P   N P   N P         N P     P   N   
Blood and blood-forming 
organs [4] 
                        F   C       F   C                               
                          N           N P                               
Mental disorders [5] 
                        F   C     C     C                             C 
                P         N           N P                           N   
Nervous system [6] 
                        F   C                         F   C             
                      P   N             P                       P       
Sense organs [7] 
                                                                        
                                  P     P                       P       
Circulatory system [8] 
                              F A C F A C F A C       F A C       F   C 
                              H N P   N   H N P         N           N   
Respiratory system [9] 
                                    F   C F   C       F   C       F     
                                      N P                       P       
Digestive system [10] 
                                          F   C       F   C             
                                            N                   P       
Genitourinary system [11] 
                                                F     F   C             
                                                                        
Pregnancy, childbirth, and 
the puerperium [12]                                                                         
Skin and subcutaneous tissue 
[13]                                                                         
Musculoskeletal system and 
connective tissue [14] 
                                                                  F   C 
                                                                    N   
Congenital anomalies [15]                                                                         
Perinatal period [16]                                                                         
Injury and poisoning [18]                                                                         
 
F African-Americans C Caucasians A Asians H Hispanics P Pacific Islanders N Native Americans 
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the digestive system (10) and genitourinary system (11) is only present in African-American 
network and not in others. Moreover, the comorbidities involving disorders of sense organs are 
more prevalent in pacific islanders. Among all, the Hispanic is least dense than others. Does that 
mean Hispanics are healthier than others on an average or are there other reasons? These findings 
are supported by the Hispanic paradox, which argues that Hispanics enjoy mortality advantage 
(Markides & Eschbach, 2005). Can comorbidity lens explain more about the health of Hispanics? 
Sociologists and medical experts have to further research on these differences from the 
comorbidity length. 
4.3 COMORBIDITY NETWORK ANALYSES OF MEDICAID AND NON-
MEDICAID PATIENTS 
 
We performed an interesting analysis to find comorbidity differences in poor and non-poor 
population. To do so, we extracted two samples; one with Medicaid patients and other without 
Medicaid. By Medicaid patients, we mean the patients who were enrolled in Medicaid programs 
throughout their lifetime and non-Medicaid patients mean that they were never enrolled in the 
Medicaid programs. There were about 15% patients in the dataset who were enrolled at least once 
in Medicare program. However, there were about 1.2 million patients (5.7%) patients who were 
always in Medicaid patients. We used only those patients assuming them as poor. To compare the 
poor with non-poor, we extracted an equivalent sized random sample of patients who were never 
enrolled in Medicaid programs at any point of time in their life.  
The networks’ statistics are listed in Table 4.3. The networks drawn from the samples show that 
the poor patients get diagnosed with 23% less number of comorbidities than the non-poor 
patients. For many years, it has been continuously reported that Medicaid patients get lower 
quality of care (Thompson et al. 2003; Yazdany et al., 2014). Due to the lower quality of care, do 
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poor patients not get diagnosed with all comorbidities? This clearly need further explanation from 
comorbidity perspective. 
 
 
 
 
 
To see the differences at the class/organ system level in two groups of patients, Figures 4.2a and 
4.2b are presented. There are only two comorbidities in Medicaid network above our cutoff. This 
is a very critical issue and require immediate attention. 
 
 
 
 
 
 
4.4 COMORBIDITY NETWORK ANALYSES OF MEDICARE AND NON-
MEDICARE PATIENTS 
Another comparison we performed was between Medicare and non-Medicare patients. This 
comparison mostly presented the comorbidity networks differences based on age. The Medicare 
      Table 4.3. Medicaid and non-Medicaid comorbidity networks properties 
Medicaid Non-Medicaid 
 
No. of patients 
 
1,253,513 1,277,998 
 
Number of unique diagnoses 
 
906 907 
 
Number of Connections 
 
7,792 10,147 
       Figure 4.2a. Medicaid Network         Figure 4.2b. Non-Medicaid Network 
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patients are at least 65 years of age. We had 3.4 million unique patients who were enrolled in any 
Medicare program. To compare the comorbidities in relatively older patients, we extracted an 
equal number of patients enrolled in other payer programs. It is well known that the number of 
diagnoses and comorbidities increases with age and we found similar results in comorbidity 
networks. Table 4.4 presents the network properties of the two networks. The number of 
comorbidities in Medicare patients were 72% more than the non-Medicare patients at our Salton 
Cosine Index cutoff of 0.04. 
 
 
 
 
 
Similar to other comparisons, we compare the Medicare and non-Medicare comorbidities at the 
organ system/class level as shown in Figures 4.3a and 4.3b. As expected, there are huge 
differences between the two networks. A lot more edges are present at the organ level in 
Medicare patients as compared to the non-Medicare patients. 
 
 
 
 
 
      Table 4.4. Medicare and non-Medicare comorbidity networks properties 
Medicare Non-Medicare 
 
No. of patients 
 
3,441,719 3,211,775 
 
Number of unique diagnoses 
 
908 908 
 
Number of Connections 
 
18,248 10,549 
Figure 4.3a. Medicare Network         Figure 4.3b. Non-Medicare Network 
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4.5 DISCUSSION 
We performed comprehensive descriptive analyses of the comorbidity networks across the US 
populations using the data analytics approach of extracting knowledge from the data. We have 
presented many comorbidity differences in the population groups. These differences are required 
to be analyzed by the researchers in the future. These differences raise many questions for the 
medical experts, social scientists, economists and policy makers to answer. The new interesting 
insights and answers to the questions can help medical experts improve their decisions. 
We add to the data analytics literature by illustrating the power of descriptive analysis. Through 
data analytics, we dig into the data and based on the results, new questions emerged. This 
approach is similar to the overarching idea of Grounded Theory Methodology (GTM) (Glaser & 
Strauss, 2009; Glaser, Strauss, & Strutzel, 1968; Strauss & Corbin, 1967). In the past, GTM is 
discussed to be similar to the data analytics methodology. For instance, Müller et al. (2016) 
suggested to use the lens of GTM in data analytics studies. The authors summed up their 
argument as follows:  
“IS researchers choosing to apply a BDA [Big Data Analytics] approach might want to consider 
some of the principles of grounded theory. Like grounded theorists, BDA researchers will spend 
an extraordinary amount of time on understanding the nature of the data, particularly if they have 
not collected them themselves.” (Müller et al., 2016, p. 3) 
Both data analytics and GTM involve discovering relationships between concepts from the data. 
There are methods available to perform data analytics such as CRISP-DM (Shearer, 2000) and 
SEMMA (Azevedo & Santos, 2008). However, these lack guidelines to connect the outcomes to 
the theoretical contribution. A methodology to perform rigorous and relevant data analytics study 
is required that can provide clear guidelines to add to the knowledge base. We believe GTM can 
provide rigorous guidelines to perform data analytics. 
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The analysis presented in this chapter has several practical implications. The effect of one disease 
on the other is explored in the past, however, we comprehensively studied all relationship 
between diagnoses in one picture. These types of analyses are only possible if such a large dataset 
equivalent to the population is available.  
The descriptive analyses provided evidence that the relationships between diagnoses are different 
across patients. Based on the differences in relationships, we provided insights on the 
comorbidities in particular. Moreover, these relationships can have different impacts on the health 
outcomes of the patients such as mortality rate, length of stay and readmission arte. Following 
this, we establish the relationship of network properties with length of stay and mortality risk in 
Chapters 5 and 6 respectively. 
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CHAPTER V 
 
 
WHEN WILL I GET OUT OF THE HOSPITAL? MODELING LENGTH OF STAY USING 
COMORBIDITY NETWORK 
ABSTRACT 
A reliable and accurate estimate of the expected hospital length of stay (LOS) of a patient is 
important to patients, hospitals, and insurance companies. But predicting LOS is a complex, ill-
structured, and dynamic decision-making problem. While recognizing that multiple factors 
interact with each other when predicting LOS, we specifically focus on the impact of co-
occurrences of diseases in a patient (known in medical terms as comorbidities). Comorbidity has 
been used most often in the previous research to explain the length of stay. However, it has rarely 
been used to predict LOS, because the information about the entire hospital visit is required to 
know the actual comorbidities.  To model and predict comorbidities from a large database 
containing medical history of patients, we create a comorbidity network in which co-occurring 
diseases form relationships. The network helps predict likely comorbidities at the point of 
admission based on the primary diagnosis of the patient. Because there is a gender disparity in 
comorbidity, we develop different networks for men and women using information on one 
million patient records in 662 US hospitals (2000-2016), The structural properties of the network 
are used to measure the comorbidities in a patient and create a model to explain and predict 
patients’ LOS using another set of 2.2 million patient visits.  The performance of our model is  
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compared with the extant models, which it outperforms. The theoretical and practical implications 
of our study are discussed.   
5.1 INTRODUCTION 
When will I get out of the hospital? This is the first question every patient asks when he or she is 
admitted to the hospital, because a longer stay increases costs in terms of health, time, and 
money. In addition to its importance to the patient, a reliable and accurate estimate of the 
expected length of stay (LOS) at the point of admission also helps healthcare providers and 
insurance companies. From a hospital’s perspective, LOS is an important metric to measure the 
quality of care as discussed by Thomas, Guire and Horvat (1997). Prolonged stays also increase 
utilization of beds, care, staff, and equipment, and negatively affect the efficiency of patient flow 
systems. Given that hospital inpatient care constitutes nearly one-third (29%) of all healthcare 
expenses in the United States, it is important to correctly estimate LOS to manage workloads 
across departments and accurately plan for discharges to minimize readmissions.  An early 
estimation of LOS is also crucial to insurance companies as it is directly related to the total 
payments made to providers. It can help with precertification (determining whether the selected 
medical services meet criteria for medical necessity under the member's benefits contract) and 
estimation of actuarial cost during admission. Given the importance of predicting LOS at the 
point of admission to different stakeholders, this paper attempts to create an explanatory and 
predictive model for estimating it. Because past attempts at predicting LOS resulted in low 
accuracy and limited applicability across multiple diseases, the problem remains open for further 
study. 
Prediction of LOS, like many other healthcare problems, is a wicked, complex, ill-structured, and 
dynamic decision-making problem, as argued by Meyer et al. (2014). A problem may be defined 
as complex and ill-structured when its underlying state is unknown, it has multiple competing 
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outcomes, and it is affected by the interaction of multiple factors (Funke, 1991; Simon, 1973). 
Moreover, the environment under which it is tackled is dynamic and unpredictable, with time-
delayed consequences for actions taken. Predicting LOS is also complex because the underlying 
reasons for a hospital stay may not be clearly identified. Moreover, several patient-level, disease-
level, hospital-level, and unknown factors (e.g. medical injuries during hospitalization) interact 
with each other in this environment. It is important to study these multiple factors to predict LOS.  
In this study, in addition to focusing on patient and hospital-level factors, we also examine the 
interactions of diseases with one another. To model complex interactions among diseases and 
symptoms in patients, we apply a network approach. This approach provides a theoretical 
understanding of the embeddedness of a disease or symptom within the web of diseases, and can 
present the complex structure of a system in a smooth and stable form. These terms were used by 
Dhar et al., (2014) when they applied the approach to convert a complex structure of products 
purchased together on Amazon.com into a network, relating structural properties with product 
demand.  
A network is a representation of interconnected parts, or nodes, of a system linked through well-
defined connections or edges. This approach cuts across all traditional disciplines of science 
including management, engineering and social sciences. We use it to create a network of diseases 
to understand the collective behavior of diseases and their effects on the health outcomes, 
particularly LOS. Our contribution is to employ network properties inferred from such analyses 
and then use those for predictive analytics through second level model building. In other words, 
properties derived from the network models are used further for predictive analysis of an outcome 
(i.e. LOS), which is exogenous to the network.  
To know how diseases form relationships and interact with each other, we use information on 
comorbidities (a medical condition in which two or more diseases are diagnosed simultaneously 
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(Feinstein, 1970)). For example, the simultaneous presence of diabetes and pneumonia in a 
patient is a comorbid condition. Comorbidity is considered an important factor in health outcomes 
such as mortality, LOS, and readmission because two diseases jointly can have a different impact 
than the same two diseases individually. This joint impact is known as syndemicity, a term coined 
by Singer (1996).  
In this paper, we develop a comorbidity network based on co-occurrences of diseases in a large 
number of patients. In our network, diseases form connections based on comorbidities. A 
connection in a comorbidity network has a different meaning than one in a traditional network, 
such as an online social network. In a social network, members make the decision to connect with 
others. In a comorbidity network, a connection represents an aggregation of comorbidities in 
patients, who are external to the network. An aggregation of a large number of patients provides a 
simple model of disease relationships. Developing such a model explicitly based on each 
disease’s attributes would be incredibly complex and probably futile.  
Comorbidity has been used most often in the previous research to explain the length of stay. 
However, it has been rarely used to predict LOS, because the information about the entire 
hospital visit is required to know the actual comorbidities for that specific patient.  In contrast, 
our comorbidity network is used to predict the possibility of other diseases in the presence of an 
index disease, and therefore can be used to make predictions for LOS at the point of admission. 
To the best of our knowledge, this is the first such use of a comorbidity network for predicting 
LOS. 
To develop our comorbidity network and make predictions, we use an Electronic Medical Record 
(EMR) containing information about more than 24.7 million patients across 662 US hospitals 
over 17 years (2000-2016). The use of this massive dataset is one of the strengths of our study. 
Due to the lack of availability of sufficient data and advanced technologies, past research largely 
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studied the impact of fewer diseases or fewer patients which may have resulted in conclusions 
that were not rigorous or complete.  
In addition, we develop separate comorbidity networks for men and women. Previous studies 
controlled for gender but rarely focused on and reported differences in males and females 
explicitly, as noted by Short, Yang and Jenkins (2013). It is important to study gender differences 
because men and women might respond differently to a disease in the presence of another. Some 
thought leaders such as Ovseiko, et al. (2016) and Johnson, et al. (2014), have strongly argued for 
the recognition of gender differences in health research, and we respond to their call. 
Our study contributes to the Information Systems literature by developing an information-based 
model for the healthcare industry that predicts LOS. This model improves decision-making 
outcomes and can be integrated to enhance existing Information Systems. Our models and 
algorithms generate business value from the data, which is one of the contributions of analytics 
research as deliberated by Agarwal and Dhar (2014). In addition, our approach is robust and 
easily implementable. 
The network approach used in our study helped us create a new measure for quantifying and 
predicting the comorbidities in patients. As Shmueli and Koppius (2011) explained in their 
commentary, measure development is one of the roles of analytics in scientific research. Our 
measure enhances the understanding of the joint impact of diseases on LOS. In addition, we add 
to the existing knowledge by comparing our approach with competing models. 
This study also contributes to the network science and analytics literature by presenting an 
application of how a network and its properties can be used for modeling. The network provides 
researchers with a new dimension that improves the contextual intelligence about comorbidities. 
The network illustrates the direct as well as indirect relationships among diseases, and the 
position of a disease in the network defines the risk associated with it, known as structural risk 
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(Coleman, 1988). The risk possessed by a disease can have several direct or indirect 
consequences on patients, hospitals, and providers. We measure structural risk through the 
network metrics such as node centralities. Our paper is one of the first to analyze this risk in the 
context of comorbidities and syndemics.  
Our network is one of a class that emerges without the intentions of its source, often referred to as 
unintentional or implicit (Roth et al., 2010). Patients are the source, but the network is formed 
without their intentions. This class differs from traditional or explicit networks, which are 
developed from the intentional actions of its members. A list of networks is presented in Table 
5.1, half of which are formed without the intentions of their source. 
Table 5.1. Different categories of network based on the purpose of formation 
Network Name Source of Network 
Intentionally Formed 
Online Social Network Users 
World Wide Web Web pages and links 
Road Network Interconnected roads 
Power Grid Network Cables connecting power units 
Airport Networks Airlines connecting airports 
Unintentionally Formed 
Co-citation Network References in documents 
Actor-Actor Network Movies 
Product-Product Network Users purchases 
Drug-Drug Network Patients or hospital visits 
Comorbidity Network Patients or hospital visits 
 
We take the application of implicit networks to next level, exploring how they impact the 
uncontrollable performance of the external source. In other words, can a collective behavior of 
the network formed unintentionally affect outcomes of the source? In our comorbidity network, 
positions of the diseases are used to predict LOS, which is an uncontrolled performance. This 
approach can be applied to solve problems in other domains. For instance, product co-purchase 
network can be used to predict future spending based on the current shopping cart. 
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In section 2, we review related works on LOS, comorbidities, and the research gaps this study 
attempts to fill. In section 3, we describe our baseline models and comorbidity network models, 
and include a demonstration of comorbidity network building.  In section 4, we discuss our data 
processing and analysis, and address issues relating to Electronic Medical Record (EMR). We 
also present the explanatory and predictive power of the models proposed in this study. In Section 
5 we discuss the implications of our results. 
 
5.2 LITERATURE REVIEW 
5.2.1 LENGTH OF STAY 
The problem of predicting length of stay (LOS) has been studied for a long time. We present a list 
of competing studies and identify the current state of art in Table 5.2. The table indicates whether 
the predictive performance of the models developed by the studies is reported, and whether the 
models are applicable at the point of admission. The majority of these studies focused on the 
entire hospital visit, and therefore did not have predictive ability.  
Previous models built to estimate LOS used common factors at the patient level and hospital level 
and some also considered external factors. Patient level factors included age, gender, race, and 
diseases diagnosed in the patients. Some studies also considered lab tests and procedures to 
explain LOS, such as Yang et al. (2010), Clague, et al. (2002), Liu et al. (2010) and Chertow, et 
al. (2005). There is some evidence that insurance type affects LOS, with Medicaid insurance 
holders having longer stays than others (Mainous, et al. 2011; Lopez-Gonzalez, et al. 2014). At 
the hospital level, the size of a medical unit, consultant, and clinical events occurring during the 
visit were found to be significant in some studies, e.g. Elixhauser et al. (1998). Huntley, et al. 
(1998) showed that LOS was affected by the number of previous admissions because it indicates 
that the patient’s situation is critical. External variables affecting LOS included the day of the 
week when a patient was admitted. For instance, Carter and Potts (2014) found a longer stay for 
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Table 5.2. A review of selected papers on Length of Stay and Comorbidity 
Paper Setting Sample Size Comorbidity Point of 
admission 
Predictive 
Performance 
Network 
Properties 
Performance 
Chertow, et al. (2005) Acute kidney injury 19,982 N N N N R-Square -33% 
Lowell & Davis (1994) Schizophrenia and Affective disorder 829 N N Y N Accuracy – 35% 
Lopez-Gonzalez et al. 
(2014) 
Medicaid, Uninsured and Private 
insurance 
20.8 million N N N N Not reported 
Thombs, et al. (2007) Acute burn injury in 70 burn centers 31,338 Y Y N N Not reported 
Librero, et al. (1999) Public healthcare system in 12 hospitals 106,673 Y N N N Not reported 
Lyketsos, et al. (2002) Psychiatric inpatients in a hospital 950 Y N N N Not reported 
Furlanetto & da Silva 
(2003) 
Inpatients in a general ward of a hospital 317 Y N N N Not reported 
Mainous et al. 2011 Ambulatory care–sensitive (13 categories 
of diseases) 
849,866 Y N N N Not reported 
Carter & Potts (2014) Knee operation 2,130 Y Y Y N Classification – 
24.5%-76.9% 
Hachesu et al. (2013) Coronary artery disease 2,064 Y N Y N Classification - 96.4% 
Liu et al. (2010) All – one healthcare system (multiple 
hospitals) 
155,474 Y Y N N R-square-14.6% 
Clague, et al. (2002) Hip fracture in a hospital 662 Y N N N R-square- 20.7% 
Huntley, et al. (1998) One Psychiatric center 769 Y Y Y N R-Square-17.6% 
Rochon et al. (1996) Spinal-cord injured 330 Y N N N R-square – 6.2% 
Elixhauser et al. (1998) Inpatients from 438 acute care hospitals 1.7 million Y N N N R-square - 12%-39% 
Yang et al. (2010) Sepsis patients in one hospital 6,929 Y N N N R-square - 21%-34% 
This Study All types of patients in 662 hospitals 
across US 
3 million Y Y Y Y R-Square-38% (Max 
72%) Accuracy: 65% 
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knee operation patients if admitted on Sunday, Tuesday, or Wednesday. Another factor 
considered by several studies was the discharge destination, which can affect hospital discharge 
decisions. Carter and Potts (2014) found shorter LOS for patients discharged to home as 
compared to those discharged to other facilities. The above brief review helped us determine the 
variables we used to create the baseline models in our study that are available at the point of 
admission, such as demographic, insurance type, admission type, and hospital size. 
As discussed earlier, prediction of LOS is a wicked and ill-structured problem, as evidenced by 
the performance of models in previous studies. The explanatory power of these models is as low 
as 6% r-square for spinal-cord injury patients as found by Rochon et al. (1996) and as high as r-
square of 39% for patients with low back pain by Elixhauser et al. (1998). With respect to the 
predictive power in terms of mean absolute error, again the accuracy is less than 35% on average. 
Some studies have also attempted to predict a range of LOS such as Carter & Potts (2014) and 
Hachesu et al. (2013). However, this approach is less practical because suggesting a range of LOS 
may not help physicians and insurance companies with decision-making. 
5.2.2 LENGTH OF STAY AND COMORBIDITY 
Comorbidity has been shown to be related to the LOS in the past, as the presence of two or more 
conditions impacts patients’ stays because more care and resources are required to cure those 
conditions jointly. Many studies focused on one disease at a time, identifying the comorbidities 
related to a hospital stay. For instance, Hachesu et al. (2013) studied comorbidities of coronary 
artery disease, Yang et al. (2010) considered sepsis, Lowell and Davis (1994) included 
schizophrenia and affective disorder, Thombs, et al. (2007) examined burn injury, Lyketsos, et al. 
(2002), Furlanetto and da Silva (2003), and Huntley, et al. (1998) analyzed psychiatric-related 
comorbidities.  
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In the literature, there is no consensus on the definition of comorbidity. The concept of 
comorbidity is theorized using four distinctions by Valderas, et al. (2009).  The first is based on 
the nature of the health conditions occurring concurrently. The second is based on the relative 
importance of the co-occurring conditions. In this case, one disease is given more importance 
than the others., and the presence of other conditions in addition to it is considered comorbidity. 
The third distinction is based on the chronology of development of the conditions. It is possible 
that multiple diseases develop concurrently or one disease leads to another, but it is not easy to 
draw causal relationships between them.  Finally, the fourth distinction considers illness burden 
and patients’ socioeconomic conditions that can play a role in the presence of multiple diseases. 
In these four distinctions, Valderas and colleagues considered patients’ clinical and 
socioeconomic factors to conceptualize comorbidity. On the other hand, Jakovljevic and Ostojic 
(2013) defined comorbidity as a medical condition in three different ways based on only diseases 
diagnosed in patients. First, it is when two diseases are present simultaneously but independently. 
Second, it is when one disease causes another, making them interdependent. Third, it is the 
presence of multiple diagnoses regardless of their causal relationships. 
These previous definitions of comorbidity do not consider the lifetime history of a patient, but 
rather look at the presence of diseases only during a hospital visit. Focusing on current patients’ 
information can better help physicians to control comorbidities; however, how the history of a 
patient is related to the current situation is not understood. If we instead look into the lifetime 
history of patients and find relationships between diseases, this will provide additional 
understanding about comorbidities. This is the approach we adopt in this paper. We define 
comorbidity as the presence of multiple diseases in the lifetime history of a patient. This 
definition has two advantages over previous definitions. First, the medical recording of a disease 
over multiple hospitals visits is only considered once. Considering the same disease as different 
across hospital visits can overestimate its presence and bias the analysis and conclusions. Second, 
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our definition incorporates the impact of a disease on other diseases across multiple hospital 
visits, thereby considering a wider span of disease developments. Our definition is also useful for 
prediction purposes because a comorbidity developed in one patient during one hospital visit may 
be observed across two hospital visits in another patient. Therefore, considering a longer time 
span allows us to draw true relationships between diseases. There is some concern about 
considering the association between diseases diagnosed during hospital visits that occur with long 
intervals in between. Given the relatively short time span of our database (17 years), the short 
average length between first and last hospital visit in the database (527 days), the average number 
of hospital visits of a patient (5.1, including all types of visits), and the statistical analysis on 
millions of patients, we mitigate the concern of false positives. 
To measure comorbidity, many comorbidity scales have been proposed. de Groot et al. (2003) 
identified twelve different indexes, concluding that the Charlson Index, the Cumulative Illness 
Rating Scale (CISR), the Index of co-existent Disease (ICED), and the Kaplan Index are reliable 
measures and can be used in clinical research. Since CISR, ICED, and Kaplan require clinical 
judgment and information, we consider only the Charlson Index when comparing the 
performance of our model because it is based on medical records.  
The Charlson Index assigns weights to 19 different medical conditions. It was originally created 
for predicting mortality. Later, it was found to be related to LOS by several studies. For instance, 
Librero, Peiró, and Ordiñana (1999) conducted a simple bivariate analysis to see the increase in 
LOS with respect to the different levels of Charlson Index comorbidity scores, finding that LOS 
increases with the Charlson Index score. Rochon et al. (1996) also found a significant relationship 
between LOS and comorbidity indexes, however with low effect (R2 = 0.06). 
Past studies have rarely used comorbidity scales for prediction purposes because information 
about an entire visit is necessary to know all diseases in a patient. Some of those studies are listed 
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in Table 5.2. If information about comorbidities at the point of admission is not available, it is 
difficult to use it to make predictive models for LOS. Therefore, a mechanism is required to first 
predict the comorbidities and then use it for LOS predictions. Another limitation of the past 
research on comorbidity is that the existing scales are unable to consider all the diseases at the 
same time. Through our network approach, we can study all interactions at once.  
From the literature review, we identify three research gaps. First, most past studies restricted their 
analyses to a few categories of diseases and patients, and their models are only applicable to the 
specific types of patients they studied. Our study aims to create a unified model for patients and 
to analyze the model performance for different categories of patients. Second, the Charlson Index 
considers only a subset of diseases. In this paper, we apply a network approach to measure all 
disease relationships from a database encompassing millions of patients in the United States. We 
also compare the model developed using our approach with the model using Charlson Index. 
Third, to the best of our knowledge no one has applied a network approach and used structural 
properties to predict LOS. Our study attempts to fill all of these research gaps. 
5.3 MODEL DEVELOPMENT 
 
In this section, we describe baseline models using the variables considered in past studies, and 
then describe how we develop a comorbidity network and use its properties to build models at 
hospital-visit level to explain and predict LOS 
5.3.1 BASELINE MODELS 
We created different baseline models to explain and predict LOS using the variables considered 
in the previous studies. From the preceding literature review, we identify the following 
information to build our baseline models: demographics (age, gender, race), visit (primary 
77 
 
diagnosis, patient type, admission type, number of previous admissions), hospital (size measured 
by number of beds), and insurance type. In addition, we also create a few new variables that can 
affect LOS. One measures the number of times a patient had already been admitted due to the 
same primary diagnosis, because it is possible that LOS decisions made by providers can be 
influenced by multiple admissions with the same diagnosis. Another variable is the number of 
different organ systems involved in the primary diagnoses and other diseases present during 
admission. This is important because LOS can be influenced by efforts and resources required to 
simultaneously cure diseases belonging to different organ systems. For instance, Braunstein et al. 
(2003) studied elderly patients with chronic heart failure and found non-cardiac comorbidities to 
be associated with health outcomes. We also calculate the Charlson Index from the known 
diseases at the time of admission to compare the performance of this extant index with our 
proposed measure. It was calculated as the weighted sum of scores of known diagnoses as 
suggested by D'hoore, Sicotte, and Tilquin (1993).  
We build four hierarchical baseline models to study the impact of different factors. In the first 
linear baseline model, only patient demographics, visit characteristics (excluding primary 
diagnosis) and hospital information are used (See equation 5.1). The patient-level information 
includes age, gender and race; visit characteristics include patient type, admission type, insurance 
(payer), number of previous admissions (visitNumber) and number of previous admissions due to 
the same disease (revisit); and hospital data include size of the hospital in terms of number of 
beds. For each multi-level variable (such as race, hospital size, admission type and payer) a set of 
parameters is estimated. Each of the parameters 𝛽3, 𝛽5, 𝛽6 and 𝛽7 represents a set. For the 
variables having one level, (i.e. 𝛽1, 𝛽2, 𝛽4, 𝛽8 and 𝛽9 ) a single value parameter is estimated. 
Baseline 1: LOS = 𝛽0 + 𝛽1𝑎𝑔𝑒 +  𝛽2𝑔𝑒𝑛𝑑𝑒𝑟 + 𝛽3𝑟𝑎𝑐𝑒 + 𝛽4𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑇𝑦𝑝𝑒 +  𝛽5𝑎𝑑𝑚𝑖𝑠𝑠𝑖𝑜𝑛𝑇𝑦𝑝𝑒 +
 𝛽6𝑝𝑎𝑦𝑒𝑟 + 𝛽7ℎ𝑜𝑠𝑝𝑖𝑡𝑎𝑙𝑆𝑖𝑧𝑒 +  𝛽8𝑟𝑒𝑣𝑖𝑠𝑖𝑡 +  𝛽9𝑉𝑖𝑠𝑖𝑡𝑁𝑢𝑚𝑏𝑒𝑟 + 𝑒         -(5.1) 
78 
 
The second baseline model is built by including the information about the primary disease of the 
patient and number of different organ systems or categories involved in the known diagnoses to 
the first baseline model (see equation 5.2). This model considers the impact of the primary reason 
for the visit on LOS. To compare the performance of our model with the existing model of 
comorbidity, a third baseline model is created to estimate LOS using a competing measure, 
Charlson Index (see equation 5.3). The final hierarchical baseline model is created using the all 
the variables defined in first three baseline models to see their joint relationship with LOS as 
presented in equation 5.4. 
Baseline 2: LOS  =Baseline 1 +𝛾.  [
𝑑1
𝑑2
⋮
𝑑𝑛
]+ e       -(5.2) 
Baseline 3: LOS = 𝛽0 +  𝛼. 𝑐ℎ𝑖 + 𝑒        -(5.3) 
Baseline 4: LOS = Baseline 1+ Baseline 2+ Baseline 3     -(5.4) 
5.3.2 MODELING USING COMORBIDITY NETWORK 
The traditional baseline models described above do not consider comorbidity; however, they 
represent important factors for explaining and predicting LOS. Since all comorbidities might not 
be known at the time of admission, we use the relationships between diseases through historical 
patterns to predict comorbidities related to the primary diagnosis. These relationships from the 
patterns can also help estimate LOS. In this sub-section, we explain the development of our 
comorbidity network and describe how network metrics such as centralities of a disease can 
impact LOS. Then, the models using network properties are described.  
 
5.3.2.1 COMORBIDITY NETWORK 
In a comorbidity network, diseases are connected to each other if they are likely to co-occur in a 
patient. As discussed earlier, comorbidity networks are implicit and a link between two diseases is 
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defined from the co-occurrences in a specified time interval. For our definition of a comorbidity, 
the lifetime history of a patient is considered as a transaction. This is analogous to creating a lifetime 
market basket for a buyer based upon multiple individual transactions. Of course, we recognize that 
the history may be incomplete. A patient may have gone to a hospital or hospitals that do not use 
same data collection system, and thus records may be missing. But this is still the best available 
compilation. A transaction may contain multiple diseases diagnosed over time, and in that case they 
will be used to discern associations among diseases. Let T(d1, d2, d3,…dt) denotes a transaction, 
where d1, d2, d3,…dt is a subset of all diseases D(d1, d2, d3,…dn) with n≥t. 
A comorbidity network developed from N patients is denoted by C (D, E) where D is a set of n 
nodes and E is a set of edges. In our comorbidity network, nodes represent diagnoses. We use an 
Electronic Medical Record (EMR) in which conditions, including both diagnoses and symptoms, 
are classified as International Classification of Diseases, Ninth Revision, Clinical Modification 
(ICD-9-CM). An ICD-9 code has three, four or five digits (xxx.xx). The first three digits 
represent the broader category of a disease, and the fourth and fifth digits represent sub-divisions 
of a disease. For example, the ICD-9 code for personality disorder is 301. At the four-digit level 
(301.x), there are ten types of personality orders and at the five-digit level (301.xx), two other 
specific personality disorders are coded. We aggregated ICD-9-CM codes to the three-digit level. 
Thus, variations of the same disease are considered as one node in the network. There are 
advantages and disadvantages of aggregation. The advantage is reduction in the measurement 
bias. A disadvantage is the compromise to granularity as different classes of the same disease can 
have dissimilar impacts.  
An edge Eij is created between two diseases di and dj ({di, dj} ∈ D and i, j = 1 to n) where i<j as 
the network is undirected. Since the focus is on relationships based on co-occurrences and not the 
causality, we created edges between diseases with no direction. For example, an edge between 
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congestive heart failure and rheumatic heart disease represents an undirected connection between 
two nodes representing two diseases.  
In the past, associations between diseases or comorbidities were modeled using a simple 
Pearson’s correlation coefficient (Divo et al., 2015; Hidalgo et al., 2009). In the network using 
Pearson’s correlation coefficient, the coefficient PCCij of an edge Eij between diseases di and dj is 
calculated as 
  𝑃𝐶𝐶𝑖𝑗 =
(𝑐𝑖𝑗∗𝑁)(𝑖𝑐∗𝑗𝑐)
√(𝑐𝑖∗𝑐𝑗)(𝑁−𝑐𝑖)(𝑁−𝑐𝑗)
              -(5.5) 
where cij is the count of patients containing both di and dj diseases, ci is the count of patients 
diagnosed with di and cj is the count of patients diagnosed with dj. However, the number of 
significant correlations is directly proportional to the number of observations used (N). The 
ability to detect rare comorbidities is lessened because of the rareness of events. Therefore, to 
establish the right measure to model a comorbidity, we use the Salton Cosine Index (SCI) (Salton 
& McGill, 1986). SCI is unaffected by the total number of observations used (Ahlgren, Jarneving, 
& Rousseau, 2003) and measures the prevalence of a relationship between two diseases 
considering their individual prevalence. Salton Cosine Index, wij, of two diseases di and dj is 
calculated as an equation 5.6. The cosine similarity has been used in the past to find phenotype 
overlaps (Chen et al. 2015; Lage et al. 2007). We propose this as an appropriate measure for 
calculating the strength of a comorbidity. 
   𝑤𝑖𝑗 =
(𝑐𝑖𝑗)
√(𝑐𝑖∗𝑐𝑗)
        -(5.6) 
Unlike correlation coefficient, SCI measure is free from N. However, it is difficult to find 
statistical significance of SCI. To find a rigorous SCI cutoff, we present an approach that results 
in statistically significant edges between diseases. We use the relationship between correlation 
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and cosine index to find a cutoff for SCI as suggested by Egghe and Leydesdorff (2009), 
following the steps listed below (referred to as Process 1 for reference during analysis). 
Step 1. Calculate number of co-occurrences, correlations, and Salton Cosine Index for all pairs of 
diseases (p) in the pseudo-population dataset containing 24.7 million patients. 
Step 2. Calculate T-statistic using PCCij of the edges as in equation 5.7. Following the most 
conservative approach, use the cij (minimum of cij, ci, and cj) as the degrees of the freedom. Using 
the T-statistic, develop a network at α=0.01, T>2.58 and cij>∑ 𝑐𝑖𝑗/p to select correlations (pairs) 
occurring more than by chance. Find number of pairs (q) at α=0.01, T>2.58 and cij> ∑ 𝑐𝑖𝑗/p. 
                                                              T=
𝑃𝐶𝐶𝑖𝑗√𝑐𝑖𝑗−2
√1−𝑃𝐶𝐶𝑖𝑗
2
            -(5.7) 
Step 3.  Find Salton Cosine Index as the cutoff (wc) where number of pairs is equal to q and 
cij>∑ 𝑐𝑖𝑗/p. 
Step 4. Use wc as the cutoff to find statistically significant comorbidities and create networks. 
These steps are used to create networks. The network is represented by a matrix, DnXn containing 
strength of connections between diseases, where the Salton Cosine Index for a pair (wij) of 
diseases indicates the strength between them. 
DnXn = [
0 𝑤12 … 𝑤1𝑛
𝑤21 0 … ⋮
⋮
𝑤𝑛1
⋮
…
⋱
⋮
0
] 
 
5.3.2.2 NETWORK METRICS 
The structural properties of a network can be measured using several metrics, including node 
centralities which define the importance of a node in the network. The most common centralities 
are degree, eigenvector, closeness, and betweenness as described in Table 5.3. In a comorbidity 
network, the degree centrality of a disease (node) denotes the number of direct connections with 
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other diseases (Freeman, 1979). If weights of the direct connections are considered, it is called 
weighted degree centrality, and calculated as a weighted sum of the strengths of direct 
relationships of a disease with others. The degree is a local property of a node, as only direct 
connections are considered. The direct connections of a disease, di, considered by the degree 
centrality, explain the other diseases likely to be diagnosed in the presence of di. Therefore, a 
higher degree of a disease increases the likelihood of it getting diagnosed with other diseases. A 
higher number of diagnoses predicts a longer stay because more resources are required for care.  
The eigenvector centrality is an extension of degree centrality that incorporates the indirect 
connections of a node. It is a metric for the influence and power of a node in the network and 
measures how well its connected nodes are further linked (Bonacich, 1987). In a social network, a 
person with high eigenvector centrality is connected to the important people in that network. An 
eigenvector centrality of a disease, di, in a comorbidity network measures how well its neighbors 
(directly connected diseases) are connected further. A disease with higher eigenvector centrality 
connects to other diseases that are central in the network. Although conceptually different, the 
eigenvector and degree centrality are highly correlated measures (Valente et al. 2008). Therefore, 
we expect eigenvector to be related to LOS in the positive direction as degree centrality. It must 
be noted that we will use only eigenvector centrality for creating models because degree and 
eigenvector centrality are highly correlated measures.  
The closeness centrality of a disease determines the average number of steps it is away from other 
diseases in the network (Freeman, 1979). Unlike degree centrality, closeness centrality is a global 
property of a disease and explains its centralization in the network. It is expressed in terms of 
distances (one connection is one distance) among the different nodes. The closeness centrality (ci) 
of a disease, di, is calculated as the average shortest distance of di, to all other diseases in the 
network, if a path exists at all. A disease with higher closeness (indicated by a small closeness 
number) is relatively fewer steps away from other diseases in the network. Therefore, a patient is 
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likely to be diagnosed with closer diseases. This measure has been shown to be related to 
mortality by Hidalgo et al. (2009). However, we expect that the closer a disease is to other 
diseases, the longer the average LOS for patients with that disease. 
Finally, the relationship betweenness centrality and LOS is studied. It is a global property of a 
disease, which describes its bridgeness in the network (Freeman, 1979). In other words, a disease 
with higher betweenness tends to form more bridges between other diseases. It is measured as the 
Table 5.3. Network measures and their interpretation in our context 
Network Measure Definition Interpretation in our context 
Nodes Nodes or vertexes are the elements 
among which relationships are studied. 
Diseases are the nodes. Each disease 
or a node is a three-digit ICD-9 
code.  
Edges An edge represents the relationship 
between nodes. 
Relationships are comorbidities. 
Degree centrality Degree of a node explains its number of 
direct connections (Freeman, 1979) 
Degree of a disease is the number of 
diseases directly connected to it. 
Weighted Degree Degree calculated as a weighted sum of 
the strength of the connections. 
Degree calculated as a weighted sum 
of the strength of the comorbidities. 
Closeness Closeness of a node gives the average 
shortest distance of that node to all other 
nodes in the network (Freeman, 1979). 
Closeness of a node di is  
               ci = 
∑ 𝑑(𝑖,𝑗)𝑛−1
𝑛−1
 ,                                                                               
where d(i, j) is the shortest distance 
between di and dj. 
Closeness centrality of a disease 
would represent how close a disease 
is to all the other diseases in the 
network. 
Betweenness Number of times a node is on a shortest 
path among all shortest paths (Freeman, 
1979). 
Betweenness of a node di is 
              bi = ∑
𝜎𝑠𝑡(𝑖)
𝜎𝑠𝑡
𝑠≠𝑖≠𝑡  ,                                                                                                                                  
where 𝜎𝑠𝑡 is total number of shortest 
paths from node s to node t and 𝜎𝑠𝑡(𝑖)  
is the number of those paths that pass 
through di. 
Number of times a disease is a 
bridge between pairs of diseases. 
Eigenvector 
Centrality 
A metric for influence of a node in the 
network measuring how well the direct 
connections of a node are further 
connected (Bonacich, 1987).  
Measures how well a disease’s 
connections are connected further. 
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number of times a disease is on the shortest path between other pairs of diseases. In a social 
network, the person with high betweenness is a point of connection between multiple 
communities and therefore has power to divide the network (Newman 2005). Similarly, a 
diagnosis with the higher betweenness in the comorbidity network acts as a bridge between other 
diagnoses. There are several symptoms that are connected to different categories of diseases; 
therefore, they are likely to act as bridges between other diseases and are consequently expected 
to have high betweenness. The patients with general symptoms are expected to have shorter stay 
as compared to the patients with actual diagnoses. Therefore, we expect betweenness of a disease 
to be negatively related to LOS.  
 
5.3.2.3 EXPLANATORY AND PREDICTIVE MODELING USING COMORBIDITY 
NETWORK 
Our aim is to add comorbidities to the baseline models using the network structure as defined in 
the previous section. As discussed in the Introduction, comorbidities vary by gender, therefore, we 
create different networks for males and females. A network of all diseases in males is created from 
a set of m number of diseases Dm={𝑑1, 𝑑2, … 𝑑𝑚}, and a network from females is created containing 
f diseases Df={𝑑1, 𝑑2, … 𝑑𝑓} where m≠f because both genders have unique diseases due to their 
biological differences. The network measures of each disease, such as betweenness (bi), closeness 
(ci), and eigenvector centrality9 (vi), are calculated separately for different genders. 
We use the network measures of the diseases diagnosed in patients at the point of admission to 
know how the relationship between diseases and position of a disease in the web of diseases can 
explain and predict LOS. First, we create a model to see the relationship of network centralities 
and LOS, and then we use actual connections with other diseases for predictions. Let 
                                                          
9 Degree and eigenvector centrality are highly correlated. In our dataset, correlation coefficient is 0.96. 
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KD1XKD={𝑑1, 𝑑2, 𝑑3, … 𝑑𝐾𝐷} be the diagnoses known during the point of admission. For a 
manageable analysis, we restricted KD<=4, which includes more than 90% of visits in the data.  
A model for explaining and predicting LOS at the hospital visit level was created using the 
aggregated sum of their network metrics as presented in equation 5.8. Although the model is 
linear, the inputs are non-linear. This model describes how the structural positions of diagnoses 
known at the time of admission are related to LOS. 
Comorbidity Model 1:  LOS=𝛽0 + 𝛽1 ∑ 𝑏𝑖
𝐾𝐷
𝑖=1 + 𝛽2 ∑ 𝑐𝑖
𝐾𝐷
𝑖=1 + 𝛽3 ∑ 𝑣𝑖
𝐾𝐷
𝑖=1 + 𝑒   -(5.8) 
 
The above model provides information about the network properties of diseases based on their 
structural positions but does not explain the actual association of the observed diagnoses with 
other likely diagnoses (which we call predicted comorbidities). For example, if a patient visits a 
hospital with d1 and d2 as known diagnoses, our aim is to search the comorbidity network and 
extract direct connections of d1 and d2 to use for modeling. The direct connections of a diagnosis 
can help predict other likely diagnoses and LOS. To add relationships to the model, we use the 
comorbidity matrix described earlier, DnXn, which represents the strength of relationships between 
diseases. Since we create separate networks for each gender, we use two separate comorbidity 
matrices. The use of connections is an alternative to adding all observed diseases in the model. 
The addition of predicted comorbidities is more theoretically robust, and expected to have more 
explanatory and predictive power.  
An algorithm created to extract the connections of the diseases in the model is presented in Table 
5.4. Since a diagnosis has multiple associations, we restrict the number of comorbidities being 
considered. In our study, the top five weighted relationships of a disease are added in the model 
as explained in Code 5.1. As discussed, we restrict our analysis to patients with a maximum of 
four observed diseases, meaning five to twenty new values in terms of relationship strengths are 
added in the model as presented in Code 5.3 in Table 5.4. If two diseases have an association with  
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Table 5.4. An algorithm to add predicted comorbidities of the known diseases at 
the point of admission 
 
Input: Array DnXn denotes the matrix generated from the comorbidity network 
containing strength between diseases 
Input: Array K1Xn denotes an array containing all the possible diseases 
Input: Array KD1Xm contains the list of diseases known during admission 
Output: Array COM1Xn contains the final diseases and strengths added to the model 
Let: 
Scalar MaxN – denotes how many connections or comorbidities of a known disease 
are used in the model 
Array RD1Xn – An array used to create a ranking order of comorbidities for each 
disease 
 
Initialize: 
Dij = 0,          Ki = 0,      COMi = 0,          KDi = 0,           ∀ i, j ∈ (1 to n)      
Code 5.1: To rank the strength of comorbidities of each disease and consider only top 
MaxN. In our paper, MaxN=5. 
For i=1 to n 
     RD1Xn = Rank (Di, Descending) 
         For j=MaxN+1 to n 
  Dij = 0  
         Loop 
 Loop 
Code 5.2: Code for creating an array to label the known diseases as present 
 For i= 1 to m 
     For j=1 to n 
        If KDi = Dj 
  Kj = 1 
         End 
     Loop 
 Loop 
 
Code 5.3: Code for creating a result arraying containing the strengths of 
comorbidities of known diseases 
For i=1 to n 
    For j=1 to n 
         COMi = COMi + Dij * Kj 
     Loop 
            Loop  
 
the same disease, the strengths are added. The measure COM calculated in Code 5.3 for each 
hospital visit is added as a metric containing the predicted comorbidities in the models. 
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The model with the predicted comorbidities is presented in equation 5.9 where five likely 
comorbidities of the primary disease and five each for other known diseases are added from the 
matrix. A set of parameters are estimated where Ω (a set of n parameters) are the coefficients and 
COM1Xn is an array of variables. This model contains the variables coming from the network built 
using secondary data. Finally, to see how COM adds value to the estimation and prediction of 
LOS, we control for the baseline model 4 in which all other factors are considered. The model 
was created by adding our variables with the baseline model as presented in equation 5.10. 
Comorbidity Model 2: LOS = 𝛽0 +  Ω. 𝐶𝑂𝑀1𝑋𝑛+ e      -(5.9) 
Comorbidity Model 3: LOS = 𝛽0 + 𝛽1𝑎𝑔𝑒 + 𝛽2𝑔𝑒𝑛𝑑𝑒𝑟 + 𝛽3𝑟𝑎𝑐𝑒 + 𝛽4𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑇𝑦𝑝𝑒 +
𝛽5𝑎𝑑𝑚𝑖𝑠𝑠𝑖𝑜𝑛𝑇𝑦𝑝𝑒 + 𝛽6𝑝𝑎𝑦𝑒𝑟 +  𝛽7ℎ𝑜𝑠𝑝𝑖𝑡𝑎𝑙𝑆𝑖𝑧𝑒 + 𝛽8𝑟𝑒𝑣𝑖𝑠𝑖𝑡 +  𝛽9𝑉𝑖𝑠𝑖𝑡𝑁𝑢𝑚𝑏𝑒𝑟 + 𝛽10𝑐𝑙𝑎𝑠𝑠𝑒𝑠 + 𝛾. 
[
𝑑1
𝑑2
⋮
𝑑𝑛
]+ 𝛼. 𝑐ℎ𝑖 +Ω. 𝐶𝑂𝑀1𝑋𝑛 + e        -(5.10)  
 
5.4 ANALYSIS AND RESULTS 
We obtained data from the Center for Health Systems Innovation (CHSI), a center at Oklahoma 
State University which houses data provided by Cerner Corporation, a major Electronic Medical 
Record (EMR) provider. The data warehouse contains records of visits of 58 million unique 
patients across 662 US hospitals (2000-2016). We used information about the demographics of 
the patients, hospitals, types of visits, and diagnoses. The diagnoses are recorded according to the 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). We 
removed hospital visits in which patients were not diagnosed with any disease or symptom, 
leaving approximately 24.7 million unique patients with sufficient information to perform our 
analysis.    
The raw health records must be organized in a transactional form to create our comorbidity 
network and models. We follow the Transparent Reporting of a multivariable prediction model 
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for Individual Prognosis or Diagnosis (TRIPOD) guidelines created by Collins et al. (2015). The 
steps followed in processing the massive data containing medical records of 24.7 million unique 
patients are presented in a flowchart in Figure 5.1. The flowchart also presents the number of 
patients and hospital visits at each step in the process. First, information about the patients, 
admissions, diseases diagnosed, and hospital was merged. The patient level information included 
gender, age, and race. The information about the hospital visit included type of insurance held by 
the patient, type of visit (inpatient, outpatient, emergency, etc.), type of admission (elective, 
newborn, urgent, etc.), and hospital size. 
At the disease level, the information available includes all diagnoses made during the visit, but 
not the exact date and time of disease development. Because it is difficult to know when a disease 
begins to develop in a patient and therefore, this is a fair limitation of the data. Nevertheless, 
priorities of diagnoses during a visit are still known, with the top priority diagnosis being the 
primary disease and the main reason for visiting the hospital. Secondary diagnoses are less 
important and annotated with lower priorities. The EMR also notes whether a disease is present at 
the point of admission. In our study, we used the information about all diagnoses to create the 
networks but used only primary diagnoses and diseases present during admission for creating 
explanatory and predictive models. 
An integration of different datasets gave us medical records of 24.7 million patients diagnosed 
with at least one disease or symptom which were used to find a cut-off for Salton Cosine Index 
using Process 1. At SCI cutoff of 0.04, we found the number of edges in the comorbidity network 
developed using SCI is equal to the number of edges in the network using Pearson’s Correlations 
Coefficient significant at α=0.01 and cij>Average (cij). From this point, we consistently use the 
SCI cutoff of 0.04 for creating an edge in different comorbidity networks. 
89 
 
Synchronize Network and Visit data 
 
4 million patients (2 million 
each for males and females) 
Build Comorbidity Networks 
 Nodes and edges at patient level 
 One network each for males and females 
 Calculate network metrics  
Data synchronization (24.7 
million patient records) 
Preprocessing step I 
 Remove as invalid records where  
 admission date-time > discharge date-time 
 next admission date<previous discharge 
date 
 males are diagnosed with female diseases 
and vice-versa 
 Calculate length of stay  
Preprocessing step II 
 Select hospital visits where  
 insurance type, race, and age are known 
 discharge type - discharge to home 
 patient type - inpatient or emergency 
 length of stay - between 1 and 30 days 
Preprocessing step I & step II 
 Create new variables (revisits and visit number) 
 Information about only the primary disease or diseases present 
during admission 
 Drop visits with ≥5 known diseases 
6.1 million females (66 M encounters), 
5 million males (42 M encounters) 
Baseline Model 1: LOS= f (Demographics, visit, admission, 
hospital variables) 
 
Baseline Model 2: LOS= f (Demographics, visit, admission, 
hospital variables, Primary diagnosis) 
 
Baseline Model 3: LOS= f (Charlson Index) 
 
Baseline Models 4: LOS= f (Demographics, visit, admission, 
hospital variables, Primary diagnosis, Charlson Index) 
 
Comorbidity Model 1: LOS= f (Diagnoses Centralities) 
 
Comorbidity Model 2: LOS= f (Comorbidity Matrix) 
 
Comorbidity Model 3: LOS= f (Demographics, visit, admission, 
hospital variables, Primary diagnosis, Charlson Index, 
Comorbidity Matrix) 
Predictive Models: Training and validation (50% each) 
Figure 5.1. Data Processing and Modeling 
Flowchart 
475,899 female patients 
483,259 male patients 
777,945 females (1.2 M encounters), 
667,392 males (986,334 encounters) 
Find Salton 
Cosine Index 
Cut-off using 
Process 1 
24.7 million patients 
Network Measures and predicted 
Comorbidities as in Table 4
Hospital Data 
 Patient Data 
 
Visit/admission Data 
 Diagnoses Data 
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Multiple random samples were extracted for creating networks and models. First, medical records 
of four million patients (sample 1) were extracted to build comorbidity networks and compute 
network properties. For modeling, an independent random sample of approximately 11 million 
patients (sample 2) was extracted. Because there were several data quality and integrity issues in 
the EMR, data cleaning was done on both samples, removing records with erroneous and 
suspicious coding. For instance, there were hospital visits that recorded the admission date and 
time later than the discharge date and time, and visits where the admission date and time were 
earlier than the previous discharge date and time. We found a few patients who were coded as 
male during one visit and female in another, and some males who were diagnosed with female 
diseases such as inflammatory disorders of female pelvic organs (ICD9–614-616), complications 
of pregnancy, childbirth, and the puerperium (ICD9–630-679) and diseases of breast (ICD9–610-
612)10. Similarly, we noticed female patients diagnosed with diseases of male genital organs 
(ICD9–600-608). Considering these as suspicious entries, we removed them from further 
analysis. The challenges of using secondary data for research are well documented (Bellazzi and 
Zupan, 2008; Shmueli and Koppius, 2011), and we experienced the same. However, the size of 
our dataset helps mitigate these issues.  
We restricted our analysis to inpatient and emergency visits that were discharged to home. 
Moreover, we considered hospital visits with LOS of at least one day and up to 30 days in order 
to remove outliers. Long-term hospital stays represent a small percentage of patients (Marazzi, et 
al. 1998) and predictive models for such patients may include other signatures. For instance, 
Spratt, et al. (2003) found the level of disability after stroke could predict the prolonged stays. 
                                                          
10 Although males can also have breast disease biologically, we considering these records suspicious and 
removed them 
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After data cleaning, the sample (sample 1) was used to create networks. Recognizing the 
difference in diagnoses and comorbidities as argued by many health researchers such as Johnson, 
et al. (2014) and Ovseiko, et al. (2016), we created separate networks for females and males. The 
network visualizations of these networks are presented in Figures 5.2a and 5.2b respectively. The 
diseases are color coded according to the 19 categories/classes/organ systems as per the ICD-9  
 
 
 
 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
ICD-9      Description 
Figure 5.2b. Male Comorbidity Network 
Figure 5.1b. Female Comorbidity Network 
001-139: Infectious and parasitic diseases  
140–239: Neoplasms 
240–279:  Endocrine, nutritional and 
metabolic diseases, and 
immunity disorders 
280–289:  Diseases of the blood and 
blood-forming organs 
290–319: Mental disorders 
320–359: Diseases of the nervous system 
360–389: Diseases of the sense organs 
390–459:  Diseases of the circulatory 
system 
460–519:  Diseases of the respiratory 
system 
520–579: Diseases of the digestive system 
 580–629: Diseases of the genitourinary 
system 
630–679:  Complications of pregnancy, 
childbirth, and the puerperium 
680–709:  Diseases of the skin and 
subcutaneous tissue 
710–739:  Diseases of the musculoskeletal 
system and connective tissue 
740–759: Congenital anomalies 
760–779:  Certain conditions originating 
in the perinatal period 
780-799:    symptoms, signs, and ill-
defined conditions 
800–999:  Injury and poisoning 
E and V:   external causes of injury 
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classification systems. Size of a disease node represents the number of direct connections to other 
diseases (degree centrality). The summary statistics of the network properties are listed in Table 
5.5. The female comorbidity network was comprised of 1,013 diagnoses/nodes with 12,046 edges 
(comorbidities). The average degree of 23.8 indicates a disease is connected to approximately 24 
other diseases in the network. The average closeness, betweenness, and eigenvector centralities 
are 0.25, 294 and 0.116 respectively. The male network had a slightly lower number of diseases 
and comorbidities (i.e. 956 and 11,065 respectively). However, the other metrics were not 
significantly different. 
Table 5.5. Network properties 
Name Female Male 
Nodes 1,013 956 
Edges 12,046 11,065 
Average Degree 23.8 23.15 
Average Weighted Degree 1.93 1.89 
Average Betweenness 294.26 280.07 
Average Closeness 0.25 0.25 
Average Eigenvector 0.116 0.118 
 
5.4.1 EXPLANATORY MODELING RESULTS AT HOSPITAL VISIT-LEVEL 
At the visit level, we created multiple models to study the value added by the comorbidities to 
explain and predict LOS. Four baseline models from the traditional variables were created. The 
variable descriptions and descriptive results are listed in Table 5.6. The final dataset contained 2.2 
million hospital visits of 1.45 million patients (55% female). The mean LOS was 1.68 days with 
71% emergency visits and the remainder inpatients. Among all the visits, 22% were covered by 
Medicaid and 14.5% were self-paid. 6.1% of patients returned for one or more visits for the same 
primary reason. 
The performance of all baseline models and comorbidity network models in terms of variance 
explained is listed in Table 5.7. The baseline model consisting of demographics, hospital, and 
admission type information explained 25% variance in LOS. The addition of primary disease of  
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Table 5.6. Variable description 
Variable Name Description Descriptive Statistics 
Length of Stay(LOS) Length of a hospital visit Average=1.68 days 
Age Age of a patient recorded during hospital visit Average: 30.4 years 
Gender Patient’s gender Visits- 55% Females 
Patients-53.8% Females 
Charlson Charlson index calculated as weighted sum of 
score of known diseases 
Average: 0.09 
Visit Number A patient’s number of visits as (inpatient or 
emergency) 
Average of maximum: 
1.62 
Classes Total number of categories of diseases diagnosed 
during admission 
Average: 1.41 
Race Race of the patient. Six different binary variables 
were created: African-American, Caucasian, 
Hispanics, Asians, Native Americans and Pacific 
Islanders. 
Afro-American: 24% 
Caucasian: 60% 
Hispanics: 5% 
Asians: 1.8% 
Native Americans: 1.6% 
Pacific Islanders: 0.19% 
Hospital Size Size of the hospital. Five different binary 
variables were created for hospital sizes: <5, 100-
199, 200-299, 300-499 and 500+. 
<5: 4.4%  
6-99: 9.9% 
100-199: 15.1% 
200-299:27.9% 
300-499: 25% 
500+: 17.7% 
Patient Type Type of patient. A single binary variable is created 
for inpatient and emergency. 
Inpatient: 28.2% 
Emergency: 71.8% 
Admission Type Type of admission. Five binary variables were 
created: emergency, urgent, elective, newborn and 
trauma center. 
Emergency: 64.7% 
Urgent: 6.6% 
Elective: 7.9% 
New Born: 5.4% 
Trauma center: 0.24% 
Payer Insurance type during the visit. Two binary 
variables were created: Medicaid and self-pay 
visits. 
Medicaid: 22% 
Self-pay: 14.5% 
Revisit Number of visits due to same primary diagnosis. Second visit: 6.1% (88,615 
patients came back at least 
once)  
 
each visit increases the variance explained to 34%. This is the highest baseline model; as other 
models did not show any significant results. The third baseline model describing the relationship 
of the Charlson Index and LOS showed poor performance with R2 of 1.8%. Because the Charlson 
Index considers only 19 categories of diagnoses, it does not explain the visits of all types of 
patients, and just 10% of the visits had a Charlson score of more than zero. A similar low effect 
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has been observed in the past by Rochon et al. (1996), in which the authors found that the 
Charlson Index could explain only 1.9% variance in LOS. As expected, the addition of the 
Charlson Index in the first two baseline models did not improve the performance significantly. 
However, the model built using network properties such as centralities (Comorbidity Model 1) 
did a better job (R2=0.07), indicating that the network position of the observed diagnoses at the 
time of admission can explain the length of stay better than the Charlson Index. Moreover, the 
model using only the comorbidity matrix (R2=0.25), Comorbidity Model 2, performed better than 
the Charlson Index and network metrics models. The best performing model used the comorbidity 
matrix to control for demographics, hospital information, and primary disease (R2=0.38), with a 
statistically significant improvement of about 4%, calculated using partial F-Test (F-value=163.3, 
p<0.0001). For a complex and ill-structured problem like LOS, this improvement is highly 
desirable. 
 
 
 
 
 
 
 
Due to the availability of medical records from millions of patients, we were able to study all 
diseases together and created a common model for all types of patients. However, there are 
several diseases for which it is difficult to predict LOS. To identify them, we sliced the best 
model results (Comorbidity Model 3) into specific diagnoses to determine where comorbidities 
did a good job. Due to the size of our database, we were able to run different models for patients 
visiting hospitals due to different sets of diagnoses (d1, d2, … dn). There were 319 types of 
patients based on the primary diagnoses. The hospital visits for which model performance was 
Table 5.7. Linear models for length of stay at hospital visit level 
Model Model R-square 
Baseline 1: Demographics + Hospital variables + Visit variables .25 
Baseline 2: Demographics + diagnoses variables .34 
Baseline 3: Only Charlson Index (CHI) .02 
Baseline 4: Demographics + disease variables + CHI .34 
Comorbidity Model 1: Only Network Centralities .07 
Comorbidity Model 2:  Only Comorbidity Matrix  .25 
Comorbidity Model 3:  Baseline 4 + Comorbidity Matrix .38 
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low include those with a single live birth (ICD9-V30, R2 = 0.07, n=103,027, mean 2.57 days), 
trauma to perineum and vulva during delivery (ICD9-664, R2 = 0.07, n=10,292, mean 2.18), acute 
myocardial infarction (ICD9-410, R2 = .09, n=7,737, mean 3.43), chronic ischemic heart disease 
(ICD9-414, R2 = .096, n=6,974, mean 2.96) and others presented in Appendix A. The 
improvement due to the comorbidity matrix in each cluster of patients based on the primary 
diagnosis is also presented in Appendix A (Comorbidity Model 3 - Baseline 4).  
 
To observe the contribution of comorbidity in different categories of patients, we aggregated the 
results of diagnoses models to nineteen clusters based on organ system or classes (see Figure 5.2), 
where (d1, … dn) 𝜖 (O1, … O19). This aggregated analysis shows which organ system diagnoses 
are affected most by the comorbidity. The average improvement in the diseases of different organ 
systems is presented in Figure 5.3 (Comorbidity Model 3 - Baseline 4). The clusters of diseases 
for which comorbidities contribute significantly in explaining LOS are endocrine, nutritional, and 
metabolic diseases, and immunity disorders (approximately 25%). For example, the endocrine 
disorder diabetes has comorbidities such as cardiovascular disease, hypertension, and obesity that 
can affect health performance, primarily in older adults (Struijs et al. 2006; Kalyani et al. 2010). 
The other clusters affected by comorbidities include disorders of the blood and blood-forming 
organs (23%) and the nervous system (21%). Nervous system diseases such as Parkinson’s 
disease, multiple sclerosis, epilepsy, and migraine are highly comorbid with other 
neuropsychiatric disorders, pain, and asthma (Ottman et al. 2011) and therefore can affect LOS. 
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Figure 5.3. Average improvement in variance explained in LOS in clusters of patients based on 
type of their primary diagnosis 
 
5.4.2 PREDICTIVE MODELING RESULTS AT HOSPITAL VISIT-LEVEL 
The above models set the stage for predictive models. The dataset was randomly partitioned into 
training and validation sets, with half used to create a predictive model and half used for 
validation. This approach is common and has been followed in other studies such as Bardhan, et 
al. (2014).  We ran general linear models, regression trees, and artificial neural network models. 
All of the models improved similarly when the comorbidity matrix was added to the baseline 
model. Regarding the general linear model, we observed an improvement in its predictive power 
due to the comorbidities in the overall model calculated in terms of average squared error and 
mean absolute percent error in the validation dataset. Overall, the average squared error improved 
from 2.34 to 2.26 and mean absolute percent error decreased from 37.5 to 36.6. 
 
Although the overall improvement in the model seems low, we further analyze the results to see 
where comorbidity added predictive power. The absolute residuals and percent errors are 
separated for different primary diagnoses (d1, d2, … dn). The absolute residuals and percent errors 
of Baseline 4 model are subtracted from Comorbidity Model 3. Then, to understand the specific 
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cluster of diseases based on organ systems (O1, O2, … O19), the improvement in residual and 
MAPE are presented in Figure 5.4 (Comorbidity Model 3 - Baseline 4). The predictive power due 
to the comorbidity improves greatly for patients with conditions originating in a perinatal period 
followed by patients with mental disorders. With the exception of patients admitted due to 
neoplasm, congenital anomalies, and diseases of skin and subcutaneous tissue, predictions for all 
other clusters of patients improved in terms of mean absolute percent error and residuals in 
predictions. 
 
 
 
Figure 5.4. Improvement in predictive power in different clusters of patients based on primary 
disease category due to comorbidity matrix 
 
 
5.5 DISCUSSION AND CONCLUDING REMARKS 
Taken as a whole, our paper suggests that use of a massive dataset and analytics techniques such 
as network analysis, which help reduce bias (Shmueli, 2010), provide an opportunity to learn 
more deeply about the complex relationships between diseases. Our focus on both explanation 
and prediction results in a strong and applicable theoretical model as explained by Hong et al., 
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(2013). In addition, building and assessing the proposed approach on mutually exclusive samples 
confirm its robustness.  
Network properties were used to explain other diseases that can occur with a primary diagnosis, 
and help predict LOS. One of the strengths of our network method, and in particular the model 
using our comorbidity measure, is that it includes all possible diseases and can therefore capture 
all possible associations. It performed better than the existing Charlson Index, which is available 
for only 10% of hospital visits because it considers just 19 categories of diseases. The Charlson 
Index can only be calculated from observed comorbidities; however, our network method was 
able to forecast diseases that may occur in presence of another disease. Because we used 
information available at the point of admission, our approach has both explanatory and predictive 
ability. 
Comparing our unified model to past studies, our model performed better overall, explaining 
about 38% variance in the data using the information present at the time of admission. Past 
studies using other comorbidity scales to explain LOS were able to account for less variance. For 
example, a model created by Rochon et al. (1996) for spinal-cord injury patients explained 6% 
variance, Chertow et al.’s (2005) model for acute kidney injury patients explained 33% variance, 
Liu et al.’s (2010) model from one healthcare unit explained 14% variance, and Huntley et al.’s 
(2014) model for patients in one psychiatric center explained only 17% variance.  
With respect to predictive power, our overall model did better than the previous studies. The 
mean absolute percent error of our model was about 36%, meaning an overall accuracy of 64%. 
Consideration of comorbidities improved the accuracy of LOS prediction by about 1%. Although 
this improvement may appear small, its practical impact is significant. In the validation dataset, 
the comorbidity based prediction accuracy increased by about 14,500 days. The practical 
significance of Big Data Analytics can be derived in terms of dollars involved as suggested by 
Lin, Lucas Jr. and Shmueli (2013). Pfuntner, Wier, and Steiner (2013) estimated that the 
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aggregate cost for all hospital stays was $387.3 billion in 2011 with a mean of $10,000 per stay. 
Considering an average stay of 1.68 days in our data, 14,500 days are equivalent to about 8,630 
visits, resulting in a better LOS forecast of $86 million. Therefore, the practical improvement due 
to the comorbidities is significant. Because the problem of LOS prediction is particularly 
notorious and ill-structured, any reasonable improvement in the accuracy is highly desirable.  
The use of our model to predict LOS can help hospitals better plan and allocate resources. In 
addition, the study of comorbidities can certainly help in clinical care and management (Valderas 
et al., 2009). Knowledge of the relationships among diseases can help predict and diagnose likely 
co-existing diseases, and disease network properties can help physicians prioritize diagnoses 
based on the position of a disease in the network. The relationship among diseases can help 
pharmaceutical companies consider multiple related diseases when developing new produce 
drugs.  
This study has a few limitations. First, comorbidities were measured based on an EMR and 
therefore, only the diagnoses recorded in hospitals were included. It is perhaps impossible to 
capture someone’s lifetime medical history in one record. Hence, this limitation exists in all 
studies that are based on medical records. Second, we considered gender differences while 
developing comorbidity networks; however, we also recognize that health disparities also exist 
based on race and ethnicity (Fine, Ibrahim & Thomas, 2005). Including such disparities is the 
next step of our research. Third, when inputting predicted comorbidities in the model, we 
restricted our analysis to the top five comorbidities of each known disease. Adding more diseases 
could further explain their relationships, and we want to explore this. Fourth, our model showed 
improvement with respect to the competing models, but there is still much room for 
improvement. We did not use patients’ laboratory reports or consider other external factors such 
as hospital conditions and quality of physicians, which could make a significant difference. We 
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employed our proposed approach to predict LOS; in the future, we intend to use it to predict other 
medical outcomes such as readmission and mortality. 
Notwithstanding these limitations, our study adds to the growing literature of analytics, 
comorbidity, and network science. The nascent measure and model we propose has tremendous 
potential to enhance existing information systems and improve decision making in healthcare and 
other related domains. Our approach is generalizable to similar problems in which unintended 
actions of individuals form a network pattern and impact their outcome.  
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CHAPTER VI 
 
 
DIAGNOSES FORM TRAPS: IDENTIFYING MORTALITY RELATED CLIQUES IN 
COMORBIDITY NETWORK 
ABSTRACT  
Mortality rate is one of the important metrics of quality of care. Different biological, sociological 
and political factors might impact mortality risk in individuals. However, for the patients in 
hospitals, the primary reasons for a mortality are the diseases. Mostly, patient develop multiple 
diseases simultaneously but often only one diagnosis is considered as the primary reason for the 
death e.g. cancer, heart failure, etc. Because, multiple diseases jointly have a different impact than 
each of them independently, we focus on identifying the clusters of diseases related to mortality. 
We apply a network approach to create relationship between diagnoses based on their co-
occurrences in the patients and then use the clique property to identify high risk cluster of 
diagnoses. To create a network of diseases, more than 8 million patient records stored in an 
Electronic Medical Record (EMR) are used. We identified eighteen mortality related cliques in 
the network and found that the mortality rate in the patients diagnosed with all the diseases in the 
cliques is significantly higher than the patients without all clique diagnoses. The results are 
validated on an independent set of 8 million patient records. The presence of the clique diagnoses 
in the patients can help physicians take preemptive decisions. The generalizability of our 
approach is discussed.
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6.1 INTRODUCTION 
For the hospitals, one of the most important metrics to measure quality of care is the mortality 
rate. Therefore, the prediction and explanation of mortality have been a topic of interest for the 
medical, bioinformatics and analytics researchers. The primary reasons for mortality of the 
patients are the specific diseases. However, in majority of the cases, patients get diagnosed with 
multiple diseases simultaneously. Therefore, it is important to understand how multiple diseases 
interact with each other that are eventually responsible for the casualty. The knowledge about the 
joint impact of multiple diseases on mortality will help physicians take preemptive decisions 
regarding the health outcomes of patients. In this paper, we identify clusters of diagnoses in the 
patients related to mortality using an information based approach. 
When an additional diagnosis is present in a patient in addition to the primary disease, the 
medical condition is called comorbidity (Feinstein, 1970). For example, the simultaneous 
presence of diabetes and hypertension in a patient is a comorbid condition. Comorbidity has been 
considered as an important factor for mortality in the past because two diseases jointly can have a 
different impact than each of them independently. This joint impact of diseases on health is 
known as syndemicity, a term coined by Singer (1996). Most studies have considered one disease 
and its comorbidities at a time. However, how direct and indirect interactions of diseases are 
related to mortality is often not focused. 
To model interactions of all diagnoses at one place, we have adapted network approach. This 
method can help explain the collective behavior of diseases and their impact on health. We create 
a comorbidity network where diagnoses form connections if these co-occur in patients. The 
network is inferred from the co-occurrences of diagnoses in large number of patients.  
How to identify which combinations of diseases are critical so as to provide guidance to 
physicians? To address this, we have used an important property of network called clique to 
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identify such combinations. In terms of a social network, a clique is a part of the network where 
all individuals know each other and form a complete structure. All members of the clique in a 
social network may share common characteristics and information. The clique property of a 
network has several implications on the performance of the members such as trust, norms and 
obligations as discussed by Coleman (1988). In addition, Adler and Kwon (2002) argued that the 
tightly connected structure favors sharing of knowledge during uncertainty. Moreover, at the 
organizational level, Provan and Sebastian (1998) found that cliques are positively related to the 
network effectiveness.  
In the comorbidity network, the clique is a complete sub-network which explains that the patients 
often get diagnosed with a collection of diseases together. A clique is a subset of the network in 
which each pair of diagnoses is adjacent. It represents a tightly connected hidden structure within 
a large network of diseases. Identification of a clique related to an outcome (mortality in our case) 
is a multi-step problem in such a network since the structure formation is not visible externally. 
Pemantle and Skyrms (2004) explained a clique as a trap state. With respect to a game, a 
reinforced state is called a trap when a player is restricted to play a specific set of actions. 
Moreover, the traps decrease performance level of the player as explained by Roca, et al. (2010). 
Different researchers have identified traps in specific problem domains. For instance, Bonacich 
and Liggett (2003) identified traps in the network of gift exchanges where the members exchange 
gift within their own clusters. Similarly, in a comorbidity network, we hypothesize certain cliques 
of diagnoses represent trapping states, which are related to mortality. These cliques are expected 
to form stable equilibria for mortality. If the fully connected diseases are diagnosed in a patient, it 
is expected to indicate a critical condition. These groups of diagnoses are the topological traps 
analogous to the traps in games from where an exit is difficult. To the best of our knowledge, we 
are the first to use clique property to enhance our understanding about the relationship between 
comorbidity and mortality. 
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We first identify the diagnoses with high mortality risk from the data and then considering these 
as base diagnoses, we identify cliques around them, if any. To explain our hypothesis, we present 
one exemplar clique containing three diagnoses (d1, d2, d3) in Figure 6.1 where d1 is the base 
disease with high mortality rate. The degree or number of direct connections of d1 is two. Here, 
we assume that d1 has degree as two, but d2 and d3 may or may not have degree as two. Let N1, N2 
and N3 represent the number of patients having a particular disease d1, d1, d3 respectively 
irrespective of the joint presence. The number of patients with all three diseases is N123 = N1 ∩ N2 
∩ N3, where N123 ≤ N1, N2, N3). Because the underlying interactions of diseases in the patients 
with all three diseases are more than others, we hypothesize that mortality risk in N123 patients to 
be significantly greater than the mortality risk in N1- N123 patients i.e. MortalityRisk (N123) ≥ 
MortalityRisk(N1- N123). In other words, a patients diagnosed with all three diseases in a clique 
has high mortality risk than a patient not having all three diseases (i.e. <3 diseases). Since, our 
focus is on the base diagnosis and a clique around it, we hypothesize only about d1. We recognize 
that the combinations other than a clique can also be related to mortality, however, we focus only 
on cliques of the base diagnoses in this study. 
 
 
 
 
 
 
 
 
Figure 6.1. A clique/triangle of three diseases with their joint impact on mortality 
d1, N1 
Number of patients with all three 
diagnoses = N123 
MortalityRisk (N123) ≥ MortalityRisk (N1- N123) 
Base Disease – d1  
Number of patients diagnosed with d1 = N1 
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We use an Electronic Medical Record (EMR) containing information of more than 24.7 million 
patients across 662 US hospitals in 17 years (2000-2016). The use of a massive dataset is one of 
the strengths of our study and overcomes the shortcomings of other studies where the sample size 
has been an issue for examining the interaction among diagnoses. Due to the lack of availability 
of sufficient data and advanced technologies, past research has largely focused on studying the 
impact of fewer diagnoses or fewer patients, which might make the conclusions derived to be less 
rigorous. Studying all diagnoses at one place can improve our understanding about the 
comorbidities. 
6.2 BACKGROUND 
Age is of course a primary reason for mortality with life expectancy of 78.8 years at birth 
(2015)11. According to the National Center for Health Statistics report, more than 75% deaths in 
United States take place after 75 years of age12. The leading causes of mortality in US are heart 
disease and cancer13. Although the primary cause of a death is a particular disease, patients 
suffering from such diseases also get diagnosed with multiple other comorbidities. For example, 
Ahluwalia et al. (2012) identified myocardial infarction, diabetes, chronic obstructive pulmonary 
disease (COPD), chronic kidney disease, dementia, depression, hip fracture, stroke, colorectal 
cancer and lung cancer to be significantly associated with increased hazard of dying in patients 
with heart failure. Similarly, Braunstein, et al. (2003) studied elderly patients with chronic heart 
failure and found non-cardiac comorbidities to be associated with mortality. The authors 
concluded that recognizing non-cardiac conditions in heart patients can improve health outcomes. 
Some authors have also studied how presence of unrelated diseases impact critical health 
outcomes. For example, Redelmeier, Tan and Booth (1998) argued that the presence of a critical 
                                                          
11 https://www.cdc.gov/nchs/data/databriefs/db267.pdf 
12 https://www.cdc.gov/nchs/data/dvs/mortfinal2007_worktable23r.pdf 
13 https://www.cdc.gov/nchs/data/databriefs/db267.pdf 
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disease in a patient consumes most of the attention, as a result of which, the other unrelated 
existing diseases might get neglected. Obviously, neglecting a particular disease can worsen the 
condition of a patient and therefore, it is important to consider comorbidities while managing the 
primary disease. 
The extant research focus on the impact of comorbidity on mortality in specific type of patients at 
a time. For example, Holguin et al. (2005) identified comorbidities related to mortality in COPD 
patients. The authors identified pneumonia, congestive heart failure, ischemic heart disease, 
thoracic malignancies, and respiratory failure to be associated with mortality. Similarly, Marrie, 
et al. (2015) found a significant effect of comorbidity on mortality in population with multiple 
sclerosis. Leontiadis et al. (2013) reviewed studies on the patients with peptic ulcer bleeding and 
found similar results. Zolbanin, Delen and Zadeh (2015) also showed that comorbidities improve 
the prediction performance of the models developed to forecast the survivability rate of the cancer 
patients.  
In general, the interplay of diseases is studied by the medical researchers through gene 
interactions. Goh et al. (2008) and Bauer-Mehren et al. (2011) used common gene expressions to 
create connection between disorder. Lee et al. (2008) also followed the same approach to create a 
network of diseases and concluded that the connectedness of a disease with other diseases is 
related to higher risk of mortality.   
Some studies have also used historical database of patients to create a network of diseases. For 
instance, Zhou et al. (2014) created a network of diseases based on the similar symptoms. Divo et 
al. (2015) created a comorbidity network from co-occurrence of diseases in COPD patients. 
Hidalgo et al. (2009) also applied a similar approach to create a comorbidity network and 
concluded that the patient developing diseases close to each other in the comorbidity network are 
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at high risk of dying sooner than others. However, to the best of our knowledge, no one in the 
past has identified cliques related to mortality in the comorbidity network. 
6.3 METHOD 
A network of diagnoses is inferred from the patient records. A connection between two diagnoses 
represents an aggregation of co-occurrences in the patients. An aggregation of a large number of 
patients reduces the complex interactions among diseases in a summarized network. 
In our comorbidity network, a connection between two diagnoses is defined if these co-occur in a 
patient within a specified time interval. Analogous to the transactional database where a 
transaction contains a set of items, the records in an EMR are converted into transactions based 
on the defined time interval. For this, we define comorbidity as the presence of multiple diseases 
in the lifetime history of a patient. The measurements of comorbidity in the past do not explain 
how the history of a patient is related to the current situation. Therefore, we consider the lifetime 
history of a patient as a transaction containing unique diagnoses as the set of items. Of course, we 
recognize that the transaction may not contain all the diagnoses of the patient because he may 
have gone to a different hospital which does not use same data collection system. But this is the 
best available compilation. A transaction may contain multiple diagnoses. The presence of 
multiple distinct diagnoses in a patient are used to discern associations among diseases. Let T(d1, 
d2, d3,…dt) denotes a transaction, where d1, d2, d3,…dt is a subset of all diagnoses D(d1, d2, d3,…dn) 
with n≥t. 
A comorbidity network developed from N patients is denoted by C (D, E) where D is a set of n 
nodes and E is a set of edges. In our comorbidity network, nodes represent diagnoses/symptoms. 
In the EMR, the diagnoses and symptoms are classified as International Classification of 
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). An ICD-9 code has three, four or 
five digits (xxx.xx). The first three digits represent the broader category of a disease, whereas the 
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fourth and fifth digits represent the sub-divisions of a disease. We aggregate these codes to their 
3-digit level. For example, there are ten types of viral hepatitis (e.g. ICD-9: 070.0, 070.1, etc.) 
according to ICD9 classification, but these are aggregated to one 3-digit code i.e. one node. An 
advantage of aggregation is reduction in the measurement bias. In contrast, a disadvantage is the 
compromise to granularity. 
An edge Eij is created between two diseases di and dj ({di, dj} ∈ D and i, j = 1 to n) where i<j as 
the network is undirected. Since the focus is on relationships based on co-occurrences and not the 
causality, we create edges between diagnoses with no direction. To model the comorbidities 
statistically, we adapt a cosine index called Salton Cosine Index (SCI) (Salton & McGill, 1986). 
Salton Cosine Index, wij, of two diagnoses di and dj is calculated as in equation 6.1, where cij is 
the number of co-occurrences of diagnoses di and dj; ci is the prevalence of diagnosis di; and cj is 
the prevalence of disease dj. The cosine similarity has been used in the past to find phenotype 
overlaps (Chen et al. 2015; Lage et al. 2007). We propose this as an appropriate measure for 
calculating the strength of a comorbidity. 
   𝑤𝑖𝑗 =
(𝑐𝑖𝑗)
√(𝑐𝑖∗𝑐𝑗)
       -(6.1) 
Since there is no test to compute the statistical significance of the Salton Cosine Index (SCI), we 
use the relationship between Pearson’s correlation coefficient and SCI to find a cut-off as 
suggested by Egghe and Leydesdorff (2009). We follow the following steps (we name these steps 
as Process 1 for reference during analysis). First, we calculate the number of co-occurrences, 
correlations and Salton Cosine Index for each pair of diagnoses in the pseudo-population dataset 
containing 24.7 million patients. The correlation coefficient of every pair of diagnoses di and dj, 
PCCij, is calculated as in equation 6.2. 
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 𝑃𝐶𝐶𝑖𝑗 =
(𝑐𝑖𝑗∗𝑁)(𝑐𝑖∗𝑐𝑗)
√(𝑐𝑖∗𝑐𝑗)(𝑁−𝑐𝑖)(𝑁−𝑐𝑗)
             - (6.2), 
Next, the T-statistic using PCCij of every pair of diagnoses is calculated as in equation 6.3. 
Following the most conservative approach, we use the cij (minimum of cij, ci, and cj) as the 
degrees of the freedom. Using the T-statistic, a network at α=0.01, T>2.58 and cij>∑ 𝑐𝑖𝑗/p (to 
select pairs occurring more than by chance) is created, where p is maximum number of pairs. In 
this network, the number of significantly correlated pairs (q) is recorded. Then, the Salton Cosine 
Index cutoff number is found where number of pairs is equal to q and cij>∑ 𝑐𝑖𝑗/p. This cut-off is 
used to create networks for identifying cliques. 
                                                    T=
𝑃𝐶𝐶𝑖𝑗√𝑐𝑖𝑗−2
√1−𝑃𝐶𝐶𝑖𝑗
2
                   - (6.3) 
The network results from the above process is represented by a matrix, DnXn containing strength of 
connections between diagnoses, where the Salton Cosine Index for a pair (wij) of diseases 
indicates the strength between them.  
DnXn = [
0     𝑤12 … 𝑤1𝑛
𝑤21 0 … ⋮
⋮
𝑤𝑛1
⋮
…
⋱
⋮
0
]  
 
6.3.1 DETECTING CLIQUES 
A clique is a subset of the network where nodes form a fully connected sub-network. Given the 
network C (D, E) where D represents the nodes, the clique Q (⊆ C) is a sub-network in which all 
nodes are adjacent to each other. Moreover, a clique is maximal when it is not fully contained in 
another clique. The problem of clique graph recognition is NP-complete as argued by Alcón, et 
al. (2009). There are different algorithms created by the researchers to identify cliques and 
maximal cliques in the graph. However, our aim in this paper is not to identify all the cliques in 
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the network but to find mortality related maximal cliques in the comorbidity network, given a 
base diagnosis.  
From the matrix resulted in the previous section (DnXn), first, the diagnoses with high mortality 
risk and then their cliques are identified, if any. From the health records in EMR, mortality risk 
associated with each diagnosis (di) is calculated as proportion of patients deceased having the 
diagnosis di. The diagnoses with mortality risk more than 0.1 are considered as high risk 
diagnoses. Because the death rate in US is 733.1 per 100,00014 (in 2015), mortality risk of 0.1 due 
to a diagnosis is significantly higher than a random death. These diagnoses are considered as the 
base diagnoses for which cliques are identified. 
The concept of a clustering coefficient is adopted to find the maximal clique of a base diagnosis. 
The clustering coefficient explains the small clusters formed by the nodes in the network. The 
clustering coefficient of a node explains how well the neighbors of a node are connected (Watts 
& Strogatz, 1998).  With respect to the comorbidity network, clustering coefficient of a disease, 
di, explains how well the direct connections of the disease, di, are connected to each other. The 
clustering coefficient of a node di can be mathematically written as 
𝑡𝑖 =
2𝑙𝑖
𝑘𝑖(𝑘𝑖−1)
,        -(6.4) 
where li is the number of links among the neighbors of the node i and ki is the degree of a node i. 
The number ti ranges from 0 to 1. At ti=0, none of the direct connections of di are connected to 
each other. On the other hand, at ti=1, all nodes are adjacent to each other making the sub-
network a clique comprising di and its adjacent diagnoses. The size of the clique is ki+1 as it 
includes di and its directly connected diagnoses.  
                                                          
14 https://www.cdc.gov/nchs/data/hus/hus16.pdf#019 
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The entire step by step process for finding mortality related cliques is presented in Table 6.1. A 
matrix named A4Xn is used to store mortality risk, high risk indicator and clustering coefficient of 
each diagnosis. In A4Xn, A1 contains the name of diagnosis (di, where i=1 to n), A2 represents the 
mortality risk, A3 indicates whether the diagnosis is high-risk or not (i.e. mortality risk>.1), and A4 
contains the clustering coefficient of each diagnosis.  
First of all, we converted the weighted matrix DnXn into unweighted network by changing the wij 
= 1 where wij>0 as in Code 6.1 in Table 6.1. In the next step, the diagnoses with high risk of 
mortality are identified. In addition, clustering coefficient of each diagnosis is calculated as in  
Table 6.1. An algorithm to find diagnoses forming cliques with high mortality rate 
 
Input: DnXn matrix of edges with weights wij ∀ i, j ∈ (1 to n)      
In our network, n=1043, the number of distinct diagnoses 
Input: A4Xn contains diagnoses with its attributes: 
1-Diagnosis, 2-Mortality Risk, 3-High risk indicator, 4-Clustering Coefficient  
Let  
Numeric MortalityRate – It denotes a cutoff to consider mortality risk as higher or lower. In 
our study, we use 0.1 as the cutoff. 
Code 6.1: Convert weighted matrix into unweighted 
For i=1 to n 
 For j=1 to n 
  If wij > 0 then wij=1 
 Loop 
Loop 
Code 6.2: Identify high mortality risk diagnoses forming cliques 
For i=1 to n 
 If Ai2 > MortalityRate then Ai3 = 1 
 Else Ai3 = 0 
            Ai4 = Cluster coefficient of Ai1 calculated as per equation 4. 
 If Ai3 = 1 and Ai4 = 1 then  
  Call Sub-routine CliqueNodes (i) 
Loop 
Code 6.3: A sub routine to direct connections of the diagnoses forming cliques 
Sub CliqueNodes (i)  
 For j=1 to n 
  If wij=1 and i ≠ j then 
  Write Di, Dj 
 Loop 
End 
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Code 6.2. The diagnoses that are high risk and have maximum clustering coefficient (i.e. 1) are 
selected. Finally, the direct connections of the identified diagnoses forming cliques are extracted 
from the matrix of connections as in Code 6.3. 
6.4 DATA DESCRIPTION AND PREPARATION 
We use an Electronic Medical Record (EMR) containing health records of more than 58 million 
patients across 662 hospitals in US (2000-2016). This EMR is provided by Cerner Corporation, a 
major EMR provider. The database includes information about all types of patients (emergency, 
inpatient, outpatient, etc.), admissions (elective, urgent, new born, etc.), hospitals and payers 
(Medicaid, Medicare, self-pay and other private payers). For our purpose, we extracted all types 
of patients and diseases diagnosed across different hospital visits. The diagnoses are recorded 
according to the International Classification of Diseases, Ninth Revision, Clinical Modification 
(ICD-9-CM). We removed hospital visits in which patients were not diagnosed with any type of 
disease or symptom. After removing such encounters, we had approximately 24.7 million unique 
patients with sufficient information to perform analysis.    
For data analysis, we follow the Transparent Reporting of a multivariable prediction model for 
Individual Prognosis or Diagnosis (TRIPOD) guidelines created by Collins et al. (2015). The 
steps followed in processing the massive data containing medical records of 24.7 million unique 
patients are presented in a flowchart in Figure 6.2. The flowchart also presents the number of 
patients and hospital visits at each step in the process. First of all, information about the patients, 
their hospital visits and diseases diagnosed were merged. An integration of different datasets 
resulted medical records of 24.7 million patients diagnosed with at least one disease or symptom. 
The entire dataset was used for find a cut-off for Salton Cosine Index using the Process 1. As 
discussed earlier, we used the relationship between Pearson’s correlation coefficient and SCI to 
find a cut-off for SCI. From the comorbidity network of 24.7 million patients developed using 
Pearson’s Correlations Coefficient significant at α=0.01 and cij>Average (cij), the number of 
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statistically significant edges were equal at the SCI cutoff of 0.04. Therefore, from here onwards, 
we consistently use SCI cutoff of 0.04 for creating an edge in the comorbidity network. 
The large dataset containing health records of 24.7 million patients was divided into two random 
samples of equal size. The first sample was used to create the comorbidity network, identify 
cliques related to the high risk diagnoses and calculate the impact of cliques in the patients. Then, 
the second random sample was used to validate the effect of cliques on mortality on an 
independent set of patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12,335,592 patients 
63,392,819 encounters 
 
Find SCI cut-off 
using Process 1 
on 24.7 million 
Patients 
 
Validate 
Results 
 
Patient Data 
Diagnoses Data  
Visit Data 
Filtered encounters less than equal to 70 years of age 
12,334,729 patients 
63,437,833 encounters 
 
10,991,281 patients 
52,351,427 encounters 
 
Removed patients who died at 71 years of age 
10,989,564 patients 
52,331,979 encounters 
 
Removed patients where last known discharge is not known and 
no further information later 
8,288,171 patients 
38,460,723 encounters 
67,521 deceased 
Nodes and Edges – 
Comorbidity Network 
Figure 6.2. Data processing 
Identify cliques related to mortality 
Merged datasets 
24.7 million 
Patients 
 
Modeling 
Robustness 
Check 
10,991,263 patients 
52,310,045 encounters 
 
10,989,558 patients 
52,290,608 encounters 
 
8,289,997 patients 
38,416,460 encounters 
67,614 deceased 
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To reduce some bias related to the age, we restricted our analysis to the patients up to 70 years of 
age. Moreover, we followed the patient records for one more year and removed those who 
deceased at 71 years of age so that the number of false positives are minimized. In addition, we 
deleted the patients from the analysis where the last known discharge of the patients was either 
not valid or unknown. These filters left us with more than 8.2 million patients in each sample. In 
both samples, the death rate is around 800 out of 100,000. 
6.5 RESULTS 
In the dataset of 12 million patients, we identify eighteen base diagnoses where the mortality risk 
of having that specific diagnoses is more than 0.1. The list including the ICD-9 codes is given in 
Table 6.2. The table also includes the size of clique, which is the number of diagnoses in a clique 
including the base diagnosis. The list includes cancers of plasma cells, lymphatic tissue, pancreas, 
stomach, esophagus, head, face, neck, thorax, abdomen, pelvis, limbs, ovary and other uterine 
adnexa. Other diagnoses include nutritional marasmus, portal vein thrombosis, acute and subacute 
endocarditis, subarachnoid hemorrhage, mycoses, abscess of lung and mediastinum, alveolar and 
parietoalveolar pneumonopathy, pneumococcal pneumonia and dementias. The encounter for 
dialysis and dialysis catheter care also forms a clique with its neighbors.  
The comparison of the mortality rate among patients with and without a specific clique, given the 
base diagnosis, is performed. Since our focus is on the base disease, we perform the comparison 
of the mortality risk in the patients with a particular base disease. For instance, Figure 6.3 
presents the clique of Portal vein thrombosis (ICD9-452) as the base diagnosis. The size of this 
clique is three, which includes chronic liver disease and cirrhosis (ICD9-571) and liver abscess 
and sequelae of chronic liver disease (ICD9-572). There were 1,327 portal vein thrombosis 
patients without the clique having the mortality rate of 18.3%. However, there were 871 portal 
vein thrombosis patients  
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diagnosed with all three diseases with mortality rate of 28.2%. It clearly indicates that clique 
increases the mortality risk significantly (p<0.05). The same comparison is done for all the base 
diagnoses. The description of all cliques including diagnoses can be found in Figures 6.4a to 6.4r. 
The increase in risk of mortality due to the clique formation within the patient is listed in Table 
6.2 and presented in Figure 6.5. Except for the cancer of esophagus, the presence of all other 
cliques have significant effect on the mortality risk. There are some diagnoses in the table where 
the number of patients with a clique is small such as patients diagnosed with nutritional 
marasmus, malignant neoplasm of pancreas, acute and subacute endocarditis, mycoses, malignant 
neoplasm of head, face, neck, thorax, abdomen, pelvis and limbs, and multiple myeloma and 
immunoproliferative neoplasms. Although the effect of clique on mortality in these patients was 
large, the issue of small sample size still exists. However, in other categories such as patients with 
portal vein thrombosis, stomach cancer, ovary and other uterine adnexa cancer, plasma cell 
cancer, abscess of lung and mediastinum, pneumococcal pneumonia and dementias, the number 
of patients deceased is significantly large. The rise in mortality risk due to clique diagnoses is 
confirmed from these types of patients. Since the mortality risk increases when cliques are 
present, it should obviously alarm the physicians.
Number of Patients without all three diagnoses– 1,327 
Deceased – 18.3% 
Portal vein thrombosis 
(ICD9-452) 
Number of Patients with all three diagnoses – 871 
Deceased – 28.2% 
Figure 6.3. A clique/triangle of three diseases with their joint impact on mortality 
Base Diagnosis - 
Portal vein thrombosis 
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Table 6.2. Mortality rate with and without cliques 
ICD-9 Description Clique 
Size 
Patient count 
w/o Clique 
Mortality rate 
w/o a clique (%) 
Patient count 
with Clique 
Mortality rate 
with clique (%) 
261* Nutritional marasmus 13 3,725 32.0 30 60 
452* Portal vein thrombosis 3 1,327 18.3 871 28.2 
157* Malignant neoplasm of pancreas 7 5,808 21.5 73 43.8 
421* Acute and subacute endocarditis 15 3,760 21.2 67 41.8 
151* Malignant neoplasm of stomach 3 2,968 17.1 427 42.9 
150 Malignant neoplasm of esophagus 3 2,772 18.8 905 19.0 
430* Subarachnoid hemorrhage 4 5,520 16.0 192 24.0 
117* Mycoses 16 6,558 15.6 21 33.3 
513* Abscess of lung and mediastinum 3 1,513 9.8 659 22.2 
516* Alveolar and parietoalveolar pneumonopathy 6 4,013 12.0 201 30.8 
510* Empyema 9 3,985 12.1 151 30.5 
195* Malignant neoplasm of head, face, neck, thorax, abdomen, pelvis and limbs 12 6,096 12.6 14 71.4 
481* Pneumococcal pneumonia 8 4,098 11.6 160 26.3 
V56* Encounter for dialysis and dialysis catheter care 9 2,074 9.5 628 18.2 
200* Lymphosarcoma and reticulosarcoma 5 3,845 10.5 375 18.1 
203* Multiple myeloma and immunoproliferative neoplasms 12 5,843 10.8 19 47.4 
183* Malignant neoplasm of ovary and other uterine adnexa 7 6,929 10.2 142 40.1 
290* Dementias 8 4,305 9.5 152 28.3 
    * The proportions are statistically different (p<0.05) 
 
 
 
 
 
 
117- Mycoses 
287- Purpura and other hemorrhagic conditions 
584- Acute kidney failure 
995- Certain adverse effects not elsewhere classified 
518- Other diseases of lung 
275- Disorders of mineral metabolism 
486- Pneumonia, organism unspecified 
288- Diseases of white blood cells 
799- Ill-defined causes of morbidity and mortality 
276- Disorders of fluid electrolyte and acid-base balance 
996- Complications peculiar to certain procedures 
285- Other and unspecified anemias 
E87- Accident during medical care 
038- Septicemia 
112- Candidiasis 
041- Bacterial infection 
Base Diagnosis – Mycoses 
(117) 
183- Malignant neoplasm of ovary and other uterine adnexa 
560- Intestinal obstruction without mention of hernia 
198- Secondary malignant neoplasm of other specified sites 
V58- Encounter for other and unspecified procedures and 
aftercare 
V10- Personal history of malignant neoplasm 
285- Other and unspecified anemias 
197- Secondary malignant neoplasm of respiratory and 
digestive systems 
 Base Diagnosis – Malignant 
neoplasm of ovary and other 
uterine adnexa (183) 
Figure 6.4a. Clique 1 Figure 6.4b. Clique 2 
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Base Diagnosis - Malignant 
neoplasm of esophagus (150) 
150- Malignant neoplasm 
of esophagus 
V10- Personal history of 
malignant neoplasm 
530- Diseases of 
esophagus 
 
151- Malignant neoplasm 
of stomach 
197- Secondary malignant 
neoplasm of respiratory and 
digestive systems 
V10- Personal history of 
malignant neoplasm 
 
 
Base Diagnosis - Malignant 
neoplasm of stomach (151) 
513- Abscess of lung 
and mediastinum 
486- Pneumonia, 
organism unspecified 
518- Other diseases of 
lung 
 
Base Diagnosis - Abscess of 
lung and mediastinum (513) 
 
430- Subarachnoid 
hemorrhage 
437- Other and ill-defined 
cerebrovascular disease 
518- Other diseases of lung 
348- Other conditions of brain 
Base Diagnosis - Subarachnoid 
hemorrhage (430) 
 
200- Lymphosarcoma, reticulosarcoma 
and malignant tumors of lymphatic tissue 
288- Diseases of white blood cells 
V58- Encounter for other and 
unspecified procedures and aftercare 
V10- Personal history of malignant 
neoplasm 
202- Other malignant neoplasms of 
lymphoid and histiocytic tissue 
Base Diagnosis - Lymphosarcoma, reticulosarcoma 
and malignant tumors of lymphatic tissue (200) 
481- Pneumococcal pneumonia 
038- Septicemia 
799- Other ill-defined and unknown causes of 
morbidity and mortality 
995- Certain adverse effects not elsewhere 
classified 
486- Pneumonia, organism unspecified 
496- Chronic airway obstruction, not elsewhere 
classified 
276- Disorders of fluid electrolyte and acid-base 
balance 
518- Other diseases of lung 
 
 
Base Diagnosis -
Pneumococcal 
pneumonia (481) 
452- Portal vein thrombosis 
572- Liver abscess and 
sequelae of chronic liver 
disease 
571- Chronic liver disease 
and cirrhosis 
Base Diagnosis - Portal vein 
thrombosis (452) 
 
Base Diagnosis - 
Malignant neoplasm 
of other and ill-
defined sites (195) 
 
285- Other and unspecified anemias 
V10- Personal history of malignant neoplasm 
V58- Encounter for other and unspecified procedures and aftercare 
V15- Other personal history presenting hazards to health 
E87- Accident during medical care 
276- Disorders of fluid electrolyte and acid-base balance 
198- Secondary malignant neoplasm of other specified sites 
196- Secondary and unspecified malignant neoplasm of lymph nodes 
195- Malignant neoplasm of other and ill-defined sites 
199- Malignant neoplasm without specification of site 
197- Secondary malignant neoplasm of respiratory and digestive 
systems 
518- Other diseases of lung 
203- Multiple myeloma and immunoproliferative neoplasms 
585- Chronic kidney disease (ckd) 
273- Disorders of plasma protein metabolism 
276- Disorders of fluid electrolyte and acid-base balance 
288- Diseases of white blood cells 
285- Other and unspecified anemias 
275- Disorders of mineral metabolism 
284- Aplastic anemia and other bone marrow failure syndromes 
287- Purpura and other hemorrhagic conditions 
V58- Encounter for other and unspecified procedures and 
aftercare 
584- Acute kidney failure 
733- Other disorders of bone and cartilage 
Base Diagnosis -
Multiple myeloma & 
immunoproliferative 
neoplasms (203) 
 
Figure 6.4c. Clique 3 Figure 6.4d. Clique 4 Figure 6.4e. Clique 5 Figure 6.4f. Clique 6 
Figure 6.4g. Clique 7 Figure 6.4h. Clique 8 Figure 6.4i. Clique 9 
Figure 6.4j. Clique 10 Figure 6.4k. Clique 11 
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290- Dementias 
401-Essential hypertension 
437- Ill-defined cerebrovascular disease 
250- Diabetes mellitus 
294- Persistent mental disorders 
276- Disorders of fluid electrolyte and 
acid-base balance 
585- Chronic kidney disease (ckd) 
V12- Personal history of certain other 
diseases Base Diagnosis – 
Dementias (290) 
 
510- Empyema 
518- Other diseases of lung 
511- Pleurisy 
995- Certain adverse effects not 
elsewhere classified 
285- Other and unspecified anemias 
038- Septicemia 
276- Disorders of fluid electrolyte and 
acid-base balance 
486- Pneumonia, organism unspecified 
041- Bacterial infection 
Base Diagnosis – 
Empyema (510) 
 
486- Pneumonia, organism unspecified 
496- Chronic airway obstruction 
515- Postinflammatory pulmonary 
fibrosis 
516- Other alveolar and 
parietoalveolar pneumonopathy 
518- Other diseases of lung 
799- Ill-defined causes of morbidity 
and mortality 
Base Diagnosis -
Alveolar & 
parietoalveolar 
pneumonopathy (516) 
V56- Encounter for dialysis and dialysis catheter care 
588- Disorders resulting from impaired renal function 
585- Chronic kidney disease (ckd) 
V45- Other postprocedural states 
E87- Accident during medical care 
276- Disorders of fluid electrolyte and acid-base balance 
285- Other and unspecified anemias 
403- Hypertensive chronic kidney disease 
996- Complications peculiar to certain procedures Base Diagnosis – 
Encounter for 
dialysis and dialysis 
catheter care (V56) 
157- Malignant neoplasm of pancreas 
V10- Personal history of malignant neoplasm 
197- Secondary malignant neoplasm of respiratory and 
digestive systems 
276- Disorders of fluid electrolyte and acid-base balance 
285- Other and unspecified anemias 
576- Other disorders of biliary tract 
577- Diseases of pancreas Base Diagnosis – 
Malignant neoplasm 
of pancreas (157) 
Base Diagnosis – 
Nutritional marasmus (261) 
261- Nutritional marasmus 
V85- Body mass index (bmi) 
263- Other and unspecified protein-calorie malnutrition 
275- Disorders of mineral metabolism 
276- Disorders of fluid electrolyte and acid-base balance 
285- Other and unspecified anemias 
038- Septicemia 
486- Pneumonia, organism unspecified 
518- Other diseases of lung 
584- Acute kidney failure 
783- Symptoms concerning nutrition metabolism and 
development 
799- Ill-defined causes of morbidity and mortality 
995- Certain adverse effects not elsewhere classified 
421- Acute and subacute endocarditis 
518- Other diseases of lung 
785- Symptoms involving cardiovascular system 
427- Cardiac dysrhythmias 
790- Nonspecific findings on examination of blood 
428- Heart failure 
584- Pneumonia in infectious diseases  
038- Septicemia 
041- Bacterial infection 
996- Complications peculiar to certain specified procedures 
585- Chronic kidney disease (ckd) 
285- Other and unspecified anemias 
276- Disorders of fluid electrolyte and acid-base balance 
424- Other diseases of endocardium 
995- Certain adverse effects not elsewhere classified 
Base Diagnosis – Acute and 
subacute endocarditis (421) 
 
Figure 6.4l. Clique 12 Figure 6.4m. Clique 13 Figure 6.4n. Clique 14 
Figure 6.4o. Clique 15 Figure 6.4p. Clique 16 
Figure 6.4q. Clique 17 Figure 6.4r. Clique 18 
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Figure 6.5. Mortality rate with and without clique 
 
Moreover, we validated the effect of cliques on mortality by performing a similar comparison on 
an independent dataset. We found similar results with cliques having more risk of mortality. The 
results on the validation dataset are listed in Table 6.3. This validation on an independent dataset 
confirms the robustness of our analysis and results. 
Although the method and findings from this study are unique, we relate these back to the 
literature of comorbidity. For instance, we found several cancer-related cliques indicating 
comorbidities impacting the mortality rate. Our finding is supported by the previous researchers. 
For example, Sarfati, Koczwara and Jackson (2016) argued that comorbidities among cancer 
patients lead to poorer survival and quality of life. Similarly, empyema is known to be related to 
multiple other diseases like pneumonia, septicemia, lung diseases as discussed by Li and Gates 
(2008), which are related to mortality. Adding to the above literature of comorbidities, using a 
novel approach, we are able to show the risk of collection of diagnoses in terms of cliques. 
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Table 6.3. Robustness Check on Validation Dataset 
ICD-9 Description Patient 
count w/o 
Clique 
Mortality 
rate w/o 
clique (%) 
Patient 
count with 
Clique 
Mortality 
rate with 
clique (%) 
261 Nutritional marasmus 3,514 31.5 36 41.7 
452* Portal vein thrombosis 1,220 18.3 902 29.6 
157* Malignant neoplasm of pancreas 5,756 21.7 54 51.9 
421* Acute and subacute endocarditis 3,792 19.2 60 50.0 
151* Malignant neoplasm of stomach 3,042 16.9 436 37.8 
150 Malignant neoplasm of esophagus 2,679 17.6 928 19.4 
430* Subarachnoid hemorrhage 5,621 16.3 172 28.5 
117 Mycoses 6,645 15.7 26 23.1 
513* Abscess of lung and mediastinum 1,468 10.5 673 22.3 
516* 
Alveolar and parietoalveolar 
pneumonopathy 
4,015 12.9 
198 
33.3 
510* Empyema 4,145 12.2 121 33.9 
195* 
Malignant neoplasm of head, face, neck, 
thorax, abdomen, pelvis and limbs 
6,045 12.2 
12 
50.0 
481* Pneumococcal pneumonia 4,194 11.8 140 33.6 
V56* 
Encounter for dialysis and dialysis 
catheter care 
2,061 10.0 
604 
18.9 
200* Lymphosarcoma and reticulosarcoma 3,770 9.2 340 16.8 
203* 
Multiple myeloma and 
immunoproliferative neoplasms 
5,694 10.7 
15 
26.7 
183* 
Malignant neoplasm of ovary and other 
uterine adnexa 
6,902 10.0 
150 
38.7 
290* Dementias 4,342 10.1 148 29.7 
* The proportions are statistically different (p<0.05) 
 
6.6 CONCLUSIONS 
We showed structure properties such as cliques of a network inferred from the co-occurrences 
effect health outcomes of the patients. We discovered underlying interaction between different 
diagnoses related to the mortality. Our study has several practical implications. Clique being a 
complete subnetwork indicates a trap of diseases. Since the mortality rate increases if a clique is 
developed, physicians should take measures to avoid such trap of diagnoses. Moreover, the 
presence of a clique in a patient should alarm the physician to take preemptive action. Studying 
the impact of multimorbidity on mortality from the clique point of view definitely increases the 
understanding about the possible impact of multiple diagnoses on mortality.  
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We recognize few limitations of our approach. First, we identified maximal cliques related to the 
base diagnosis. However, it is possible that some diagnoses are redundant and may not be related 
to mortality. In the future, we will find the high risk sub-network of the clique by eliminating the 
redundant diagnoses. Second, we acknowledge that there are several diagnoses that are highly 
related to mortality but not forming the cliques. We did not include such diagnoses in our analysis 
because the main focus was on the clique property. 
Notwithstanding the limitations, the approach presented in this paper is generalizable to multiple 
other business and social problems where a network can be inferred from the actions of the users. 
For example, a clique of products in the product purchase network can help vendors to create 
bundles of products to sell. In this case, the cliques of products can be identified based on the 
profitability, analogous to mortality in our case. A similar idea can be applied to find cliques of 
mobile apps in the mobile-apps network, which can be inferred from the usage patterns of users. 
Such cliques of mobile apps can be bundled together on the online store. Another application of 
our approach is in finding cliques of locations in the network of locations inferred from the travel 
patterns of the tourists. Some tourist spots may emerge as profitable cliques and therefore, travel 
agents can create holiday packages comprising clique locations.
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CHAPTER VII 
 
 
CONCLUSIONS 
7.1. CONTRIBUTIONS AND GENERALIZABILITY 
Our network is one of a category that emerges without the intentions of its source, often referred 
to as unintentional, inferred or implicit. Patients are the source, but the network is formed 
implicitly unknowingly. This class differs from traditional or explicit networks, which are 
developed from the intentional actions of its members. The method and applications presented in 
this dissertation has practical, methodological and theoretical contributions.  
Inferring network itself is a challenge. Therefore, the contribution of Chapter 2 is significant 
where we proved that a cosine index is a better choice than a correlation coefficient. We showed 
that selecting an index independent of the sample size provides valid network comprising true 
relationships. This contribution can be generalizable to all implicit networks inferred from the 
sample. For example, affinity between products in a market basket of buyers in a grocery store 
should be computed using an index independent of the number of buyers.  
Moreover, in Chapter 2, we proved that the comorbidity network follows the small-world 
topology. This is a significant contribution to the comorbidity and medical literature. The small-
world property of the network has several practical implications for the providers. For example, 
the clusters in the network can be used to lay out departments. Moreover, clusters of diseases can 
guide pharmaceutical companies to understand the side-effects of a medicine. Generally, the  
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network properties can help the physicians prioritize the diagnoses based on the position of a 
disease in the network. 
A network emerged from the unintended actions can be different in groups because groups might 
behave differently in different situations. Like in Chapter 3 and 4, we discovered different 
behavior of diseases in different population groups based on gender, race, and insurance, this is 
true for other inferred networks as well. For instance, the co-purchasing pattern of males and 
females may form two different structures. Therefore, the approach of analyzing different 
network is different population groups is generalizable to other networks to gain more insights 
about the phenomenon. 
The network method can also help create models in high dimensional space by summarizing the 
relationships between different components of a system. A network can be a basis for the 
algorithms to predict future outcomes. In Chapters 5 and 6, we described two algorithms using 
the network properties. The algorithms were used to create models of different levels i.e. i.e. at 
the network level and the performance outcome level. Therefore, this dissertation has algorithmic 
contributions. These algorithms can be applied in other problems domains where inferred 
network can be used to build models at different levels. 
Because a network can handle high dimensional space, a scale incorporating high dimensionality 
to quantify any phenomenon can be created. In Chapter 5, we used network properties to devise a 
measure to compute comorbidity at a patient level. This is another contribution of this dissertation 
like Shmueli and Koppius (2011) explained in their commentary that a measure development is 
one of the roles of analytics in scientific research. 
The measure developed from the network was used to predict exogenous outcome i.e. length of 
stay. Here, we take the application of implicit networks to next level, exploring how these impact 
the uncontrollable performance of the external source. Similarly, in other inferred networks, 
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structural properties can be used to explain and predict outcomes external to the network. The use 
of network variables for modeling is itself a major contribution of this dissertation. This approach 
provides researchers a new dimension to understand the phenomenon. 
A network embeds several inherent structural properties resulting from the interactions between 
the nodes. Understanding these properties theoretically is important. In Chapter 6 of this 
dissertation, we theorized a very critical inherent property of the comorbidity network i.e. cliques. 
A clique was theorized as a trap state from where the exit is difficult. The cliques identified were 
related to high mortality risk. To the best of our knowledge, no one in the past has theorized a 
clique property of the comorbidity network in the form of a trap state. Moreover, the method of 
finding cliques related to an exogenous property (mortality in our case) can be applied in other 
networks. Finding Clique is a never ending problem and a simpler algorithm described in Chapter 
6 to find these based on prevalent outcomes is a methodological contribution of this dissertation.  
7.2. FUTURE WORK 
We identified comorbidity differences across population groups in Chapter 3 and 4. To increase 
the usefulness of our results for practical purposes, we are creating a website describing the 
comorbidity differences interactively. Physicians will be able to use our website to predict future 
diagnoses and understand the state of a patient.  
In addition, we primarily focused on the length of stay and mortality as the health outcomes. 
However, in future, we will study how network properties influence other health outcomes of 
patients such as readmission probability. In addition, we will study how a network can be used to 
design new interventions. 
The comorbidity networks created in this dissertation were undirected with no directions between 
the diagnoses. However, if we consider the time of a diagnosis, a directed network with direction 
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between the diagnoses can be created. It will explain how one disease leads to another disease. 
This will help explain the causal relationship between diagnoses. 
As a part of our future work, we will generalize our methodology and approach to other domains.  
We will extend our method to the retail industry problems. One future project is to create a network 
of products based on shopping cart of customers in a grocery store. The structural properties of 
product network will be utilized to study performance outcomes of the customers. For example, the 
structural properties of the products in current shopping cart might predict the future cart and future 
spending.  
Our approach can also be applied to understand technology related behavioral outcomes. For 
instance, an implicit network formed from technology use might explain performance outcomes 
such as technology addiction, satisfaction, etc. An example of such an implicit network is the 
smartphone app network formed from the use of multiple apps one after the other by users.  
Similarly, we will explore different hidden networks in various domains. 
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APPENDICES 
 
Appendix A. Performance of the hospital length of stay models for patients with a specific primary diagnosis 
 
ICD Name N Mean 
Baseline 4 
R-square 
COM 3  
R-square  
ICD Name N Mean 
Baseline 4 
R-square 
COM 3  
R-square 
002  Typhoid and paratyphoid fevers 4389 1.2422 0.318 0.496 
 
649 
 Other conditions or status of the mother 
complicating pregnancy, childbirth 
2043 2.4258 0.095 0.215 
003  Other salmonella infections 6617 2.3350 0.231 0.254  650  Normal delivery 10455 2.2477 0.045 0.115 
005  Other food poisoning (bacterial) 1794 1.3016 0.370 0.381  651  Multiple gestation 578 3.3789 0.112 0.225 
008  Intestinal infections due to other organisms 3671 2.1370 0.287 0.382  652  Malposition and malpresentation of fetus 2164 3.0231 0.047 0.117 
009  Ill-defined intestinal infections 572 2.3794 0.391 0.661  654  Abnormality of organs and soft tissues of pelvis 9271 2.7025 0.059 0.118 
034  Streptococcal sore throat and scarlet fever 6871 1.0971 0.189 0.234 
 
655 
 Known or suspected fetal abnormality affecting 
management of mother 
917 2.4089 0.265 0.325 
038  Septicemia 4669 5.1527 0.101 0.207 
 
656 
Other fetal and placental problems affecting 
management of mother 
2796 2.6692 0.042 0.136 
041 
 Bacterial infection in conditions classified 
elsewhere 
2153 2.5235 0.319 0.602 
 
658 
 Other problems associated with amniotic cavity 
and membranes 
3823 3.4057 0.030 0.078 
053  Herpes zoster 1224 1.4232 0.418 0.532 
 
659 
Other indications for care or intervention related 
to labor 
6071 2.6655 0.045 0.108 
054  Herpes simplex 804 1.7674 0.343 0.469  660  Obstructed labor 959 2.9124 0.061 0.142 
057  Other viral exanthemata 1334 1.0997 0.244 0.309  661  Abnormality of forces of labor 2432 2.9416 0.122 0.216 
074  Specific diseases due to coxsackie virus 1542 1.0759 0.282 0.405 
 
663 
 Umbilical cord complications during labor and 
delivery 
3649 2.2710 0.049 0.138 
079 
 Viral and chlamydial infection in conditions 
classified elsewhere 
18690 1.1546 0.296 0.395 
 
664  Trauma to perineum and vulva during delivery 10292 2.1785 0.038 0.071 
110  Dermatophytosis 2586 1.1257 0.283 0.575 
 
669 
 Other complications of labor and delivery not 
elsewhere classified 
2016 2.9122 0.098 0.210 
112  Candidiasis 3199 1.2813 0.624 0.780  681  Cellulitis and abscess of finger and toe 2955 1.4115 0.428 0.547 
133  Acariasis 1764 1.0884 0.251 0.320  682  Other cellulitis and abscess 39685 1.6068 0.419 0.451 
153  Malignant neoplasm of colon 530 5.2792 0.109 0.205  684  Impetigo 1335 1.1363 0.313 0.382 
140 
 
162 
 Malignant neoplasm of trachea bronchus 
and lung 
547 5.0494 0.136 0.262 
 
686 
Other local infections of skin and subcutaneous 
tissue 
1230 1.3846 0.371 0.693 
174  Malignant neoplasm of female breast 960 2.0479 0.150 0.327  691  Atopic dermatitis and related conditions 2141 1.2644 0.294 0.565 
185  Malignant neoplasm of prostate 1698 1.8893 0.122 0.362  692  Contact dermatitis and other eczema 7949 1.1250 0.266 0.492 
218  Uterine leiomyoma 2988 2.0576 0.159 0.235  698  Pruritus and related conditions 1448 1.1250 0.378 0.663 
244  Acquired hypothyroidism 870 2.5667 0.149 0.558  704  Diseases of hair and hair follicles 1188 1.1052 0.338 0.462 
250  Diabetes mellitus 13397 2.3259 0.227 0.342  708  Urticaria 5151 1.0641 0.181 0.248 
251 
Other disorders of pancreatic internal 
secretion 
1165 2.0077 0.282 0.504 
 
709  Other disorders of skin and subcutaneous tissue 2914 1.2172 0.237 0.379 
272  Disorders of lipoid metabolism 2214 2.6500 0.061 0.373  715  Osteoarthrosis and allied disorders 6552 2.3288 0.175 0.307 
274  Gout 1214 1.4185 0.454 0.759  716  Other and unspecified arthropathies 2080 1.3620 0.365 0.653 
276 
 Disorders of fluid electrolyte and acid-base 
balance 
14732 2.1792 0.257 0.338 
 
719  Other and unspecified disorders of joint 36318 1.1642 0.244 0.355 
278 
 Overweight, obesity and other 
hyperalimentation 
3499 2.3172 0.150 0.442 
 
721  Spondylosis and allied disorders 1739 1.8735 0.142 0.277 
280  Iron deficiency anemias 840 2.5405 0.170 0.478  722  Intervertebral disc disorders 5082 1.8851 0.127 0.201 
282  Hereditary hemolytic anemias 2911 2.5737 0.306 0.412  723  Other disorders of cervical region 11664 1.1526 0.210 0.293 
285  Other and unspecified anemias 4126 2.8323 0.178 0.350  724  Other and unspecified disorders of back 42330 1.1911 0.269 0.340 
287  Purpura and other hemorrhagic conditions 1078 2.6503 0.241 0.589  726  Peripheral enthesopathies and allied syndromes 2118 1.2899 0.426 0.505 
288  Diseases of white blood cells 1533 3.2857 0.212 0.442  727  Other disorders of synovium tendon and bursa 1712 1.3271 0.408 0.597 
289 
Other diseases of blood and blood-forming 
organs 
1422 1.8432 0.402 0.620 
 
728  Disorders of muscle ligament and fascia 2460 1.9459 0.313 0.569 
291  Alcohol-induced mental disorders 2552 3.2692 0.271 0.370  729  Other disorders of soft tissues 42639 1.2080 0.337 0.397 
292  Drug-induced mental disorders 2091 2.2975 0.391 0.509  733  Other disorders of bone and cartilage 3514 1.5677 0.316 0.505 
294 
 Persistent mental disorders due to 
conditions classified elsewhere 
510 3.5137 0.436 0.560 
 
737 Curvature of spine 591 4.4196 0.278 0.409 
295  Schizophrenic disorders 4978 6.5749 0.302 0.346 
 
745 
Bulbus cordis anomalies and anomalies of cardiac 
septal closure 
1048 5.7424 0.194 0.330 
296  Episodic mood disorders 13858 4.8611 0.256 0.287 
 
765 
Disorders relating to short gestation and low 
birthweight 
2635 6.4159 0.174 0.294 
298  Other nonorganic psychoses 3691 3.9225 0.376 0.452 
 
766 
Disorders relating to long gestation and high 
birthweight 
1173 2.4859 0.062 0.132 
300 
 Anxiety, dissociative and somatoform 
disorders 
13556 1.6713 0.409 0.474 
 
770 
 Other respiratory conditions of fetus and 
newborn 
1637 5.4319 0.197 0.360 
303  Alcohol dependence syndrome 5750 1.6957 0.445 0.503  774  Other perinatal jaundice 2953 2.5645 0.158 0.291 
304  Drug dependence 775 4.7871 0.383 0.430 
 
778 
Integument and temperature regulation of fetus 
and newborn 
595 2.7193 0.144 0.506 
305  Nondependent abuse of drugs 17013 1.9214 0.321 0.419 
 
779 
 Other and ill-defined conditions originating in the 
perinatal period 
2718 3.2826 0.239 0.377 
307 
 Special symptoms or syndromes not 
elsewhere classified 
2477 2.8292 0.674 0.708 
 
780  General symptoms 124364 1.4193 0.317 0.364 
309  Adjustment reaction 2536 2.7165 0.338 0.443 
 
781 
Symptoms involving nervous and musculoskeletal 
systems 
2793 1.7333 0.245 0.575 
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311 
 Depressive disorder, not elsewhere 
classified 
8074 2.7524 0.363 0.419 
 
782 
 Symptoms involving skin and other 
integumentary tissue 
30349 1.2404 0.292 0.399 
312 
 Disturbance of conduct not elsewhere 
classified 
1483 2.1908 0.458 0.547 
 
783 
 Symptoms concerning nutrition metabolism and 
development 
1724 3.6990 0.230 0.407 
314  Hyperkinetic syndrome of childhood 532 4.2519 0.418 0.513  784  Symptoms involving head and neck 56072 1.1691 0.316 0.384 
338  Pain, not elsewhere classified 3415 1.5356 0.310 0.573  785  Symptoms involving cardiovascular system 9361 1.4525 0.319 0.490 
345  Epilepsy and recurrent seizures 6650 2.0329 0.242 0.332 
 
786 
Symptoms involving respiratory system and other 
chest symptoms 
137777 1.4710 0.317 0.359 
346  Migraine 9547 1.2151 0.315 0.467  787  Symptoms involving digestive system 54882 1.3368 0.346 0.393 
348  Other conditions of brain 1183 3.4725 0.176 0.486  788  Symptoms involving urinary system 13048 1.1914 0.296 0.516 
351  Facial nerve disorders 1036 1.1931 0.458 0.701  789  Other symptoms involving abdomen and pelvis 122241 1.3435 0.387 0.422 
362  Other retinal disorders 1300 1.2500 0.435 0.829  790  Nonspecific findings on examination of blood 4868 2.1781 0.328 0.463 
366  Cataract 527 1.1006 0.543 0.724  794  Nonspecific abnormal results of function studies 559 2.8068 0.182 0.446 
368  Visual disturbances 1649 1.3869 0.301 0.555  796  Other nonspecific abnormal findings 1296 1.4915 0.239 0.528 
372  Disorders of conjunctiva 9741 1.0813 0.135 0.234 
 
799 
 Other ill-defined and unknown causes of 
morbidity and mortality 
3047 2.6754 0.201 0.428 
373  Inflammation of eyelids 2340 1.1440 0.371 0.457  802  Fracture of face bones 2943 1.5912 0.245 0.355 
379  Other disorders of eye 8543 1.0912 0.266 0.367 
 
805 
 Fracture of vertebral column without mention of 
spinal cord injury 
1867 2.6133 0.239 0.389 
380  Disorders of external ear 4340 1.1187 0.295 0.483  807  Fracture of rib(s) sternum larynx and trachea 1871 2.0208 0.257 0.509 
381 
 Nonsuppurative otitis media and eustachian 
tube disorders 
555 1.1135 0.356 0.404 
 
810  Fracture of clavicle 1858 1.2374 0.391 0.572 
382  Suppurative and unspecified otitis media 25208 1.0948 0.171 0.210  812  Fracture of humerus 3943 1.3779 0.225 0.380 
386 
 Vertiginous syndromes and other disorders 
of vestibular system 
753 1.3997 0.347 0.420 
 
813  Fracture of radius and ulna 8166 1.2103 0.201 0.299 
388  Other disorders of ear 11850 1.1097 0.164 0.198  814  Fracture of carpal bone(s) 528 1.1553 0.226 0.310 
401 Essential hypertension 16603 1.8777 0.260 0.394  815  Fracture of metacarpal bone(s) 1851 1.0929 0.195 0.256 
403  Hypertensive chronic kidney disease 512 3.4785 0.230 0.401  816  Fracture of one or more phalanges of hand 3526 1.1075 0.116 0.239 
410  Acute myocardial infarction 7737 3.4349 0.036 0.092  821  Fracture of other and unspecified parts of femur 691 3.0564 0.241 0.399 
411 
 Other acute and subacute forms of ischemic 
heart disease 
1413 2.5718 0.075 0.174 
 
823  Fracture of tibia and fibula 2644 2.1048 0.277 0.365 
414 
 Other forms of chronic ischemic heart 
disease 
6974 2.9604 0.030 0.096 
 
824  Fracture of ankle 4045 1.5773 0.241 0.359 
415  Acute pulmonary heart disease 1911 4.2575 0.121 0.303 
 
825 
 Fracture of one or more tarsal and metatarsal 
bones 
2123 1.3118 0.366 0.562 
424  Other diseases of endocardium 521 5.3647 0.129 0.303  826  Fracture of one or more phalanges of foot 1345 1.0900 0.202 0.594 
427  Cardiac dysrhythmias 11823 2.7515 0.149 0.234  829  Fracture of unspecified bones 758 1.4024 0.323 0.466 
428  Heart failure 6959 3.8817 0.133 0.197  831  Dislocation of shoulder 1255 1.0988 0.260 0.347 
433 
 Occlusion and stenosis of precerebral 
arteries 
1909 1.9460 0.266 0.391 
 
832  Dislocation of elbow 1994 1.0507 0.112 0.226 
434  Occlusion of cerebral arteries 3384 3.3502 0.085 0.252  840  Sprains and strains of shoulder and upper arm 3944 1.0649 0.097 0.198 
435  Transient cerebral ischemia 2381 2.1277 0.115 0.285  841  Sprains and strains of elbow and forearm 515 1.1262 0.462 0.850 
142 
 
440  Atherosclerosis 523 3.1243 0.202 0.339  842  Sprains and strains of wrist and hand 6249 1.0570 0.110 0.128 
441  Aortic aneurysm and dissection 678 3.2478 0.301 0.409  843  Sprains and strains of hip and thigh 1347 1.0995 0.228 0.308 
453  Other venous embolism and thrombosis 2341 3.0880 0.286 0.430  844  Sprains and strains of knee and leg 5855 1.0828 0.149 0.199 
455  Hemorrhoids 2020 1.3619 0.352 0.598  845  Sprains and strains of ankle and foot 14357 1.0499 0.058 0.198 
458  Hypotension 1927 2.5817 0.231 0.484  846  Sprains and strains of sacroiliac region 518 1.1293 0.168 0.238 
461  Acute sinusitis 2857 1.1491 0.345 0.429 
 
847 
 Sprains and strains of other and unspecified parts 
of back 
22641 1.0509 0.079 0.157 
462  Acute pharyngitis 22449 1.0923 0.137 0.286  848  Other and ill-defined sprains and strains 2903 1.0568 0.242 0.419 
463  Acute tonsillitis 2499 1.1493 0.256 0.343  850  Concussion 6848 1.1513 0.193 0.245 
464  Acute laryngitis and tracheitis 5039 1.1861 0.192 0.354 
 
852 
 Subarachnoid subdural and extradural 
hemorrhage following injury 
594 3.3754 0.107 0.331 
465 
 Acute upper respiratory infections of 
multiple or unspecified sites 
43320 1.0932 0.233 0.331 
 
870  Open wound of ocular adnexa 560 1.0911 0.312 0.542 
466  Acute bronchitis and bronchiolitis 22947 1.5328 0.326 0.365  872  Open wound of ear 593 1.0742 0.237 0.282 
473  Chronic sinusitis 4275 1.1539 0.313 0.550  873  Other open wound of head 31786 1.0788 0.174 0.250 
477  Allergic rhinitis 1996 1.1728 0.284 0.488 
 
879 
 Open wound of other and unspecified sites 
except limbs 
2870 1.4160 0.357 0.522 
478  Other diseases of upper respiratory tract 4415 1.3905 0.260 0.483  881  Open wound of elbow forearm and wrist 4093 1.1481 0.266 0.486 
482  Other bacterial pneumonia 1392 3.8111 0.239 0.371  882  Open wound of hand except finger(s) alone 6850 1.0778 0.190 0.265 
486  Pneumonia, organism unspecified 17078 2.5750 0.319 0.371  883  Open wound of finger(s) 14455 1.0706 0.153 0.187 
487  Influenza 6241 1.3259 0.380 0.535 
 
884 
 Multiple and unspecified open wound of upper 
limb 
984 1.1047 0.242 0.310 
490  Bronchitis, not specified as acute or chronic 7927 1.1629 0.349 0.412  890  Open wound of hip and thigh 641 1.2559 0.346 0.575 
491  Chronic bronchitis 6218 3.0317 0.276 0.322  891  Open wound of knee leg (except thigh) and ankle 5015 1.1741 0.279 0.357 
493  Asthma 28397 1.5484 0.324 0.390  892  Open wound of foot except toe(s) alone 3579 1.1260 0.264 0.583 
496 
 Chronic airway obstruction, not elsewhere 
classified 
2295 2.6078 0.273 0.382 
 
893  Open wound of toe(s) 1258 1.0588 0.148 0.259 
511  Pleurisy 1825 3.0104 0.386 0.508 
 
910 
 Superficial injury of face neck and scalp except 
eye 
4553 1.0995 0.279 0.525 
512  Pneumothorax and air leak 588 4.6497 0.119 0.267  911  Superficial injury of trunk 1488 1.1559 0.240 0.721 
518  Other diseases of lung 3533 4.7220 0.137 0.269  913  Superficial injury of elbow forearm and wrist 1624 1.1305 0.232 0.805 
519  Other diseases of respiratory system 1636 1.5348 0.258 0.558  916  Superficial injury of hip thigh leg and ankle 2574 1.1076 0.269 0.362 
521  Diseases of hard tissues of teeth 3880 1.0907 0.333 0.855  917  Superficial injury of foot and toe(s) 575 1.0974 0.217 0.306 
522  Diseases of pulp and periapical tissues 5741 1.1312 0.419 0.471  918  Superficial injury of eye and adnexa 3266 1.0582 0.134 0.515 
525 
 Other diseases and conditions of the teeth 
and supporting structures 
13928 1.0556 0.097 0.177 
 
919 
 Superficial injury of other multiple and 
unspecified sites 
6477 1.0871 0.300 0.464 
528 
Oral soft tissues excluding lesions specific for 
gingiva and tongue 
3220 1.2891 0.346 0.501 
 
920  Contusion of face, scalp, and neck except eye(s) 11273 1.0931 0.151 0.296 
530  Diseases of esophagus 6458 1.8741 0.239 0.405  921  Contusion of eye and adnexa 625 1.1488 0.505 0.566 
535  Gastritis and duodenitis 6808 1.3819 0.397 0.544  922  Contusion of trunk 7317 1.1152 0.148 0.266 
536  Disorders of function of stomach 1549 2.0575 0.348 0.469  923  Contusion of upper limb 10982 1.0533 0.112 0.195 
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540  Acute appendicitis 5994 2.8223 0.035 0.107 
 
924 
 Contusion of lower limb and of other and 
unspecified sites 
15534 1.0811 0.233 0.565 
541  Appendicitis, unqualified 606 2.7508 0.079 0.187  930  Foreign body on external eye 1287 1.0645 0.063 0.092 
550  Inguinal hernia 1243 1.5414 0.226 0.339  931  Foreign body in ear 1983 1.0756 0.153 0.173 
553 
 Other hernia of abdominal cavity without 
mention of obstruction or gangrene 
2398 2.4854 0.245 0.368 
 
932  Foreign body in nose 1439 1.0737 0.110 0.198 
555  Regional enteritis 1047 3.5244 0.232 0.376  935  Foreign body in mouth esophagus and stomach 1371 1.1758 0.159 0.420 
558 
 Other and unspecified noninfectious 
gastroenteritis and colitis 
20523 1.2614 0.365 0.443 
 
938  Foreign body in digestive system, unspecified 1641 1.1395 0.254 0.469 
560 
 Intestinal obstruction without mention of 
hernia 
4558 4.1057 0.136 0.196 
 
941  Burn of face head and neck 523 1.8260 0.248 0.484 
562  Diverticula of intestine 5127 3.0971 0.256 0.309  943  Burn of upper limb except wrist and hand 501 1.6946 0.387 0.453 
564 
 Functional digestive disorders not 
elsewhere classified 
13421 1.2843 0.362 0.514 
 
944  Burn of wrist(s) and hand(s) 2099 1.3149 0.385 0.501 
566  Abscess of anal and rectal regions 593 1.9224 0.316 0.423  945  Burn of lower limb(s) 1128 1.9025 0.419 0.598 
569  Other disorders of intestine 5600 1.9546 0.368 0.434  949  Burn unspecified site 1233 1.5750 0.322 0.377 
571  Chronic liver disease and cirrhosis 763 4.3172 0.190 0.302  959  Injury other and unspecified 57468 1.1375 0.225 0.306 
574  Cholelithiasis 6227 2.5405 0.267 0.325 
 
965 
 Poisoning by analgesics antipyretics and 
antirheumatics 
1680 1.8268 0.261 0.456 
575  Other disorders of gallbladder 1741 3.0689 0.136 0.265  969  Poisoning by psychotropic agents 1228 1.9992 0.234 0.408 
577  Diseases of pancreas 4637 3.9198 0.145 0.213 
 
977 
 Poisoning by other and unspecified drugs and 
medicinal substances 
1602 1.4313 0.324 0.434 
578  Gastrointestinal hemorrhage 5587 2.8341 0.260 0.346 
 
989 
 Toxic effect of other substances chiefly 
nonmedicinal as to source 
4021 1.1450 0.285 0.420 
584  Acute kidney failure 3318 4.5069 0.070 0.177  995  Certain adverse effects not elsewhere classified 12151 1.3123 0.333 0.547 
585  Chronic kidney disease (ckd) 1196 3.6455 0.214 0.410 
 
996 
 Complications peculiar to certain specified 
procedures 
4480 2.9498 0.209 0.302 
590  Infections of kidney 4924 1.9175 0.400 0.473 
 
997 
 Complications affecting specified body system 
not elsewhere classified 
1616 3.3923 0.198 0.357 
592  Calculus of kidney and ureter 8884 1.3540 0.256 0.415 
 
998 
 Other complications of procedures not elsewhere 
classified 
4459 2.3290 0.317 0.431 
593  Other disorders of kidney and ureter 2005 2.5416 0.222 0.419  E81  Motor vehicle traffic accident 3118 1.2017 0.381 0.532 
595  Cystitis 1471 1.1924 0.408 0.562  E84 Vehicle accidents not elsewhere classifiable 531 1.1921 0.553 0.880 
597 
Urethritis not sexually transmitted and 
urethral syndrome 
1328 1.0497 0.238 0.264 
 
E88  Accidental fall 3438 1.3048 0.274 0.414 
599  Other disorders of urethra and urinary tract 29431 1.4133 0.379 0.472  E90 Accident due to weather 1186 1.2057 0.397 0.747 
600  Hyperplasia of prostate 853 2.1290 0.176 0.370 
 
E91 
Accidents caused by submersion, suffocation, and 
foreign bodies 
570 1.2035 0.388 0.510 
604  Orchitis and epididymitis 1310 1.2382 0.533 0.627  E92 Late effects of accidental injury 580 1.3259 0.250 0.473 
605  Redundant prepuce and phimosis 1057 2.1116 0.246 0.548 
 
E96 
Homicide and injury purposely inflicted by other 
persons 
687 1.9563 0.285 0.544 
607  Disorders of penis 1662 1.2196 0.248 0.651 
 
V01 
 Contact with or exposure to communicable 
diseases 
1500 1.1520 0.458 0.583 
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608  Other disorders of male genital organs 3254 1.3190 0.334 0.406 
 
V15 
 Other personal history presenting hazards to 
health 
1755 1.6171 0.404 0.725 
611  Other disorders of breast 2009 1.4191 0.251 0.396  V20  Health supervision of infant or child 1355 1.7063 0.565 0.650 
614 
 Inflammatory disease of ovary fallopian 
tube pelvic cellular tissue and peritoneum 
1576 1.8433 0.383 0.588 
 
V22  Normal pregnancy 20230 2.4254 0.116 0.190 
616 
 Inflammatory disease of cervix vagina and 
vulva 
3966 1.1377 0.386 0.444 
 
V23  Supervision of high-risk pregnancy 1348 2.9206 0.075 0.243 
617 Endometriosis 561 2.0321 0.189 0.270  V24  Postpartum care and examination 2278 2.7428 0.055 0.162 
618 Genital prolapse 1274 1.5785 0.032 0.139  V27  Outcome of delivery 1322 2.3215 0.123 0.356 
620 
Noninflammatory disorders of ovary 
fallopian tube and broad ligament 
3658 1.3857 0.266 0.317 
 
V30  Single liveborn 103027 2.5700 0.022 0.069 
623 Noninflammatory disorders of vagina 9226 1.0942 0.135 0.247  V31  Twin birth mate liveborn 2630 5.9167 0.061 0.121 
625 
Pain and other symptoms associated with 
female genital organs 
7314 1.2177 0.269 0.485 
 
V39 
 Liveborn unspecified whether single twin or 
multiple 
1598 2.3949 0.098 0.340 
626 
Disorders of menstruation and other 
abnormal bleeding from female genital tract 
3548 1.4594 0.263 0.355 
 
V45  Other postprocedural states 1910 2.8215 0.110 0.312 
632  Missed abortion 550 1.3927 0.198 0.277  V55  Attention to artificial openings 1153 2.9809 0.407 0.565 
633  Ectopic pregnancy 769 1.5475 0.166 0.220  V57  Care involving use of rehabilitation procedures 1890 10.214 0.057 0.193 
634  Spontaneous abortion 1497 1.1643 0.162 0.269 
 
V58 
 Encounter for other and unspecified procedures 
and aftercare 
9968 1.5058 0.349 0.532 
637  Unspecified abortion 520 1.1327 0.332 0.699  V62  Other psychosocial circumstances 3227 2.5696 0.394 0.453 
640  Hemorrhage in early pregnancy 6315 1.0515 0.135 0.221 
 
V64 
 Persons encountering health services for specific 
procedures not carried out 
1798 1.1107 0.140 0.223 
641 
 Antepartum hemorrhage abruptio 
placentae and placenta previa 
1262 2.6006 0.163 0.190 
 
V65  Other persons seeking consultation 1581 1.2739 0.096 0.205 
642 
 Hypertension complicating pregnancy 
childbirth and the puerperium 
4815 3.4636 0.070 0.155 
 
V67  Follow-up examination 1144 1.3706 0.341 0.589 
643  Excessive vomiting in pregnancy 2595 1.3145 0.392 0.442  V68  Encounters for administrative purposes 5862 1.1682 0.164 0.227 
644  Early or threatened labor 5106 2.5805 0.112 0.176  V70  General medical examination 3294 1.8352 0.360 0.513 
645  Late pregnancy 5648 2.6084 0.070 0.149 
 
V71 
 Observation and evaluation for suspected 
conditions not found 
8451 1.1619 0.241 0.501 
646 
 Other complications of pregnancy not 
elsewhere classified 
6245 1.3894 0.313 0.366 
 
V72  Special investigations and examinations 770 2.0792 0.246 0.583 
647 
 Infective and parasitic conditions in the 
mother classifiable 
689 2.3237 0.210 0.567 
 
V82  Special screening for other conditions 1417 1.0607 0.120 0.202 
648 
Other current conditions in the mother 
classifiable elsewhere 
15413 1.9507 0.257 0.303 
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